<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Nano</journal-id><journal-id journal-id-type="iso-abbrev">ACS Nano</journal-id><journal-id journal-id-type="publisher-id">nn</journal-id><journal-id journal-id-type="coden">ancac3</journal-id><journal-title-group><journal-title>ACS Nano</journal-title></journal-title-group><issn pub-type="ppub">1936-0851</issn><issn pub-type="epub">1936-086X</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7534801</article-id><article-id pub-id-type="doi">10.1021/acsnano.0c06109</article-id><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Engineering Antiviral Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Zhou</surname><given-names>Xingwu</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="notes1" ref-type="notes">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Jiang</surname><given-names>Xing</given-names></name><xref rid="aff4" ref-type="aff">&#x02225;</xref><xref rid="notes1" ref-type="notes">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Qu</surname><given-names>Moyuan</given-names></name><xref rid="aff5" ref-type="aff">&#x022a5;</xref><xref rid="notes1" ref-type="notes">&#x025cf;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Aninwene</surname><given-names>George E.</given-names><suffix>II</suffix></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Jucaud</surname><given-names>Vadim</given-names></name><xref rid="aff10" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Moon</surname><given-names>James J.</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Gu</surname><given-names>Zhen</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff7" ref-type="aff">&#x02207;</xref><xref rid="aff8" ref-type="aff">&#x025cb;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath8"><name><surname>Sun</surname><given-names>Wujin</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff7" ref-type="aff">&#x02207;</xref><xref rid="aff10" ref-type="aff">&#x000b6;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath9"><name><surname>Khademhosseini</surname><given-names>Ali</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff6" ref-type="aff">#</xref><xref rid="aff7" ref-type="aff">&#x02207;</xref><xref rid="aff8" ref-type="aff">&#x025cb;</xref><xref rid="aff9" ref-type="aff">&#x025c6;</xref><xref rid="aff10" ref-type="aff">&#x000b6;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department of Bioengineering,
<institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095, <country>United
States</country></aff><aff id="aff2"><label>&#x02021;</label>Center for Minimally Invasive
Therapeutics, <institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095,
<country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>Department of Pharmaceutical Sciences,
<institution>University of Michigan</institution>, Ann Arbor,
Michigan 48109, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>School of Nursing,
<institution>Nanjing University of Chinese
Medicine</institution>, Nanjing 210023,
<country>China</country></aff><aff id="aff5"><label>&#x022a5;</label>The Affiliated Stomatology Hospital,
Zhejiang University School of Medicine, Key Laboratory of Oral
Biomedical Research of Zhejiang Province, <institution>Zhejiang
University School of Stomatology</institution>, Hangzhou 310006,
<country>China</country></aff><aff id="aff6"><label>#</label>Department of Chemical and Biomolecular
Engineering, <institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095,
<country>United States</country></aff><aff id="aff7"><label>&#x02207;</label>California NanoSystems Institute,
<institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095, <country>United
States</country></aff><aff id="aff8"><label>&#x025cb;</label>Jonsson Comprehensive Cancer Center,
<institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095, <country>United
States</country></aff><aff id="aff9"><label>&#x025c6;</label>Department of Radiological Sciences,
<institution>University of California, Los
Angeles</institution>, Los Angeles, California 90095, <country>United
States</country></aff><aff id="aff10"><label>&#x000b6;</label><institution>Terasaki Institute for
Biomedical Innovation</institution>, Los Angeles, California
90064, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email:
<email>khademh@terasaki.org</email>.</corresp><corresp id="cor2"><label>*</label>Email:
<email>wsun@terasaki.org</email>.</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>10</month><year>2020</year></pub-date><elocation-id>acsnano.0c06109</elocation-id><history><date date-type="received"><day>21</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement/><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for
unrestricted RESEARCH re-use and analyses in any form or by any
means with acknowledgement of the original source. These
permissions are granted for the duration of the World Health
Organization (WHO) declaration of COVID-19 as a global
pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0006" id="ab-tgr1"/></p><p>Despite the vital role of vaccines in fighting viral pathogens,
effective vaccines are still unavailable for many infectious
diseases. The importance of vaccines cannot be overstated during
the outbreak of a pandemic, such as the coronavirus disease 2019
(COVID-19) pandemic. The understanding of genomics, structural
biology, and innate/adaptive immunity have expanded the toolkits
available for current vaccine development. However, sudden
outbreaks and the requirement of population-level immunization
still pose great challenges in today&#x02019;s vaccine designs.
Well-established vaccine development protocols from previous
experiences are in place to guide the pipelines of vaccine
development for emerging viral diseases. Nevertheless, vaccine
development may follow different paradigms during a pandemic.
For example, multiple vaccine candidates must be pushed into
clinical trials simultaneously, and manufacturing capability
must be scaled up in early stages. Factors from essential
features of safety, efficacy, manufacturing, and distributions
to administration approaches are taken into consideration based
on advances in materials science and engineering technologies.
In this review, we present recent advances in vaccine
development by focusing on vaccine discovery, formulation, and
delivery devices enabled by alternative administration
approaches. We hope to shed light on developing better solutions
for faster and better vaccine development strategies through the
use of biomaterials, biomolecular engineering, nanotechnology,
and microfabrication techniques.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>pandemics</kwd><kwd>infectious disease</kwd><kwd>vaccine</kwd><kwd>immunotherapy</kwd><kwd>drug discovery</kwd><kwd>drug delivery</kwd><kwd>biomedical devices</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>nn0c06109</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>nn0c06109</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">The appearance of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)
has caused unprecedented global disruption to health, economy, and social
stability.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> SARS-CoV-2 causes coronavirus disease
2019 (COVID-19) in which individuals can suffer from mild to severe symptoms
once infected.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Global scientific communities are working
together to fight the crisis caused by this pandemic. The initial efforts to
combat this pandemic included identifying infected patients and ramping up
clinical trials for repurposing existing drugs.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> However,
the development of effective vaccines to prevent SARS-CoV-2 infection is
believed by many to be the most effective long-term solution.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p><p>The pathway from identifying a virus to having a vaccine is lengthy and
expensive. After billions of dollars spent and multiple years of trials,
researchers generally face high rates of failure in the traditional vaccine
development paradigms (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>a).<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Despite rapid responses from the
scientific community and the pharmaceutical industry, vaccines have
historically not been ready even after an epidemic becomes manageable, such
as severe acute respiratory syndrome (SARS), Zika, and Ebola.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Considering economic factors, funding for vaccine
development may be reallocated after a substantial drop in infection cases
is observed, as in the 2015&#x02013;2016 Zika and SARS epidemics. The
2014&#x02013;2016 Ebola outbreak in Africa resulted in over 28,000 cases and
11,000 deaths.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> After continuous research funding
support, in December 2019, the FDA granted the first approval to Ervebo (a
single-dose, live attenuated virus vaccine from Merck) for Ebola virus
prevention.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Benefiting from egg- and cell-based
platforms, vaccine approval for the most recent 2009 H1N1 pandemic was
relatively fast following the peak of the outbreak, and the vaccine was
ultimately incorporated in the seasonal influenza vaccine.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> Since the initiation and ending of epidemics are highly unpredictable,
the rapid deployment of vaccine development may still be too slow for a
sudden outbreak.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Summary of vaccine development paradigms and major types of
vaccines. (a) Paradigms of vaccine development in a traditional
condition <italic>vs</italic> during a pandemic.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> (b) Snapshot of the vaccine landscape for
COVID-19 with the different types of vaccine candidates in
various clinical stages as of August 25, 2020.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> (c) Schematic of major types of vaccines,
including virus-based (weakened and inactivated), viral
vector-based (replicating and nonreplicating), nucleic
acid-based (DNA and mRNA), protein and peptide-based, and
cell-based.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0001" id="gr1" position="float"/></fig><p>To tackle a pandemic, a different vaccine development process is needed to
rapidly produce safe and effective vaccines against novel viruses. This
process is characterized by overlapping phases, multiple potential vaccine
candidates, and early ramp-up of manufacturing capacities (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>a).<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> After the
initial release of the genetic sequence of SARS-CoV-2, researchers worldwide
started to develop vaccines for the prevention of COVID-19. The first dose
was administered into humans by Moderna Inc. on March 16, 2020.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> This method utilized lipid nanoparticles (LNPs) with a
formulated mRNA vaccine.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> This work was fast-tracked at
an unprecedented pace, even though mRNA-based vaccines have never been
licensed before.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> A snapshot of the landscape of COVID-19
vaccines (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>b) shows that
around 31 vaccines have entered clinical trials as of August 25,
2020.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> A high diversity of vaccine candidates is
seen in these forerunners, which includes six mRNA-based, five inactivated
virus-based, five nonreplicating viral vector-based, one replicating viral
vector-based, four DNA-based, and one cell culture-based vaccines as well as
nine protein-based vaccines (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>b,c). The incomplete understanding of the SARS-CoV-2
interactions with the human immune system became one of the major obstacles
in vaccine development. A recent report on a second COVID-19 infection in
the same patient further raises the question of protective immunity and
immune memory. For instance, it is still unknown how durable the immune
memory response induced by SARS-CoV-2 could be or what is the threshold of
antibodies titers that can protect the patients against
reinfection.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> In addition, protective immunity
against SARS-CoV-2 should also be comprehensively studied, where the balance
of cellular and humoral immunity, the ratio of effector to memory T cells,
the maintenance of memory B cells, and functional features of activated T
cells should be characterized.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> These aspects could ultimately
facilitate vaccine designs and evaluations.</p><p>In this review, we aim to provide engineering insights on vaccine development
by covering vaccine discovery, vaccine formulations in terms of different
materials (lipid, polymer, and inorganic particles), and vaccine delivery
devices. We will present how some of the existing challenges could
potentially be addressed by nano/micro/macroscale engineering approaches. We
will also discuss some emerging technologies that may contribute to future
vaccine development pipelines.</p><sec id="sec2"><title>Vaccine Discovery</title><p>After a virus is identified, different categories of vaccines can be developed,
which includes virus-, viral vector-, nucleic acid-, protein/peptide-,
and/or cell-based vaccines (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>c).<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Virus-based vaccines commonly
require patient-derived viruses, while other types can utilize the viral
genomic sequences to accelerate vaccine development. Previously approved
vaccines mostly fall into the virus-based and the recombinant protein-based
categories, but not into the nucleic acid-based one (<xref rid="fig2" ref-type="fig">Figure
<xref rid="fig2" ref-type="fig">2</xref></xref>a).<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> The discovery
process of each vaccine type is distinct with corresponding pros and cons
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>b&#x02013;d).</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Vaccine discovery processes for different types of vaccines. (a)
Timeline of previously approved antiviral vaccines.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> (b) Virus-based vaccines require the seeding
and culture of specific viruses derived from patients. By
manipulating the genetic sequences of the virus or inactivating
the virus directly with chemicals, weakened and inactivated
virus vaccines can be produced.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> (c) Viral
vector-based and nucleic acid-based vaccines are independent of
virus culture and rely on the genetic sequence of the virus
and/or the selection of immunogenic sequences of the virus. By
selecting commonly developed vectors, virus-specific sequences
can be inserted.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Nucleic acid vaccines
require further formulations for optimal efficacy. (d)
Structure-based understanding of native viral proteins can
validate the expressed recombinant proteins and predict the
peptide sequences desirable as vaccines. Protein/peptide
vaccines require further formulations for optimal
efficacy.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0002" id="gr2" position="float"/></fig><sec id="sec2.1"><title>Virus-Based Vaccines</title><p>Virus-based vaccines, including the weakened and inactivated types, are
still the most widely used to date. The effective prevention of the
polio epidemic by vaccination in the 20th century represented a
landmark success in medical history.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> This
vaccination regimen included the use of the inactivated polio vaccine
(IPV) and oral polio vaccine (OPV).<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The IPV was
made by inactivating lab-cultured poliovirus by formalin. The OPV was
weakened live poliovirus.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> Weakened viruses are
highly immunogenic and are commonly developed by the deletion of viral
genes. Nevertheless, mutations could cause virulence reversion as
observed for vaccine-derived polioviruses that have been responsible
for recent polio outbreaks.<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> This represents an
obstacle for polio eradication and, more importantly, a concern for
the weakened virus-based vaccines in general. Further genetic
manipulation strategies are therefore required to prevent this issue.
For instance, modifying the 5&#x02032; untranslated region (UTR), 2C
coding region, and 3D polymerase region resulted in a genetically
stabilized OPV strain that was less likely to regain virulence and
exhibited limited viral adaptability.<sup><xref ref-type="bibr" rid="ref20">20</xref></sup></p><p>On the contrary, inactivated virus vaccines generally do not have
virulence reversion issues. They also do not rely on extensive genetic
manipulations, but the inactivation process may cause the loss of
antigenicity of viral immunogens. This vaccine type has been quickly
adapted to cope with COVID-19, where patient-derived viruses were
inactivated with &#x003b2;-propiolactone, followed with purification by
chromatography, and formulated with Al(OH)<sub>3</sub> as the
adjuvant.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> The vaccine protected nonhuman
primates from SARS-CoV-2 challenges with no notable side
effects.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Advantages of these virus-based
methods include well-developed methodologies, well-established
regulation policies, and existing manufacturing facilities from
previous practices. Nevertheless, the requirement of virus seeding and
culture along with unknown safety issues necessitates alternative
practices for the development of other vaccines.</p></sec><sec id="sec2.2"><title>Viral Vector-Based Vaccines</title><p>Viral vector-based vaccines work by inserting viral antigen-encoding DNA
sequences into host cells, which leads to the expression of viral
antigens by the host cells.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> The rationale is
based on the capability of viruses to infect cells efficiently through
viral genome integration mechanisms.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> This method
could also be problematic since the genome of the host could be
altered and cause other diseases. The selection of viruses is
therefore crucial in balancing the efficacy (efficient infectivity)
and safety (limited pathogenicity). Another common obstacle is the
host&#x02019;s pre-existing immunity to certain vectors that would
mitigate the efficacy of a vaccine. The selected viral vectors could
be further genetically modified to be nonreplicable by disrupting
genes responsible for replication. Adenoviruses (Ad) are the most
extensively used vectors for vaccines because of several advantages:
infectious to various cell types, efficient transgene expression, high
<italic>in vitro</italic> growth, lack of genome integration,
and genetic stability.<sup><xref ref-type="bibr" rid="ref21">21</xref></sup> For instance, Johnson
&#x00026; Johnson (J &#x00026; J) deployed the Ad26 vector to deliver gene
encoding surface proteins of the SARS-CoV-2, and CanSino Biological
used the Ad5 vector.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The spike (S) glycoprotein
of SARS-CoV-2 was cloned with the tissue plasminogen activator signal
peptide gene in the early region 1 (E1) and early region 3 (E3)
deleted Ad5 vector. The E1 and E3 deletions render the Ad5 vector
nonreplicating. Even though rapid humoral and T cell responses were
induced by the vaccine, pre-existing anti-Ad5 immunity partially
diminished the immune responses among healthy adults.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> To address the pre-existing immunity to Ad,
chimpanzee Ad (ChAdOX1) represents an alternative solution that
provided broad protective immunity against the Middle East Respiratory
Syndrome Coronavirus (MERS-CoV).<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> An
investigational vaccine for SARS-CoV-2 from the University of Oxford
is based on this vector.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> Their preclinical study
showed the prevention of SARS-CoV-2 pneumonia in rhesus macaques with
no evidence of subsequent immune-enhanced diseases.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> However, viral loads were more significantly reduced in the lower
respiratory tract but not in the nasal swabs. In general, because of
previous vaccine programs, the manufacturing capacity and protocols
for this method are already well-established; therefore, less effort
may be needed to shift toward the large-scale production of
vector-based vaccines. However, both the pre-existing immunity toward
certain vectors and previously demonstrated safety concerns over the
increased risk of human immunodeficient virus type 1 (HIV-1)
acquisition should be carefully evaluated.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup></p></sec><sec id="sec2.3"><title>Nucleic Acid-Based Vaccines</title><p>DNA- and mRNA-based vaccines have the greatest potential for rapid
development because of their synthetic nature that circumvents the
need for cell culture or fermentation of viruses. The synthetic nature
of this method also results in a high safety profile and rapid
manufacturing ability.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> However, this method
generally requires further delivery formulations or better delivery
devices to boost vaccine efficacy.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In contrast to
RNA, the increased stability of DNA decreases the need for frozen
storage and low-temperature transportation.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> One
of the forerunners among COVID-19 vaccines is DNA-based
(Inovio).<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Similar DNA-based vaccines have
had promising results for the prevention of MERS.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup>
In the discovery phase of DNA-based vaccines, strategies such as
codon/RNA optimization and the addition of highly efficient
immunoglobulin leader sequences are needed to enhance the magnitude
and breadth of the immune response.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> For instance,
Muthumani <italic>et al</italic>. designed a consensus DNA sequence
for the S protein by analyzing S protein sequences, where sequences
from clades A and B can be both involved.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> To
enhance the <italic>in vivo</italic> expression, the immunoglobulin E
(IgE) leader sequence was added to the immunogen sequence. The insert
was further incorporated into the pVax1 vector, which allowed a
high-level transient expression of proteins of interest in mammalian
cells.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> The strategies of adding the IgE
leader sequence and the use of the pVax1 vector could be quickly
adapted to the different virus sequences as well.</p><p>Due to their high potency, rapid development, and low cost for
manufacturing, mRNA vaccines have emerged as a promising alternative
vaccination development strategy for various infectious diseases and
cancers.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> No mRNA-based vaccine is currently
FDA-approved. Several strategies have been proposed to solve the
common drawbacks of mRNA-based vaccines, which include mRNA
instability and high innate immunogenicity.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup> The
5&#x02032; and 3&#x02032; UTR of mRNA has significant regulatory
influences on both stability and translatability.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup>
Half-life and expression can be enhanced when these sequences come
from viral genes: A 5&#x02032; cap is essential for efficient protein
expression, and a poly(A) tail affects mRNA translation and
stability.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup> Furthermore, the replacement of
rare codons with frequently used synonymous codons also enhances
protein expression.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup> Additional optimization
strategies include increasing G:C content and introducing modified
nucleosides.<sup><xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> In spite of the innate
immunostimulatory effect of exogenous or unpurified mRNA, further
investigations are required to assess the advantages of their use for
vaccines specifically.<sup><xref ref-type="bibr" rid="ref33">33</xref></sup> Innate immune sensing
mechanisms of mRNA have resulted in the inhibition of antigen
expression and a decreased immune response.<sup><xref ref-type="bibr" rid="ref34">34</xref></sup>
Therefore, further formulations for vaccine delivery could potentially
reduce innate mRNA-associated immunogenicity and favor immune
activation.</p></sec><sec id="sec2.4"><title>Subunit Protein/Peptide Vaccines</title><p>Unlike nucleic acid-based vaccines, which produce viral protein after
administration, the direct application of viral protein antigens may
be a more straightforward method to trigger immunity. This approach
currently represents the largest category of COVID-19 vaccines under
preclinical investigation.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> Full-length proteins are
advantageous because they can induce the development of antibodies
against multiple epitopes. Importantly, there is a higher probability
that the developed antibodies could bind to the native conformation of
the viral protein. However, this also increases the chance of inducing
nonspecific cross-reactive antibodies.<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> In
addition to the high cost of recombinant protein technologies, the
recombinant protein products may not fully match all the molecular
features of the corresponding viral proteins, which may lead to
ineffective induction of broad neutralizing antibodies (bNAb).<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> Optimizing peptide sequences in the discovery
phase can improve the stabilization of epitopes associated with bNAb
while reducing the antigenicity of non-NAb epitopes.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p><p>Given that only specific amino acid sequences of the full-length protein
antigens are responsible for effective immune responses, minimally
immunogenic peptides, mimicking B and T cell epitopes, have been
proposed for vaccines.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> Early approaches used
short peptide sequences (8&#x02013;10 amino acids) that could
potentially be presented by major histocompatibility complex (MHC) I
molecules. Importantly, the memory immune response of cytotoxic T
cells could not be efficiently induced with such T cell
epitope-mimicking peptides.<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> One proposed
rationale is that <italic>in vivo</italic> direct loading of short
peptides occurs for all cells expressing MHC molecules, including T
and B cells. Unlike DCs, they are incapable of generating an effective
immune response.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> These early findings benefitted
the design of synthetic long peptide (SLP) vaccines where both helper
T cells (T<sub>H</sub>) peptides and toll-like receptor (TLR) ligand
or peptides could be hybridized to enhance the immune response. For
example, Jackson <italic>et al</italic>. demonstrated one single SLP
vaccine that can target TLR 2 can serve as self-adjuvant and contain
both MHC I- and II-specific peptides (T cell epitopes).<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> SLPs cannot directly bind with MHC I and have to
be internalized by DCs for further presentation. Furthermore,
<italic>in silico</italic> computer-based approaches can be used
to benefit the discovery of peptide vaccines by enabling quicker
screening and more accurate predictions of peptide sequences with high
immunogenicity and binding affinities to MHC I and II
molecules.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> These approaches have been used
to accelerate the development pipeline of vaccines, and particularly
for emerging viral diseases such as COVID-19. These computational
approaches can predict the binding affinity of specific peptides
sequences to either MHC I and II molecules or B cell
receptors/antibodies. In this regard, theoretical B and T cell
epitopes specific to SARS-CoV-2 were synthesized to generate a
multiepitope protein.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> The antigenicity,
allergenicity, physiochemical parameter, and secondary and tertiary
structures of these multiepitope proteins were determined <italic>in
silico</italic>. However, the processing in the
endosomal/lysosomal compartments of the designed multiepitope
SARS-CoV-2 antigens remains to be addressed.</p></sec><sec id="sec2.5"><title>Cell-Based Vaccines</title><p>DCs are the most potent antigen-presenting cells (APCs) at the interface
of innate and adaptive immunity to sense the &#x0201c;danger
signals&#x0201d;, process the antigens, and present the
nonself-antigens.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Unlike other types of
vaccines, DC vaccines are manipulated <italic>ex vivo</italic> to be
antigen-specific, and thus they are ready to initiate immune responses
after being reinfused <italic>in vivo</italic>. The DC vaccine is
quality controllable and natively able to traffic efficiently
<italic>in vivo</italic>. Different methodologies have been
developed to produce modified DC vaccines <italic>ex vivo</italic>,
including loading DCs with immunogenic peptides or proteins (subunit
DCs), viral transduction to express immunogenic peptides,<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> or using mRNA-based DCs.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup>
Different strategies may produce DC vaccines with different potency,
for instance, genetically modified DCs may be more efficacious in
immune activation than subunit DC vaccines.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> In
addition, supplementary immunomodulatory genes could be incorporated
to enhance the potency. However, the process of producing cell-based
vaccines is labor-intensive and expensive.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Thus,
this method could be the most challenging to be scaled up as a
universal vaccine for a global pandemic.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup></p></sec></sec><sec id="sec3"><title>Vaccine Formulations</title><sec id="sec3.1"><title>Action Mechanisms</title><p>Vaccines are commonly administered intramuscularly, making it less
efficient in interacting with the abundant immune cells present within
the skin. Alternative strategies, including oral or intranasal
deliveries, are also widely studied because of their ease of
use.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The effectiveness of alternative
strategies is based on mucosal immunity.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup>
Nonetheless, different strategies rely on the activation of the
adaptive immune system, which involves the interactions between T
cells and APCs (DCs and B cells).<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> As shown in
<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a, APCs can
internalize exogenous antigens and process them into antigenic peptide
fragments. The peptide fragments can subsequently be loaded onto the
MHC II molecules and displayed on the surface of the
APCs.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> CD4<sup>+</sup> helper T
cells could recognize peptides presented by MHC class II through T
cell receptors (TCRs), which could induce the production of cytokines,
such as IL-2, that are essential to the normal function of immune
cells.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> B cells can directly capture
antigens through B-cell receptors (BCRs). The antigens can be
internalized and subsequently processed into antigenic peptides for
presentation by MHC class II to CD4<sup>+</sup> helper T cells. This
process is required for the clonal expansion and differentiation of B
cells into IgG antibody-secreting plasma cells and memory B cells,
which is classified as humoral immunity.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup>
Generally, only endogenous antigens could be degraded into peptides
and loaded onto MHC class I molecules for presentation to
CD8<sup>+</sup> T cells.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Cross-presentation
is the ability of certain APCs to uptake, process, and present
extracellular antigens in an MHC class I-dependent manner to
CD8<sup>+</sup> T cells. Cross-presentation can be achieved by
several cell types, including DCs (the primary cell type),
neutrophils, macrophages, and endothelial cells.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>
The MHC class I presented peptide fragments can activate
CD8<sup>+</sup> cytotoxic T cells through TCR recognition.
Antigen-specific CD8<sup>+</sup> cytotoxic T cells can then recognize
these peptide fragments presented by target cells and kill them, which
refers to cellular immunity.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> Lastly, DCs are
also capable of detecting &#x0201c;danger signals&#x0201d;
<italic>via</italic> an array of receptors called pattern
recognition receptors (PRRs). PRRs are capable of recognizing
pathogenic molecules as part of the innate immunity for a response to
virus infection by identifying pathogen-associated molecular patterns
(PAMPs) from viruses or microbes. The understanding of innate immunity
could benefit the development of adjuvants to enhance the immune
response further. Together, the understanding of the action mechanisms
facilitates the design of vaccine formulations to boost their
efficacy.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup></p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Action mechanisms of vaccine formulations. (a) Vaccines
generate humoral and cellular immunity within lymph nodes
(LNs): I. DCs can process the antigens and present the
peptide fragments <italic>via</italic> both MHC class I
and class II molecules. II. B cells can directly recognize
the antigens <italic>via</italic> BCRs and present the
antigenic peptide fragments by MHC class II to helper T
cells (CD4<sup>+</sup>). Stimulated B cells can
subsequently initiate a humoral immune response. III.
Cytotoxic T cells (CD8<sup>+</sup>) can recognize the
antigenic peptide fragments presented by MHC class I
through TCRs and trigger the cellular immune
response.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> (b)
Intracellular response of DCs to antigen presentation for
different types of vaccines through PRRs. I. Vaccine
formulations can be effectively internalized by cells,
followed by II. Endosomal release. Before III. MHC loading
of antigen peptide, peptide vaccine undergoes enzymatic
processing, DNA vaccine undergoes transcription and
translation, and mRNA vaccine undergoes
translation.<sup><xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref37">37</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0003" id="gr3" position="float"/></fig></sec><sec id="sec3.2"><title>Requirement of Formulations</title><p>Based on the current understanding of eliciting optimal immune responses,
materials-based nanoengineering approaches could improve the efficacy
of vaccines. In this regard, different methodologies could be applied
based on different types of vaccines, with either distinct or shared
requirements. Virus and viral vector-based vaccines generally do not
require further formulations, and their efficacy and safety profiles
are largely dependent on the purification and inactivation strategies,
the optimization of culturing of viral particles, and the choice of
vectors.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> They have efficient innate
advantages in delivery due to their small sizes, and they are easily
recognized by the immune system. Although inactivated or weakened
virus-based vaccines still make up most of the effective vaccines
today, they are not effective for all pathogens.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup>
Similarly, the potency of DC vaccines is mostly dependent on how DCs
are manipulated <italic>ex vivo</italic>. Strategies in further
potentiating cell-based immunotherapies, such as the decoration with
nanoparticles (NPs),<sup><xref ref-type="bibr" rid="ref48">48</xref></sup> are mainly developed for
cancer immunotherapies, but they may be less suitable for large-scale
manufacturing that is needed for the production of antiviral
vaccines.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>List of the Representative Formulations Used for
Vaccines</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col/><col/><col/><col/><col/></colgroup><thead><tr><th style="border:none;" align="center">materials</th><th style="border:none;" align="center">formulations</th><th style="border:none;" align="center">cargos (vaccine
types)</th><th style="border:none;" align="center">functions</th><th style="border:none;" align="center">refs</th></tr></thead><tbody><tr><td rowspan="5" style="border:none;" valign="middle">lipids</td><td style="border:none;">ionizable lipid</td><td style="border:none;">mRNA (glycoprotein 100 (gp100) and
tyrosinase-related protein 2 (TRP 2)) and
adjuvants lipopolysaccharide (LPS)</td><td style="border:none;">stabilization, enhanced cellular
uptake</td><td style="border:none;">(<xref ref-type="bibr" rid="ref54">54</xref>)</td></tr><tr><td style="border:none;">covalently cross-linked lipid
bilayers</td><td style="border:none;">protein/adjuvants (Monophosphoryl lipid A
(MPLA))</td><td style="border:none;">stabilization, sustained delivery,
co-delivery</td><td style="border:none;">(<xref ref-type="bibr" rid="ref55">55</xref>)</td></tr><tr><td style="border:none;">net negative charged formulations by tuning
cationic lipids and mRNA ratio</td><td style="border:none;">mRNA (influenza virus hemagglutinin (HA)
and OVA)</td><td style="border:none;">LN targeting, stabilization</td><td style="border:none;">(<xref ref-type="bibr" rid="ref56">56</xref>)</td></tr><tr><td style="border:none;">nanodiscs <italic>via</italic> sHDL</td><td style="border:none;">peptide neoantigens/adjuvants (CpG); dual
adjuvants (CpG and MPLA)</td><td style="border:none;">co-delivery, enhanced uptake</td><td style="border:none;">(<xref ref-type="bibr" rid="ref57">57</xref>, <xref ref-type="bibr" rid="ref58">58</xref>)</td></tr><tr><td style="border:none;">lipids with cyclic amino headgroup</td><td style="border:none;">mRNA (OVA and E7)</td><td style="border:none;">immunostimulatory function</td><td style="border:none;">(<xref ref-type="bibr" rid="ref59">59</xref>)</td></tr><tr><td rowspan="10" style="border:none;" valign="middle">polymers</td><td style="border:none;">modified dendrimer</td><td style="border:none;">mRNA (H1N1 influenza, Ebola viruses, and
<italic>Toxoplasma gondii</italic>
parasite)</td><td style="border:none;">enhanced loading, cellular uptake, and
endosomal release</td><td style="border:none;">(<xref ref-type="bibr" rid="ref60">60</xref>)</td></tr><tr><td style="border:none;">stearic acid conjugated low MW PEI</td><td style="border:none;">peptide (TRP 2) and mRNA (HIV-1)</td><td style="border:none;">lowered charge density, higher
biocompatibility</td><td style="border:none;">(<xref ref-type="bibr" rid="ref61">61</xref>, <xref ref-type="bibr" rid="ref62">62</xref>)</td></tr><tr><td style="border:none;">cyclodextrin conjugated PEI</td><td style="border:none;">mRNA (HIV)</td><td style="border:none;">lowered charge density, higher
biocompatibility</td><td style="border:none;">(<xref ref-type="bibr" rid="ref63">63</xref>)</td></tr><tr><td style="border:none;">PLGA NPs</td><td style="border:none;">protein (OVA)</td><td style="border:none;">controlled antigen release</td><td style="border:none;">(<xref ref-type="bibr" rid="ref64">64</xref>)</td></tr><tr><td style="border:none;">PEI/chitosan/poly lysine coated
PLGA/PLA</td><td style="border:none;">protein (HBV surface antigen)</td><td style="border:none;">enhanced loading and cellular uptake,
intrinsic immunostimulatory function</td><td style="border:none;">(<xref ref-type="bibr" rid="ref65">65</xref>&#x02212;<xref ref-type="bibr" rid="ref67">67</xref>)</td></tr><tr><td style="border:none;">PBAE and PLGA</td><td style="border:none;">plasmid DNA (Luciferase)</td><td style="border:none;">enhanced loading and lower
cytotoxicity</td><td style="border:none;">(<xref ref-type="bibr" rid="ref68">68</xref>)</td></tr><tr><td style="border:none;">ionizable amino polyester</td><td style="border:none;">mRNA (luciferase)</td><td style="border:none;">spleen targeting</td><td style="border:none;">(<xref ref-type="bibr" rid="ref69">69</xref>)</td></tr><tr><td style="border:none;">oligopeptide-modified PBAE</td><td style="border:none;">mRNA (enhanced green fluorescent
protein)</td><td style="border:none;">APC targeting</td><td style="border:none;">(<xref ref-type="bibr" rid="ref70">70</xref>)</td></tr><tr><td style="border:none;">albumin and albumin-binding lipids</td><td style="border:none;">peptide (OVA) /adjuvant (CpG)</td><td style="border:none;">LN targeting</td><td style="border:none;">(<xref ref-type="bibr" rid="ref71">71</xref>)</td></tr><tr><td style="border:none;">polysaccharide from microbial cell wall and
PEI</td><td style="border:none;">mRNA (OVA)</td><td style="border:none;">immunostimulatory, enhanced loading and
endosomal release</td><td style="border:none;">(<xref ref-type="bibr" rid="ref72">72</xref>)</td></tr><tr><td rowspan="7" style="border:none;" valign="middle">inorganic
particles</td><td style="border:none;">aluminum hydroxide</td><td style="border:none;">phosphoserine conjugated protein antigen
(HIV trimer)</td><td style="border:none;">immunostimulatory, sustained
release</td><td style="border:none;">(<xref ref-type="bibr" rid="ref73">73</xref>)</td></tr><tr><td style="border:none;">chemically functionalized Au NPs with
hydrophobicity</td><td style="border:none;">&#x02013;</td><td style="border:none;">intrinsic immunostimulatory
function</td><td style="border:none;">(<xref ref-type="bibr" rid="ref74">74</xref>)</td></tr><tr><td style="border:none;">aspect ratio optimized and surface modified
Au NRs</td><td style="border:none;">plasmid DNA (HIV-1)</td><td style="border:none;">enhanced cellular uptake, intrinsic
immunostimulatory function</td><td style="border:none;">(<xref ref-type="bibr" rid="ref75">75</xref>, <xref ref-type="bibr" rid="ref76">76</xref>)</td></tr><tr><td style="border:none;">sized optimized Au NPs</td><td style="border:none;">peptide (OVA) and adjuvant (CpG)</td><td style="border:none;">enhanced DC activation</td><td style="border:none;">(<xref ref-type="bibr" rid="ref77">77</xref>)</td></tr><tr><td style="border:none;">mesoporous Si NPs</td><td style="border:none;">adjuvant; protein (E2 of diarrhea
virus)</td><td style="border:none;">intrinsic immunostimulatory
function</td><td style="border:none;">(<xref ref-type="bibr" rid="ref78">78</xref>, <xref ref-type="bibr" rid="ref79">79</xref>)</td></tr><tr><td style="border:none;">antigen density tunable/Size controllable
QDs</td><td style="border:none;">peptide (self-antigen from multiple
sclerosis)</td><td style="border:none;">LN homing and higher density of antigens
leads to more effective tolerance, intrinsic
antiviral effects</td><td style="border:none;">(<xref ref-type="bibr" rid="ref80">80</xref>, <xref ref-type="bibr" rid="ref81">81</xref>)</td></tr><tr><td style="border:none;">oxidized multiwalled CNTs</td><td style="border:none;">protein (NY-ESO-1) and adjuvant
(CpG)</td><td style="border:none;">co-delivery, enhanced uptake</td><td style="border:none;">(<xref ref-type="bibr" rid="ref82">82</xref>)</td></tr></tbody></table></table-wrap><p>In contrast, synthetic vaccines (nucleic acid-based and
protein/peptide-based ones) generally require additional formulation
designs for optimal efficacy.<sup><xref ref-type="bibr" rid="ref49">49</xref></sup> These synthetic
molecules all have essential secondary or higher-order structures that
could be disrupted in physiological conditions.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup>
Various endogenous enzymes (such as nuclease or protease) can digest
these synthetic molecules before reaching immunocompetent cells, such
as APCs, or immunocompetent sites, such as secondary lymphoid
organs.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Furthermore, physiochemical
features of these synthetic molecules may pose challenges for cells to
efficiently uptake and process them. For instance, DNA and mRNA are
too large to directly diffuse across the cellular membrane and their
dense negative charge repels them from cell membranes, which further
prevents efficient cellular uptake.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> Even after
penetrating the membrane, the vaccine formulations need to reach the
endosomal compartments either to be processed into peptides
(protein/peptide-based vaccines), released for further transcription
(DNA-based vaccines), or translation (mRNA-based vaccines). The
resulting peptide fragments can be further loaded onto MHC molecules
and exported to the membrane surface for antigen presentation to T
cells (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b).<sup><xref ref-type="bibr" rid="ref50">50</xref></sup></p><p>We refer vaccine formulations to engineering approaches that could
facilitate the <italic>in vivo</italic> delivery of vaccines and
enhance immune responses.<sup><xref ref-type="bibr" rid="ref51">51</xref></sup> We categorize the
vaccine formulations in terms of commonly used materials: lipids,
polymeric materials, and inorganic particles (<xref rid="fig4" ref-type="fig">Figure
<xref rid="fig4" ref-type="fig">4</xref></xref>). Commonly pursued feature goals
include protection of cargo, improving loading capacity, and enhancing
cellular uptake (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>a).<sup><xref ref-type="bibr" rid="ref52">52</xref></sup> In addition, the ideal
microenvironment for initiating and amplifying immune responses is
secondary lymphoid organs where APCs, T cells, and B cells are in
close proximity for cell-to-cell interactions. Therefore, targeting DC
or LN can be one type of approach to pursue (<xref rid="fig4" ref-type="fig">Figure
<xref rid="fig4" ref-type="fig">4</xref></xref>b).<sup><xref ref-type="bibr" rid="ref53">53</xref></sup> To
further boost immune responses, immunostimulatory components or
adjuvants are usually required, and coformulation approaches have been
widely explored for developing immunostimulatory vaccine formulations
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>c). Relevant
studies have been summarized in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Materials-based vaccine formulations for important
immunological functions. (a) Vaccine formulations that
protect the active &#x0201c;cargo&#x0201d; and enhance
cellular uptake may be based on lipids, polymeric
materials, and/or inorganic particles. (b) Vaccine
formulations that allow LN targeting by forming extra
small-sized albumin-based vaccine complexes, tuning the
net charge to be negative and incorporating targeting
ligands. (c) Vaccine formulations that promote
immunostimulatory effects by using microbial wall-derived
polysaccharides as nanocarriers, co-delivering adjuvants
with peptide antigens, and exploring innate
immunostimulatory lipids.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0004" id="gr4" position="float"/></fig></sec><sec id="sec3.3"><title>Lipids</title><p>Lipid molecules are suitable for vaccine formulations because of their
high safety profile and tunable physiochemical
features.<sup><xref ref-type="bibr" rid="ref55">55</xref>,<xref ref-type="bibr" rid="ref59">59</xref></sup> These advantages also make
them the leading platform in developing vaccines quickly. Currently,
there are two mRNA vaccine forerunners in development for COVID-19
that are based on lipid formulations (Moderna and BioNTech).<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Lipids are a class of amphiphiles that contain
hydrophilic head groups and hydrophobic tails. Interactions between
those molecules can drive the formation of spherical vesicles to
encapsulate vaccine formulations either with one (unilamellar) or more
(multilamellar) lipids bilayers.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Lipid molecules
have also been explored to achieve distinct biological
functions.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> For instance, cationic lipids
are commonly used for efficient cellular uptake and increase the
loading of negatively charged mRNA and DNA.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup>
DOTMA, DOTAP, and DOPE are common examples.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup>
However, cationic lipids are commonly associated with high toxicity
and neutralization by anionic serum proteins, which reduce the
delivery efficacy.<sup><xref ref-type="bibr" rid="ref83">83</xref></sup> Therefore, ionizable lipids
that can change their charge state at different pH conditions can be
utilized to maintain efficacy, to reduce toxicity, and to facilitate
the endosomal release of cargos.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup> Some common
strategies to improve the efficacy of LNPs include enhancing cellular
uptake and promoting endosomal escape by incorporating cholesterol,
polyethylene glycol (PEG) lipids, or helper lipids DOPE.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> Hydrophobic cholesterol can fill the gaps between
lipid tails to stabilize the vesicle. PEG lipids can shield the
vesicles and protect them from clearance when systemically
delivered.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> Helper lipids have unsaturated
bonds to form an unstable hexagonal lamellar phase that enhances the
endosomal escape.<sup><xref ref-type="bibr" rid="ref85">85</xref></sup> In addition, good
biocompatibility of lipids makes it possible for expedited FDA
approvals.<sup><xref ref-type="bibr" rid="ref86">86</xref></sup> Therefore, LNPs can be optimized
in vaccine formulations to stabilize and enhance uptake of cargo, to
improve immunostimulatory functions for antigens, and for targeted
delivery. Oberli <italic>et al</italic>. utilized an ionizable lipid,
a phospholipid, cholesterol, and a PEG anchored lipid as LNP
formulations for mRNA vaccine delivery, which resulted in stable
nanoformulations, efficient antigen presentation, and elicitation of a
strong T cell response.<sup><xref ref-type="bibr" rid="ref54">54</xref></sup> However, the <italic>in
vivo</italic> potency of LNP-based vaccines could be limited by
their suboptimal physiological stability, which can cause the fast
release of antigens before initiating any immune response. Moon
<italic>et al</italic>. developed a hyperstabilized lipid-based
vaccine formulation by covalently cross-linking two lipid molecule
layers between their head groups using a mild chemical condition that
is compatible with loaded antigens.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> The resulting
vesicles are stabilized multilamellar structures that could trap high
levels of protein antigens. Combined with PEGylation as a
well-established stabilization strategy, the hyperstabilized NPs can
sustain the release of antigens up to 30 days in the presence of
serum, which significantly enhanced the humoral immune
response.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> By adding the lipid-like
monophosphoryl lipid A (MPLA) as adjuvants, the vaccine formulation
can further enhance T cell-mediated humoral responses.</p><p>In addition, LNPs formulations can be optimized for LN targeting, thereby
enhancing the immune response <italic>in situ</italic>. One notable
study by Kranz <italic>et al</italic>. demonstrated that a designed
mRNA-lipoplexes (RNA-LPX) could target DCs <italic>in vivo</italic>
simply by using lipid molecules.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> They established
a library of RNA lipoplexes by tuning the lipid to RNA ratios.
Cationic lipids DOTMA or DOTAP and the helper lipid DOPE or
cholesterol were used. The charge ratio, size, &#x003b6; potential,
colloidal properties, and RNA stability also varied with the shifting
of lipid to RNA ratios. Interestingly and unexpectedly, all negatively
charged particles displayed selective targeting to the spleen. The
negatively charged formulation (1.3:2 lipid:RNA) displayed effective
targeting of DCs and formed monodisperse NPs (&#x0223c;300 nm) that
protected encapsulated mRNA. The authors demonstrated the <italic>in
vivo</italic> efficacy using RNA-LPX encoding for the influenza
virus hemagglutinin (HA), where DCs, NK, B, and T cells were activated
by a single intravenous injection of HA-LPX. They also observed an
enhanced IFN-&#x003b1; production by vaccination, which is a typical
hallmark of APCs sensing for antiviral environment development induced
by RNA virus infections through TLR3 and TLR7.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup></p><p>To enhance immunostimulatory effects, a common strategy is to co-deliver
adjuvants to stimulate immune responses. Kuai <italic>et al</italic>.
designed an antigen and adjuvant co-delivery nanodisc platform based
on synthetic high-density lipoprotein (sHDL).<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> One
of the striking features of the nanodisc is its extra-small size:
&#x0223c;10 nm in diameter, which contributed to the enhanced
trafficking to LNs.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> Exploiting the endogenous
role of HDL as a cholesterol carrier, adjuvant CpG was modified with
cholesterol to efficiently insert into preformed nanodiscs. This
strategy also allowed the co-loading of more than one adjuvant, which
promoted a synergistic immune activation.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup>
Together, these features contributed to the sustained antigen
presentation by DCs. Recently, there is a growing interest in
exploring innate immunostimulatory functions of lipid molecules. To
expand the diversity of lipid molecules, Miao <italic>et al</italic>.
developed a library of lipids through a one-step three-component
reaction that included amines, isocyanides, and alkyl ketones.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> This strategy significantly increased the
diversity of synthesized lipids compared to traditional two-component
reactions.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup> They showed that the
immunostimulatory effect of lipids was dependent on the head groups.
The identified lipids with cyclic amino head groups displayed immune
cell activation efficacy through the intracellular stimulator of
interferon genes (STING) pathway. The lipids could be further
formulated with mRNA to form LNPs as mRNA vaccine formulations to
efficiently deliver the oligonucleotide products. Another advantage is
that the formulation could activate the mRNA-independent intracellular
STING pathway rather than TLRs, which could reduce systemic toxicity.
In addition, inhibition of the antigen expression related to the TLRs
binding by exogenous mRNA was prevented to favor an optimal immune
response.<sup><xref ref-type="bibr" rid="ref27">27</xref></sup></p></sec><sec id="sec3.4"><title>Polymers</title><p>Aside from the lipids system, polymers have been widely explored for the
delivery of different vaccine candidates. Specifically, cationic and
ionizable polymers are promising in nucleic acid-based vaccine
formulations. Positively charged polymers can condense nucleic acids
as nanocomplexes for efficient cellular uptake and endosomal release.
In addition, early studies showed that cationic materials tend to
induce an inflammatory response.<sup><xref ref-type="bibr" rid="ref90">90</xref></sup> One commonly
applied polymer category is polyamines, such as polyethylene imine
(PEI) and its derivatives.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Chahal <italic>et
al</italic>. utilized modified dendrimer for antigen-encoding
mRNA replicon complexation to form monodisperse NPs.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> This delivery system, with self-amplifying mRNA,
enabled immunization in mice, which protected them from various virus
challenges, including H1N1 influenza, Ebola virus, and the
<italic>Toxoplasma gondii</italic> parasite.<sup><xref ref-type="bibr" rid="ref60">60</xref></sup> However, their high molecular weight (MW) and branched polymer
structure (needed to allow a massive loading of vaccine therapeutics)
also lead to severe cytotoxicity, which limits wider
applications.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup> Zhao <italic>et al</italic>.
developed a low MW PEI with modifications (stearic acid and 2 kDa PEI
conjugates) to form self-assembled micelles for delivering mRNA
encoding HIV-1 group-specific antigen (gag).<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> Li
<italic>et al</italic>. used 2 kDa PEI conjugated with
cyclodextrin for intranasal delivery of HIV antigen-encoding mRNA that
was able to stimulate HIV-specific immune response.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> Cyclodextrin modification provided mucosal permeation and mitigated
cytotoxicity by lowering the charge density. Other commonly used
polymers include polyester-based, such as
poly(lactic-<italic>co</italic>-glycolic acid) (PLGA) and
poly(lactic acid) (PLA), because of their biocompatibility and
biodegradability.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup> Several studies have
demonstrated the delivery of protein antigens in PLGA NPs with
enhanced immune responses as compared to soluble
formulations.<sup><xref ref-type="bibr" rid="ref94">94</xref>,<xref ref-type="bibr" rid="ref95">95</xref></sup> In addition, such solid
polymer particles can control the kinetics of antigens released from
the polymer core based on different biodegradation
profiles.<sup><xref ref-type="bibr" rid="ref64">64</xref>,<xref ref-type="bibr" rid="ref96">96</xref></sup> However, nonmodified PLGA is
generally negatively charged, and as a result, it has a limited
cellular uptake efficiency and loading of anionic antigens.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> Therefore, various coating or modification
strategies (such as PEI,<sup><xref ref-type="bibr" rid="ref65">65</xref>,<xref ref-type="bibr" rid="ref97">97</xref></sup> chitosan,<sup><xref ref-type="bibr" rid="ref66">66</xref></sup> and poly-<sc>l</sc>-lysine (PLL) coatings) have been demonstrated
to enable the delivery of vaccines and promote interactions with
negatively charged cellular membranes.<sup><xref ref-type="bibr" rid="ref67">67</xref></sup> Notably,
the cationic polymeric delivery carrier itself could induce T helper
cell responses through TLR-4 dependent IL-12
secretion.<sup><xref ref-type="bibr" rid="ref67">67</xref>,<xref ref-type="bibr" rid="ref98">98</xref></sup> Poly(&#x003b2;-amino esters)
(PBAE) is also extensively used in delivering plasmids DNA or mRNA
vaccines because of its nontoxic and biodegradable nature.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup> Fields <italic>et al</italic>. developed NPs
formulations for plasmid DNA delivery by combining PLGA and PBAE to
reconcile the drawbacks from each component: the low DNA loading
efficiency of PLGA and the cytotoxicity of PBAE.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup>
Other polymeric materials have also been explored, such as
polysaccharides<sup><xref ref-type="bibr" rid="ref100">100</xref></sup> and block
copolymers.<sup><xref ref-type="bibr" rid="ref101">101</xref></sup></p><p>In terms of targeted delivery to immune cells, versatility in polymer
chemistry shows great potential in developing tissue-selective
formulations. For instance, a large library of PBAE-based polymers
could be easily synthesized and screened for desirable target
polymers.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> Kowalski <italic>et al</italic>.
designed an ionizable amino polyester (APE) for mRNA delivery through
the ring opening of lactones with amino alcohols.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup>
Tissue-selective delivery was achieved by different APE candidates,
including APCs within the spleen.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> Oligopeptides
have been used to modify PBAE to allow the tuning of the charge status
of NPs.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> Initially, this was done to optimize
cargo loading and mitigate cytotoxicity. Later, Fornaguera <italic>et
al</italic>. demonstrated that specific oligopeptide
modifications lead to APCs targeting within the spleen and exhibited
an efficient transfection of mRNA.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> Inspirations
also come from using native LN trafficking molecules. Clinically,
visualization of sentinel LNs is achieved by injecting dyes that bind
to albumin because of the LN trafficking capability of albumin
particles.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup> Inspired by the endogenous role
of albumin, Liu <italic>et al</italic>. designed a vaccine by
conjugating the adjuvants or antigens to the albumin-binding lipid
tail.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> The vaccines displayed a notable
increased accumulation in the LNs, which decreased the systemic
distribution of the vaccines and prolonged the vaccine
bioavailability. These features limited the systemic toxicity while
increasing the potency of vaccination for OVA antigen, HIV antigen,
and human papillomavirus (HPV) antigen.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup></p><p>Some polymeric delivery carriers have been demonstrated to have
immunostimulatory effects, such as polymers with cationic charge and
hydrophobic domains.<sup><xref ref-type="bibr" rid="ref104">104</xref>,<xref ref-type="bibr" rid="ref105">105</xref></sup> In addition, inspired by
microbes&#x02019; immunostimulatory effect, Son <italic>et al</italic>.
designed sugar capsules that were derived from microbial cell walls
for vaccine NPs coating.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> The coating process was
achieved by using silicate NPs (Si NPs) as a template, followed by its
removal after the mRNA was loaded and the sugar capsules were entirely
coated. Notably, the removal of Si NPs renders relatively flexible
nanostructures that are beneficial for lymphatic drainage and
accumulation.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> The mRNA cargos can be
efficiently loaded by PEI coating due to electrostatic interactions.
The PEI coating was also expected to facilitate the endosomal release
for mRNA translation and antigen presentation. The sugar capsule
itself functioned as a strong DC activator by eliciting the production
of a variety of pro-inflammatory factors, including IL-6, TNF-&#x003b1;,
and IL-12 p40, without the use of exogenous adjuvants.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup></p></sec><sec id="sec3.5"><title>Inorganic Particles</title><p>Inorganic materials have been used in vaccine formulations for a long
time. Back in 1926, an aluminum compound (alum) was discovered to be
able to precipitate the toxoid to enhance the immunogenicity.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> Alum is still the most widely used adjuvant
today. In spite of over 80 years of development, the underlying
mechanisms for alum as an adjuvant are still controversial.<sup><xref ref-type="bibr" rid="ref107">107</xref></sup> Popular explanations include the &#x0201c;depot
theory&#x0201d; for extended antigen release<sup><xref ref-type="bibr" rid="ref106">106</xref></sup> and
enhanced uptake by APCs through antigen absorption on alum.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> Various immunity signaling and activation
pathways have also been identified to contribute to the function of
the adjuvants.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> Recently, Moyer <italic>et
al</italic>. utilized the interaction between alum and
phosphoserine (pSer) to engineer a short peptide-immunogen conjugate
to significantly prolong the immunogen release from
pSer-immunogen:alum complexes.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> The complexes
could form NPs for efficient trafficking to LNs and initiated antigen
processing and presentation by APCs.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup>
Site-specific pSer modification on the base of the HIV trimer could
enable the immunogen (HIV trimer) to be displayed with a specific
orientation, which could prevent the induction of undesired
NAbs.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup> Apart from alum, other inorganic
materials have been proposed that may stimulate vaccine-specific
immune responses, such as silica crystal<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> and
calcium phosphate.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup></p><p>In addition to the traditional use as immunostimulatory adjuvants, a wide
range of biocompatible inorganic particles have also been developed as
vaccine formulations,<sup><xref ref-type="bibr" rid="ref111">111</xref></sup> including quantum dots
(QDs),<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> gold nanoparticles (Au NPs),<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> carbon nanotubes (CNTs),<sup><xref ref-type="bibr" rid="ref82">82</xref></sup> and
Si NPs.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> The physical properties of formulations,
such as surface charge, hydrophobicity, and aspect ratios, are closely
associated with the efficacy of vaccines.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup>
Inorganic materials have a high degree of tunability to allow them to
fulfill the requirements of vaccine formulations. Easy preparation and
good storage stability are additional advantages of inorganic
particles.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup> For example, Au NPs have been
chemically functionalized to investigate the relationship between
surface hydrophobicity and the associated immune activity.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> It is also expected that other functional groups
may bring a pathway-dependent immune activation that is specifically
desirable for antiviral defense. Xu <italic>et al</italic>. described
surface-engineered Au nanorods (NRs) for plasmid DNA vaccine
delivery.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> With certain surface
modifications and aspect ratios, cellular toxicity of Au NRs can be
lowered, internalization can be enhanced, and intrinsic adjuvant
features can be utilized.<sup><xref ref-type="bibr" rid="ref76">76</xref></sup><italic>In vivo</italic> vaccination with HIV-1 envelope glycoprotein
(Env) plasmids demonstrated enhanced cellular and humoral
immunity.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> Zhou <italic>et al</italic>.
synthesized a series of Au NPs (15 to 80 nm) for co-delivery of
antigens (OVA peptides) and adjuvants (CpG) by surface
conjugation.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> Particles of 60 and 80 nm
outperformed other sizes (15, 30, and 40 nm) in activating DCs; this
was most likely due to a higher payload of antigens. Notably, they
promoted DC homing to the LNs and induced potent cellular immune
response.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup> High tunability is also
achievable in other organic particles, such as adjuvant-based
mesoporous Si NPs,<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> mesoporous Si NP-based
antigen/adjuvant co-delivery systems,<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> antigen
density tunable QDs,<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> size-controlled antiviral
QDs,<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> and surface oxidized
antigen/adjuvant-based multiwall CNTs.<sup><xref ref-type="bibr" rid="ref82">82</xref></sup></p></sec></sec><sec id="sec4"><title>Vaccine Delivery Devices</title><p>If the vaccine formulations are considered as utilizing nanoscale engineering,
then vaccine delivery devices utilize micro/macroscale engineering to
improve vaccine efficiency and efficacy. Beyond the optimization of the
vaccine itself and designing appropriate delivery carriers, the efficacy of
a vaccine also depends on pharmacokinetics (PK) of the antigens after
administration.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup> When the body is exposed to an
exogenous antigen, both humoral and cellular immune responses are initiated
to neutralize it, which also leads to immunological memory.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> During a virus infection, the replication process
typically takes one to several weeks to sustainably stimulate the immune
system with a continuous supplement of antigens.<sup><xref ref-type="bibr" rid="ref115">115</xref></sup> In
contrast, typical vaccines show a rapid clearance and can only be detected
in LNs within days.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup> Although still poorly understood,
the PK of a vaccine, which refers to the dynamics of the antigens presence
during immunization, has a profound impact on immune response.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> One study indicated that increasing the dosage of
vaccines over 2 weeks at both priming and boost stages induced a durable
immune response and increased antibody production compared to traditional
bolus immunization.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> Also, computational models
suggested that antigens can be better captured in germinal centers (GCs) if
antigen availability is extended.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup> In addition to the
advantages of extended antigen availability, traditional vaccination
strategies often fail to yield the desired optimized immune responses in a
single dose. Furthermore, vaccine regimes are often designed to be multiple
shots, thus achieving an even longer immune protection by rechallenging the
immune system with the same antigens in secondary &#x0201c;boosting&#x0201d;
shots administered after the primary shots.<sup><xref ref-type="bibr" rid="ref117">117</xref></sup> Therefore,
vaccine delivery devices have been widely investigated, to develop
single-dose vaccines, minimal invasively administered vaccines, and
self-administrable vaccines (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>a,b). However, its potential can only be realized if various
design principles are met (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Summary of Typical Designs, Advantages, and Limitations of
Different Vaccine Delivery Devices</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col/><col/><col/><col/><col/><col/></colgroup><thead><tr><th style="border:none;" align="center">delivery devices</th><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">designs</th><th style="border:none;" align="center">advantages</th><th style="border:none;" align="center">limitations</th><th style="border:none;" align="center">refs</th></tr></thead><tbody><tr><td rowspan="3" style="border:none;" valign="middle">MNs vaccine
(minimally invasive; minimal requirement on
medical professionals and medical
equipment)</td><td style="border:none;">fast-dissolving MNs</td><td style="border:none;">fast-dissolving polymers as MNs
matrix</td><td style="border:none;">fast and enhanced transdermal delivery; could
be cold-chain free</td><td style="border:none;">multiple administrations; vaccine
formulations may get denatured from MNs
fabrication</td><td style="border:none;">(<xref ref-type="bibr" rid="ref118">118</xref>&#x02212;<xref ref-type="bibr" rid="ref121">121</xref>)</td></tr><tr><td style="border:none;">sustained-release MNs</td><td style="border:none;">controlled biodegradable materials as MNs
matrix</td><td style="border:none;">potential to be single shot; protect the
vaccine formulations in the physiological
environment; could be cold-chain free</td><td style="border:none;">vaccine formulations may get denatured from
MNs fabrication</td><td style="border:none;">(<xref ref-type="bibr" rid="ref122">122</xref>&#x02212;<xref ref-type="bibr" rid="ref124">124</xref>)</td></tr><tr><td style="border:none;">liquid-eluting MNs</td><td style="border:none;">hollow MNs with different
architectures</td><td style="border:none;">compatible with liquid vaccine formulation;
fast and enhanced transdermal delivery</td><td style="border:none;">multiple administrations; requirement of
cold-chain transport</td><td style="border:none;">(<xref ref-type="bibr" rid="ref125">125</xref>)</td></tr><tr><td rowspan="3" style="border:none;" valign="middle">injectable
materials assisted vaccine (potential for
single-shot vaccines to reduce the requirement of
medical resources)</td><td style="border:none;">pulse-released microparticle</td><td style="border:none;">materials with different biodegradation
profiles</td><td style="border:none;">optimal release for a potent immune
responses; release kinetic can be optimized by
materials engineering</td><td style="border:none;">vaccine formulations may get denatured during
the fabrication</td><td style="border:none;">(<xref ref-type="bibr" rid="ref126">126</xref>&#x02212;<xref ref-type="bibr" rid="ref128">128</xref>)</td></tr><tr><td style="border:none;">scaffold vaccine</td><td style="border:none;">solid scaffolds that could tune the release
of different immunomodulatory factors</td><td style="border:none;">continuously modulate the immune response
<italic>in situ</italic></td><td style="border:none;">injectability need to be achieved to avoid
surgical implantation</td><td style="border:none;">(<xref ref-type="bibr" rid="ref129">129</xref>&#x02212;<xref ref-type="bibr" rid="ref134">134</xref>)</td></tr><tr><td style="border:none;">hydrogel vaccine</td><td style="border:none;">biomimicking gellable materials with tunable
biophysical properties and high
cytocompatibility</td><td style="border:none;">compatible with various types of vaccines,
including cell-based vaccines; simple fabrication
process and the water environment help protect the
cargos</td><td style="border:none;"><italic>in situ</italic> gelation may be weak
to achieve sustained release</td><td style="border:none;">(<xref ref-type="bibr" rid="ref135">135</xref>&#x02212;<xref ref-type="bibr" rid="ref143">143</xref>)</td></tr></tbody></table></table-wrap><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Summary and characteristics of various vaccine delivery devices.
(a) Drug delivery devices developed for vaccine administration:
I. Traditional vaccine-containing solutions for bolus injection.
II. Minimally invasive microneedle devices (including
fast-dissolving, sustained-released, and liquid-eluting hollow
microneedles). III. Injectable drug delivery devices (such as
microparticles, solid scaffolds, and hydrogel-based). IV. Other
devices for enhancing vaccine efficacy (such as electroporation
and iontophoresis). (b) Schematic for representative PKs of
vaccine and administration features for different vaccine
delivery devices: I. Traditional bolus injection is invasive and
may require multiple doses. II. Fast dissolving or liquid
eluting MNs can be self-administrable and minimally invasive but
still require multiple doses.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> III.
Sustained released MNs can be both minimally invasive, with only
one dose necessary,<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> while scaffold and gel
vaccines could be injectable to avoid implantation and also only
require one dose. IV. Pulse-released microparticles can mimic a
multiple-dose regimen with only one
injection.<sup><xref ref-type="bibr" rid="ref127">127</xref>,<xref ref-type="bibr" rid="ref128">128</xref></sup> (c)
Schematic of representative mechanisms for vaccine delivery
devices. I. Scaffold vaccines: The scaffold could sustainably
release recruiting factors to home DCs, and encapsulated
antigens could further be processed by DCs <italic>in
situ</italic>.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> II. Gel vaccines:
Hydrogel microenvironment can be engineered to support
encapsulated cell vaccines (such as DC vaccines) by
incorporating cell adhesive peptides and supplementary
factors.<sup><xref ref-type="bibr" rid="ref136">136</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c06109_0005" id="gr5" position="float"/></fig><sec id="sec4.1"><title>Microneedles Vaccines</title><p>Transdermal microneedles (MNs) patches have been proposed as a promising
drug delivery device for immunotherapies<sup><xref ref-type="bibr" rid="ref144">144</xref>&#x02212;<xref ref-type="bibr" rid="ref147">147</xref></sup> based on the minimally invasive nature of MNs
and the highly active immune environment of the skin. Additionally,
since MNs patch-based vaccines can be easily administered without the
need for significant medical training, these vaccines can be easily
deployed both in areas with limited medical resources, such as
developing countries and during times of significant medical crisis,
as seen during an outbreak or pandemic. Early studies include the use
of vaccine-coated metal MNs<sup><xref ref-type="bibr" rid="ref118">118</xref></sup> and fast-dissolving
polymer-based MNs.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> Recently, the dissolving MNs
(carboxymethyl cellulose-based) were used for adjuvants and Ad5-based
vaccine co-delivery in an attempt to address COVID-19.<sup><xref ref-type="bibr" rid="ref147">147</xref></sup> A 1 month storage of MNs vaccine at 4 &#x000b0;C
maintained the immunogenicity of Ad, where no significant loss in
antibody responses was shown in mice studies.<sup><xref ref-type="bibr" rid="ref147">147</xref></sup>
Similar dissolving MNs are also being investigated to deliver the
SARS-CoV-2 subunit spike protein (S1).<sup><xref ref-type="bibr" rid="ref120">120</xref></sup> Potent
virus-specific antibody responses were elicited in mice as early as 2
weeks after the immunization with MNs. The dissolvable MNs for
influenza vaccine have been previously evaluated in a phase I clinical
trial compared to the traditional intramuscular hypodermic injection
of a single-dose vaccine.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> The MN patch was
well-tolerated and immunogenic after a single-dose vaccination. In
addition, self-administration exhibited efficacies comparable to the
administration by medical workers. The dissolving feature leaves no
sharp wastes, and self-administration could significantly relieve the
pressure on medical resources, which could be especially critical in
coping with a pandemic. Beyond these milestones, advances in
microfabrication, materials engineering, and vaccine formulation
optimization have provided additional opportunities to enhance vaccine
efficacies.<sup><xref ref-type="bibr" rid="ref148">148</xref></sup></p><p>Recent advances in microfabrication, such as 3D printing and
stereolithography, can allow for more sophisticated MNs
designs.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> Liquid-based vaccine formulations
are still the most widely used.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> However,
liquid-based vaccine formulations are incompatible with most
solid-based MNs forms. Inspired by the capability of snake-fangs to
efficiently inject venom, Bae <italic>et al</italic>. used an exposure
lithography-based strategy to produce MNs patches with snake-fang
architectures for efficient liquid formulations delivery.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> The design was compatible with most existing
vaccine formulations, and the patch can be applied with the pressure
of the thumb and achieve an efficient transdermal delivery.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> Nevertheless, solid-based vaccines, including
MNs-based ones, also attracted significant attention because of the
decreased cost of vaccine manufacturing, transport, and storage when
compared to the liquid-based formulations.<sup><xref ref-type="bibr" rid="ref149">149</xref></sup> One
of the key challenges faced by these MNs patches is the loss of
vaccine activity during the drying or heating process of MNs patch
fabrication,<sup><xref ref-type="bibr" rid="ref150">150</xref></sup> where molecular structures of
vaccines may be disrupted.<sup><xref ref-type="bibr" rid="ref151">151</xref></sup> Different strategies
can be adopted, such as the use of lyoprotective polymers as MNs
matrices, which include silk fibroin,<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> gelatin,
dextran, and PVP,<sup><xref ref-type="bibr" rid="ref152">152</xref></sup> or adding sugar molecules as
stabilizing excipients, including trehalose and
sucrose.<sup><xref ref-type="bibr" rid="ref147">147</xref>,<xref ref-type="bibr" rid="ref152">152</xref></sup> In the vaccine discovery
phase, the introduction of certain mutations can improve the thermal
stability of vaccines as well,<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> which can be
further applied to specific MNs formulations. Additionally, a
hyperstabilized vaccine formulation, such as the
interbilayer-cross-linked multilamellar vesicles, helped protect
vaccines during the drying process of MNs fabrication and have
outperformed other traditional delivery strategies in inducing a
potent antigen-specific immune response.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup></p><p>MNs also provide advantages in tuning optimal release profiles of
vaccines. As mentioned earlier, the sustained availability of vaccines
is a desirable feature for immunization. Vaccines targeting different
infectious diseases may vary in terms of optimal release profiles
based on the unique features of each virus. Initially, MNs for
vaccination were mainly an upgrade to traditional bolus delivery by
using a fast-dissolving MNs matrix,<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> which
requires multiple doses for sufficient immunity. With the exploration
of the desired PK of vaccines, MNs can play a much more important
role. For example, a silk matrix with crystallized structures could be
used as an MNs matrix to sustainably release loaded vaccines over 2
weeks and to elicit potent immune responses with one single
administration.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> In addition, biodegradable
polymers with known degradation kinetics can be used to encapsulate
the vaccines and tune antigen release profiles. These polymers include
biodegradable cationic PBAE<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> and PLGA.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup></p></sec><sec id="sec4.2"><title>Injectable Material-Assisted Vaccines</title><p>Macroscale biomaterials strategies have recently boosted the field of
immunotherapy.<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> There are many advantages
in controlled release and encapsulation of various cargos, ranging
from small molecules to proteins and cells.<sup><xref ref-type="bibr" rid="ref153">153</xref></sup>
These varied cargo elements can help to meet the need for diverse
types of vaccine candidates. In terms of controlling PKs of vaccines,
both sustained and pulsatile releases could be possibly
achieved.<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> In addition, materials
engineering can enable devices that do not require surgically invasive
administrations.<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> Together, they could
minimize the requirement of medical resources without mitigating the
vaccine efficacy.</p><p>PLGA has also been developed for a single-shot vaccine based on the
tunability of its biodegradation profile.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> In the
case of polio vaccines, two to three administrations over several
months are required. Tzeng <italic>et al</italic>. demonstrated that
IPV could be encapsulated within PLGA microspheres stably and released
through two bursts that were one-month apart.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup>
They examined the effect of adding cationic excipients (Eudragit E,
PLL, and branched PEI) to stabilize IPV antigens, protecting them from
denaturation by acidic byproducts, and modulate degradation profiles
of PLGA microspheres.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Notably, a single shot of
PLGA microsphere-based vaccines could elicit the production of NAb as
potent as two bolus injections.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Combined with
the advances in microfabrication and additive manufacturing, McHugh
<italic>et al</italic>. fabricated microscale (&#x0223c;400
&#x003bc;m) hollow PLGA-based microparticles that were
injectable.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> The microparticles can be
filled with vaccine formulations, and the degradation rate of the
microparticle shell (a lactic/glycolic copolymer) can be tuned to
achieve controlled release spanning from a few days to a few
months.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Such a design can accomplish the
goals of general transdermal vaccine injection and achieve temporally
controlled pulsed delivery of antigens in a single injection.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> Recently, a similar PLGA-based microparticles
platform was applied to release a STING agonist (cyclic guanosine
monophosphate-adenosine monophosphate (cGAMP)) in a pulsatile manner
over a long period (&#x0223c;16 days).<sup><xref ref-type="bibr" rid="ref128">128</xref></sup> One single
injection of the pulsatile drug-releasing microparticles induced
potent immunity as effective as three separate injections. These
engineered platforms are versatile in terms of encapsulating different
cargos required by vaccine formulations and tuning release kinetics
correspondingly. However, even though the use of FDA-approved PLGA
could facilitate the clinical translation to a certain degree, several
design limitations need to be overcome for translating PLGA-based drug
delivery devices into clinical applications. For instance, the
pulsatile release was achieved with hollow microparticles that have
thick PLGA shells to encapsulate the drugs in the hollow core for
controlled release. This design significantly sacrificed their loading
efficiency due to the limited volume of the core. Clinically, patients
need a high drug dosage, and this formulation needs further
optimization to meet the dosage requirement. In addition, PLGA can
create an acidic microenvironment during biodegradation, damaging the
encapsulated drugs.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Furthermore, the
encapsulated vaccines need to survive the fabrication process; brief
heating requires thermally stable vaccines.<sup><xref ref-type="bibr" rid="ref127">127</xref>,<xref ref-type="bibr" rid="ref128">128</xref></sup> All
these aspects could compromise their applications for a broader
collection of drugs or vaccines.</p><p>Traditionally, <italic>ex vivo</italic> modification of antigen-specific
DC vaccines is a multistep process associated with high costs and high
levels of complexity.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> It was proposed that
<italic>in situ</italic> DC recruitment, activation, and further
trafficking to LNs would be more desirable compared to the <italic>ex
vivo</italic> modification strategy (<xref rid="fig5" ref-type="fig">Figure
<xref rid="fig5" ref-type="fig">5</xref></xref>c).<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> The
early study by Ali <italic>et al</italic>. demonstrated the use of
macroporous scaffold vaccines based on PLGA, which presented cytokines
(GM-CSF), danger signals (CpG), and antigens in a spatiotemporally
defined manner. GM-CSF can be sustainably released from the scaffolds
over 20 days for effective DC recruitment.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> By
co-loading the CpG through PEI-mediated electrostatic interactions,
CpG was immobilized on the scaffolds for local internalization by the
recruited DCs. This process mimicked an infection and was able to
continuously recruit and activate DCs.<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> This
specific scaffold vaccine was surgically implanted; nevertheless, it
encouraged further development of injectable vaccines that work
similarly. Kim <italic>et al</italic>. demonstrated the use of
mesoporous silica rods (MSRs) with a high-aspect-ratio that could be
injected with a syringe needle.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> They could
self-assemble <italic>in vivo</italic> as macroporous scaffolds to
initiate potent immune responses.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> The DCs could
be recruited into the scaffolds where the inflammatory signals
(GM-CSF), adjuvants (CpG), and antigens (OVA) were sustainably
released from the scaffolds for <italic>in situ</italic> DC activation
and maturation. It was also demonstrated that locally injected
scaffold vaccines based on MSRs could elicit strong systemic immune
responses with the increase in levels of antigen-specific B cells,
helper T cells, and cytotoxic T cells.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> A PEI
coating was later added to the design to enable antigen loading
through adsorption for enhanced immunogenicity.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup>
This specific system was recently utilized for synthetic peptide
vaccines and small antigens.<sup><xref ref-type="bibr" rid="ref132">132</xref></sup> This strategy was
able to bypass multiple immunization requirements but sustained a more
robust antibody response, compared to traditional bolus or alum
vaccine formulations.<sup><xref ref-type="bibr" rid="ref132">132</xref></sup></p><p>Scaffold-based vaccines have displayed efficacy in inducing systemic
immune response through <italic>in situ</italic> immune modulations.
<italic>In vivo</italic> self-assembled scaffolds provide a good
alternative to bypass surgically implantation; however, the
self-assembling process is commonly undefined in terms of how long it
could take for self-assembling.<sup><xref ref-type="bibr" rid="ref133">133</xref></sup> Materials
engineering facilitates the fabrication of scaffolds maintaining
injectability. Bencherif <italic>et al</italic>. described a strategy
for fabricating injectable scaffolds with shape memory based on
cryotropic gelation.<sup><xref ref-type="bibr" rid="ref134">134</xref></sup> The cryogels were based on
alginate methacrylate, and they were capable of being reversibly
deformed, over 90% strain, after being chemically cross-linked in a
frozen condition (&#x02212;20 &#x000b0;C).<sup><xref ref-type="bibr" rid="ref134">134</xref></sup> The ice
crystals hindered the cross-linking in frozen spots and therefore
formed the macroporous pores that not only enabled the shape memory
for the gel but also allowed the DCs infiltration.<sup><xref ref-type="bibr" rid="ref134">134</xref></sup></p><p>Hydrogels have been extensively explored in the field of
immunotherapy.<sup><xref ref-type="bibr" rid="ref153">153</xref></sup> They have advantages in
terms of controllable delivery of multiple cargos, <italic>in
situ</italic> immunomodulation, and mild fabrication process for
various vaccine formulations (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>c). Early pioneering work includes the loading of
<italic>ex vivo</italic> antigen-primed DC vaccines within
Ca<sup>2+</sup> cross-linked alginate gel by Hori <italic>et
al</italic>.<sup><xref ref-type="bibr" rid="ref135">135</xref></sup> Activated DCs have a short
lifespan, and continuous immune responses may be suppressed if no
sufficient host DCs and T cells could be recruited and primed
<italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref135">135</xref></sup> Therefore,
cell-based vaccines delivered by gels are expected to improve cell
survival and prolong the presence of DCs.<sup><xref ref-type="bibr" rid="ref136">136</xref></sup> Both
host DCs and cytotoxic T cells can be recruited to the injection site
by cytokines and chemokines secreted from the injected DCs. In
addition, the enhanced efficacy of transplanted cells can be enhanced
by supplementing the gels with other immunomodulatory molecules, such
as cytokines (IL-2) or adjuvants (CpG).<sup><xref ref-type="bibr" rid="ref137">137</xref></sup> The
increased persistence of transplanted cells could be achieved by
designing gels mimicking ECM by the incorporation of cell-adhesive
peptides, such as RGD.<sup><xref ref-type="bibr" rid="ref154">154</xref></sup></p><p>Apart from cell-based vaccines, other types of vaccines could also be
incorporated into gel systems, where the release profiles can be
tuned. Roy <italic>et al</italic>. utilized the <italic>in
situ</italic> cross-linking mechanism of tetrafunctional
poly(ethylene oxide) amine and poly(ethylene oxide) succinimidyl
glutarate to encapsulate plasmid DNA.<sup><xref ref-type="bibr" rid="ref138">138</xref></sup> The
gelation did not interfere with the supercoiled structure of plasmid
DNA, and the gelling ability can be tuned by adjusting the
concentrations of these two components. Notably, gene expression
levels were comparable to bare DNA, but the duration of expression was
significantly longer. Other <italic>in situ</italic> gel systems
explored for vaccination include temperature-responsive gels<sup><xref ref-type="bibr" rid="ref139">139</xref></sup> and Michael-addition-type hydrogels.<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> Singh <italic>et al</italic>. engineered dextran
and PEG-based hydrogels that could be cross-linked <italic>in
situ</italic> for antigen/adjuvant
delivery.<sup><xref ref-type="bibr" rid="ref141">141</xref>,<xref ref-type="bibr" rid="ref142">142</xref></sup> Umeki <italic>et
al</italic>. designed an immunostimulatory CpG DNA-based hydrogel for
antigen delivery.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> To achieve a sustained release
of antigens, they proposed to cationize the antigens by
ethylenediamine conjugation where antigens could form complexes with a
negatively charged DNA hydrogel matrix. The innate immunostimulatory
function of gel and prolonged antigen presence leads to an enhanced
antigen-specific immune response with less toxicity.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup><italic>In situ</italic> gelling strategies or physically cross-linked
gels from these studies generally take minutes to hours, which renders
limited control on cargos release and material properties during the
gelling period.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> Therefore, the development of
gel systems that are both injectable and display defined cargo
release/biodegradation profiles could be desirable for vaccine
administration.</p></sec><sec id="sec4.3"><title>Other Delivery Devices</title><p>Many more investigations are currently ongoing to engineer alternative
drug delivery devices. For instance, to promote the uptake of DNA
vaccine by cells, electroporation is one of the traditional and
effective strategies to enhance the uptake of plasmids.<sup><xref ref-type="bibr" rid="ref155">155</xref></sup> Different parameters, such as electrical features
(voltage, current, and frequency) and length of the electrode
(intradermal or intramuscular targets), need to be optimized to ensure
efficacy and safety and to minimize pain. This process has recently
demonstrated promising clinical phase I results for MERS.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> The same electroporation device (CELLECTRA) is
also being investigated for a DNA vaccine of SARS-CoV-2 from
Inovio.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> The S protein of SARS-CoV-2
encoding DNA vaccine demonstrated potent antigen-specific T cell
responses and the production of neutralization antibodies in
preclinical mice and guinea pigs studies.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> In
order to incorporate the advantages of MNs, electroactive MNs devices
have also been developed for the electroporation of DNA vaccine in a
minimally invasive manner.<sup><xref ref-type="bibr" rid="ref157">157</xref></sup> Similar devices using
iontophoresis can also enhance the transdermal delivery of
vaccines.<sup><xref ref-type="bibr" rid="ref158">158</xref></sup> Recently, Tadros <italic>et
al</italic>. designed millimeter-scale star-shaped particles,
termed STAR particles, based on aluminum oxide for topical vaccine
delivery,<sup><xref ref-type="bibr" rid="ref159">159</xref></sup> and the minimally invasive STAR
particles elicited an immune response comparable to intramuscular
injection.<sup><xref ref-type="bibr" rid="ref159">159</xref></sup> Even though STAR particles are
simple to manufacture and well-tolerated by the immune system, a much
higher dosage was administered compared to intramuscular injection. In
addition, potential human-to-human variability in administration and
drug leftovers on the skin may result in differential efficacy and
undesirable toxicity.</p><p>In terms of reducing the demands for medical resources, vaccines that
could be intranasally or orally administered are desired if their
efficacy is comparable to transdermal delivery.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup>
The main strategy for intranasal or oral vaccine development is
currently limited to weakened viral vaccines mimicking natural
infections. Nonliving vaccines are safer but less immunogenic and thus
may benefit greatly from drug delivery formulations and
devices.<sup><xref ref-type="bibr" rid="ref160">160</xref></sup> A variety of drug delivery
devices have been proposed for oral vaccination delivery. For
instance, the micromotor-driven microparticles for oral delivery of
antigens.<sup><xref ref-type="bibr" rid="ref161">161</xref>,<xref ref-type="bibr" rid="ref162">162</xref></sup> The micromotor vaccine can
efficiently enter the intestine to enhance the antigen uptake. Aran
<italic>et al</italic>. designed a needle-free oral microjet
where the high-pressure liquid jet of the vaccine was produced by a
self-contained gas-producing reaction.<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> It was
shown that a buccal immunity response was enhanced, and this method
was able to elicit a potent humoral immune response both locally and
systemically.<sup><xref ref-type="bibr" rid="ref163">163</xref></sup> Abramson <italic>et
al</italic>. engineered a self-orienting system for oral
delivery that could attach to the gastric wall by autonomously
positioning to maximize the delivery efficiency.<sup><xref ref-type="bibr" rid="ref164">164</xref></sup>
Innovations in drug delivery devices will significantly transform
traditional vaccination regimes.</p></sec></sec><sec id="sec5"><title>Summary and Future Directions</title><p>The devastating disruptions caused by the sudden outbreak of COVID-19 has urged
vaccine development at an unprecedented speed.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Within 70
days of the first release of the genetic information on SARS-CoV-2, the
first dose of a vaccine was administered to human participants.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> As of August 25, 2020, 31 vaccine candidates are in
various stages of clinical trials, and around 142 candidates are in
preclinical trials.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Apart from the high diversity of
the vaccine candidates, many candidates are based on different technological
platforms, such as nanotechnology delivered mRNA vaccine, electroporation
device-enabled DNA vaccine, and MN-delivered vaccine. The COVID-19 pandemic
has accelerated the deployment of different vaccine formulations and
delivery devices. It is reasonable to expect that more efforts will be
dedicated to further optimize the vaccine designs to help fight future
outbreaks.</p><p>Here, we reviewed recent research efforts in the field of vaccine discovery,
vaccine formulation development, and vaccine delivery device designs.
Because of the deployment of various engineering technologies, it is
expected that future vaccines will not only need to demonstrate safety and
efficacy but also to be relatively convenient and simple to use for better
coping with population-level vaccinations or sudden outbreaks worldwide.
Nanoengineered formulations could enhance the immune response by delivering
the required components together and maximizing their uptake by
immunocompetent cells. To expedite the future preparedness of vaccines for
the occurrence of a pandemic, synthetic vaccines have demonstrated great
potential for rapid clinical applications because they are molecularly
defined and independent of the time-consuming culture of viruses, which can
accelerate the initial vaccine development. However, synthetic vaccines are
also the ones that need to be formulated the most, which constitutes the
major part of their time costs. To accelerate the development of synthetic
vaccines, the nanoengineered formulations need to be simple and robust to
manufacture in terms of chemistry or the selection of raw
materials.<sup><xref ref-type="bibr" rid="ref165">165</xref>,<xref ref-type="bibr" rid="ref166">166</xref></sup> In terms of vaccine delivery
devices, self-administrable vaccines, single-shot vaccines, and solid
MN-based vaccines could further enhance the availability of vaccines to a
broader population. For instance, self-administrable vaccines can be mailed
to patients at home without the need of medical experts.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup> Single-shot vaccines can be much more convenient compared to the
traditional immunization regimens that require multiple shots. Furthermore,
solid MN-based vaccines that are cold chain free could simplify the vaccine
transportation and distribution process. All of these aspects could be
enabled by engineering approaches to accelerate the development of vaccines
at a pandemic speed.<sup><xref ref-type="bibr" rid="ref165">165</xref>,<xref ref-type="bibr" rid="ref166">166</xref></sup> Although combining the advantages
of vaccine formulations and vaccine delivery devices is promising,
micro/macro-engineering still needs to develop solutions that do not require
&#x0201c;harsh&#x0201d; conditions to be compatible with nanoengineered
formulations.<sup><xref ref-type="bibr" rid="ref167">167</xref></sup> Expectedly, platform technologies
that can be quickly adapted to address emerging viral diseases could speed
up the pace of vaccine development.</p><p>However, several challenges remain before these goals can be fully achieved.
First, a differently identified virus is unknown in terms of its
interactions with our immune system and which type of immune responses are
most desirable to trigger prolonged immunity. An improved understanding of
our immune system and its interactions with viruses are the basis for
designing an effective vaccine, which also guides the steps for designing
corresponding vaccine administration regimens. Second, innovative
formulations or delivery devices for vaccines are mostly in the preclinical
stage, which have not been approved by the FDA yet. For example, MN-based
vaccines showed encouraging results from a phase I trial of dissolvable
MN-based influenza vaccine and indicated a promise of using it as an
alternative strategy for vaccination.<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> However, patient
compliance with this approach and its efficacy needs to be tested in a
larger population, considering only 100 human subjects are currently
involved. Also, the efficacy of vaccines by self-administration should be
further validated in comparison to those performed by medical experts. In
addition, the proposed formulations and delivery devices should be easy to
manufacture with minimal batch-to-batch variability to simplify the quality
control process. The raw materials used could prioritize the FDA-approved
ones to simplify the regulatory process, and the required chemistry is
preferred to be simple and robust. Even though advanced manufacturing
technologies excel in reducing batch-to-batch variability, a high cost may
be associated. The improved efficacy of a vaccine from these formulations
and delivery devices should not be complicated by the fabrication process so
that it can facilitate the clinical translation and regulatory
approvals.<sup><xref ref-type="bibr" rid="ref165">165</xref></sup></p><p>Additional challenges for vaccine development also exist during a pandemic.
Multiple vaccine candidates flush into different stages of clinical trials
that could burden the regulatory process by the FDA for selecting promising
candidates and deciding final ones.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> Furthermore, human
trials are starting even before the most suitable animal models for safety
and efficacy are defined.<sup><xref ref-type="bibr" rid="ref168">168</xref></sup> Based on previous successful
preclinical and early stage clinical data for a similar platform, animal
studies are even skipped directly for human administrations.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Other engineering approaches such as
organs-on-a-chip<sup><xref ref-type="bibr" rid="ref169">169</xref>&#x02212;<xref ref-type="bibr" rid="ref171">171</xref></sup> or screening using
organoids<sup><xref ref-type="bibr" rid="ref172">172</xref></sup> may serve as a promising tool in
future clinical trials for efficacy and toxicity determination. Ethically
controversial human challenge trials by deliberately infecting humans with a
virus have been proposed and pursued to accelerate the process of vaccine
development.<sup><xref ref-type="bibr" rid="ref173">173</xref></sup> Therefore, potentially we should
have vaccine clinical trials specifically designed for different scenarios
by incorporating engineering advances and regulatory guidelines readily
outlined for unusual trials. In conclusion, human health and societal
stability are constantly challenged by sudden virus outbreaks, and the rapid
development of effective vaccines is believed to be an ultimate solution. We
expect to observe faster and more efficient vaccine development paradigms in
the future by combining the advances in different engineering fields.</p></sec></body><back><notes notes-type="" id="notes1"><title>Author Contributions</title><p><sup>&#x025cf;</sup> These authors contributed equally to this work.</p></notes><notes notes-type="COI-statement" id="NOTES-d7e2099-autogenerated"><p>The authors declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was supported by National Institute of Health (CA214411, GM126831,
and AR069564).</p></ack><glossary id="dl1"><def-list><title>Vocabulary</title><def-item><term><bold>Coronavirus disease 2019 (COVID-19)</bold></term><def><p>a disease caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and has been declared as a pandemic by WHO since
March 11, 2020</p></def></def-item><def-item><term><bold>antiviral vaccine</bold></term><def><p>a biological preventive preparation strategy to train the immune
systems to fight against viral pathogens</p></def></def-item><def-item><term><bold>vaccine formulations</bold></term><def><p>biomaterial engineering strategies aiming to boost the efficacy or
reduce side effects of vaccines through co-delivering adjuvants,
targeting immune cells, or protecting vaccines activities</p></def></def-item><def-item><term><bold>vaccine delivery devices</bold></term><def><p>tools for administering the vaccine formulations, and they can be
used by medical workers or the patients themselves</p></def></def-item><def-item><term><bold>pattern recognition receptors (PRRs)</bold></term><def><p>proteins that can recognize pathogenic molecules as part of innate
immunity in response to virus infection, including identifying
pathogen-associated molecular patterns from a virus</p></def></def-item><def-item><term><bold>adjuvants</bold></term><def><p>supplementary agents that could be co-delivered with vaccines to
boost the immune response, minimize the dosage of antigens, and
maintain longer immunity</p></def></def-item><def-item><term><bold>lymph nodes</bold></term><def><p>round or bean-shaped clusters of cells containing abundant immune
cells that can initiate the robust immune response toward viral
infections</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Bedford</surname><given-names>J.</given-names></name>; <name><surname>Enria</surname><given-names>D.</given-names></name>; <name><surname>Giesecke</surname><given-names>J.</given-names></name>; <name><surname>Heymann</surname><given-names>D. L.</given-names></name>; <name><surname>Ihekweazu</surname><given-names>C.</given-names></name>; <name><surname>Kobinger</surname><given-names>G.</given-names></name>; <name><surname>Lane</surname><given-names>H. C.</given-names></name>; <name><surname>Memish</surname><given-names>Z.</given-names></name>; <name><surname>Oh</surname><given-names>M.-d.</given-names></name>; <name><surname>Sall</surname><given-names>A. A.</given-names></name>; <name><surname>Schuchat</surname><given-names>A.</given-names></name>; <name><surname>Ungchusak</surname><given-names>K.</given-names></name>; <name><surname>Wieler</surname><given-names>L. H.</given-names></name>
<article-title>COVID-19: Towards Controlling of a
Pandemic</article-title>. <source>Lancet</source>
<year>2020</year>, <volume>395</volume>, <fpage>1015</fpage>&#x02013;<lpage>1018</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30673-5</pub-id>.<pub-id pub-id-type="pmid">32197103</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><person-group person-group-type="allauthors"><name><surname>Berlin</surname><given-names>D. A.</given-names></name>;
<name><surname>Gulick</surname><given-names>R.
M.</given-names></name>;
<name><surname>Martinez</surname><given-names>F.
J.</given-names></name></person-group><article-title>Severe Covid-19</article-title>. <source>N. Engl. J.
Med.</source><year>2020</year>, <pub-id pub-id-type="doi">10.1056/NEJMcp2009575</pub-id>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Rome</surname><given-names>B. N.</given-names></name>; <name><surname>Avorn</surname><given-names>J.</given-names></name>
<article-title>Drug Evaluation during the Covid-19
Pandemic</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>2282</fpage>&#x02013;<lpage>2284</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp2009457</pub-id>.<pub-id pub-id-type="pmid">32289216</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Lurie</surname><given-names>N.</given-names></name>; <name><surname>Saville</surname><given-names>M.</given-names></name>; <name><surname>Hatchett</surname><given-names>R.</given-names></name>; <name><surname>Halton</surname><given-names>J.</given-names></name>
<article-title>Developing Covid-19 Vaccines at Pandemic
Speed</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>1969</fpage>&#x02013;<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp2005630</pub-id>.<pub-id pub-id-type="pmid">32227757</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Fauci</surname><given-names>A. S.</given-names></name>; <name><surname>Morens</surname><given-names>D. M.</given-names></name>
<article-title>Zika Virus in the Americas &#x02014; Yet Another
Arbovirus Threat</article-title>. <source>N. Engl. J. Med.</source>
<year>2016</year>, <volume>374</volume>, <fpage>601</fpage>&#x02013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMp1600297</pub-id>.<pub-id pub-id-type="pmid">26761185</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Regules</surname><given-names>J. A.</given-names></name>; <name><surname>Beigel</surname><given-names>J. H.</given-names></name>; <name><surname>Paolino</surname><given-names>K. M.</given-names></name>; <name><surname>Voell</surname><given-names>J.</given-names></name>; <name><surname>Castellano</surname><given-names>A. R.</given-names></name>; <name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Mu&#x000f1;oz</surname><given-names>P.</given-names></name>; <name><surname>Moon</surname><given-names>J. E.</given-names></name>; <name><surname>Ruck</surname><given-names>R. C.</given-names></name>; <name><surname>Bennett</surname><given-names>J. W.</given-names></name>; <name><surname>Twomey</surname><given-names>P. S.</given-names></name>; <name><surname>Guti&#x000e9;rrez</surname><given-names>R. L.</given-names></name>; <name><surname>Remich</surname><given-names>S. A.</given-names></name>; <name><surname>Hack</surname><given-names>H. R.</given-names></name>; <name><surname>Wisniewski</surname><given-names>M. L.</given-names></name>; <name><surname>Josleyn</surname><given-names>M. D.</given-names></name>; <name><surname>Kwilas</surname><given-names>S. A.</given-names></name>; <name><surname>Van Deusen</surname><given-names>N.</given-names></name>; <name><surname>Mbaya</surname><given-names>O. T.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; et al. <article-title>A Recombinant Vesicular Stomatitis Virus Ebola
Vaccine</article-title>. <source>N. Engl. J. Med.</source>
<year>2017</year>, <volume>376</volume>, <fpage>330</fpage>&#x02013;<lpage>341</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1414216</pub-id>.<pub-id pub-id-type="pmid">25830322</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Mulangu</surname><given-names>S.</given-names></name>; <name><surname>Dodd</surname><given-names>L. E.</given-names></name>; <name><surname>Davey</surname><given-names>R. T.</given-names></name>; <name><surname>Tshiani Mbaya</surname><given-names>O.</given-names></name>; <name><surname>Proschan</surname><given-names>M.</given-names></name>; <name><surname>Mukadi</surname><given-names>D.</given-names></name>; <name><surname>Lusakibanza Manzo</surname><given-names>M.</given-names></name>; <name><surname>Nzolo</surname><given-names>D.</given-names></name>; <name><surname>Tshomba Oloma</surname><given-names>A.</given-names></name>; <name><surname>Ibanda</surname><given-names>A.</given-names></name>; <name><surname>Ali</surname><given-names>R.</given-names></name>; <name><surname>Coulibaly</surname><given-names>S.</given-names></name>; <name><surname>Levine</surname><given-names>A. C.</given-names></name>; <name><surname>Grais</surname><given-names>R.</given-names></name>; <name><surname>Diaz</surname><given-names>J.</given-names></name>; <name><surname>Lane</surname><given-names>H. C.</given-names></name>; <name><surname>Muyembe-Tamfum</surname><given-names>J.-J.</given-names></name>; <name><surname>The</surname><given-names>P. W. G.</given-names></name>
<article-title>A Randomized, Controlled Trial of Ebola Virus Disease
Therapeutics</article-title>. <source>N. Engl. J. Med.</source>
<year>2019</year>, <volume>381</volume>, <fpage>2293</fpage>&#x02013;<lpage>2303</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1910993</pub-id>.<pub-id pub-id-type="pmid">31774950</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Fineberg</surname><given-names>H. V.</given-names></name>
<article-title>Pandemic Preparedness and Response &#x02014; Lessons
from the H1N1 Influenza of 2009</article-title>. <source>N. Engl. J. Med.</source>
<year>2014</year>, <volume>370</volume>, <fpage>1335</fpage>&#x02013;<lpage>1342</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1208802</pub-id>.<pub-id pub-id-type="pmid">24693893</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Le</surname><given-names>T. T.</given-names></name>; <name><surname>Andreadakis</surname><given-names>Z.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Roman</surname><given-names>R. G.</given-names></name>; <name><surname>Tollefsen</surname><given-names>S.</given-names></name>; <name><surname>Saville</surname><given-names>M.</given-names></name>; <name><surname>Mayhew</surname><given-names>S.</given-names></name>
<article-title>The COVID-19 Vaccine Development
Landscape</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2020</year>, <volume>19</volume>, <fpage>305</fpage>&#x02013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1038/d41573-020-00073-5</pub-id>.<pub-id pub-id-type="pmid">32273591</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="weblink" id="cit10"><article-title>Draft Landscape
of COVID-19 Candidate Vaccines</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</uri>
(accessed <year>2020</year>-08-28).</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Cox</surname><given-names>R. J.</given-names></name>; <name><surname>Brokstad</surname><given-names>K. A.</given-names></name>
<article-title>Not Just Antibodies: B Cells and T Cells Mediate
Immunity to COVID-19</article-title>. <source>Nat. Rev. Immunol.</source>
<year>2020</year>, <fpage>581</fpage>&#x02013;<lpage>582</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-020-00436-4</pub-id>.<pub-id pub-id-type="pmid">32839569</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Irvine</surname><given-names>D. J.</given-names></name>; <name><surname>Swartz</surname><given-names>M. A.</given-names></name>; <name><surname>Szeto</surname><given-names>G. L.</given-names></name>
<article-title>Engineering Synthetic Vaccines Using Cues from Natural
Immunity</article-title>. <source>Nat. Mater.</source>
<year>2013</year>, <volume>12</volume>, <fpage>978</fpage>&#x02013;<lpage>990</lpage>. <pub-id pub-id-type="doi">10.1038/nmat3775</pub-id>.<pub-id pub-id-type="pmid">24150416</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Callaway</surname><given-names>E.</given-names></name>
<article-title>The Race for Coronavirus Vaccines: A Graphical
Guide</article-title>. <source>Nature</source>
<year>2020</year>, <volume>580</volume>, <fpage>576</fpage><pub-id pub-id-type="doi">10.1038/d41586-020-01221-y</pub-id>.<pub-id pub-id-type="pmid">32346146</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Nabel</surname><given-names>G. J.</given-names></name>
<article-title>Designing Tomorrow&#x02019;s Vaccines</article-title>. <source>N. Engl. J. Med.</source>
<year>2013</year>, <volume>368</volume>, <fpage>551</fpage>&#x02013;<lpage>560</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1204186</pub-id>.<pub-id pub-id-type="pmid">23388006</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Gao</surname><given-names>Q.</given-names></name>; <name><surname>Bao</surname><given-names>L.</given-names></name>; <name><surname>Mao</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Xu</surname><given-names>K.</given-names></name>; <name><surname>Yang</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>N.</given-names></name>; <name><surname>Lv</surname><given-names>Z.</given-names></name>; <name><surname>Gao</surname><given-names>H.</given-names></name>; <name><surname>Ge</surname><given-names>X.</given-names></name>; <name><surname>Kan</surname><given-names>B.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Cai</surname><given-names>F.</given-names></name>; <name><surname>Jiang</surname><given-names>D.</given-names></name>; <name><surname>Yin</surname><given-names>Y.</given-names></name>; <name><surname>Qin</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; et al. <article-title>Development of an Inactivated Vaccine Candidate for
SARS-CoV-2</article-title>. <source>Science</source>
<year>2020</year>, <volume>369</volume>, <fpage>77</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>.<pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Ura</surname><given-names>T.</given-names></name>; <name><surname>Okuda</surname><given-names>K.</given-names></name>; <name><surname>Shimada</surname><given-names>M.</given-names></name>
<article-title>Developments in Viral Vector-Based
Vaccines</article-title>. <source>Vaccines</source>
<year>2014</year>, <volume>2</volume>, <fpage>624</fpage>&#x02013;<lpage>641</lpage>. <pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id>.<pub-id pub-id-type="pmid">26344749</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Hos</surname><given-names>B. J.</given-names></name>; <name><surname>Tondini</surname><given-names>E.</given-names></name>; <name><surname>van Kasteren</surname><given-names>S. I.</given-names></name>; <name><surname>Ossendorp</surname><given-names>F.</given-names></name>
<article-title>Approaches to Improve Chemically Defined Synthetic
Peptide Vaccines</article-title>. <source>Front. Immunol.</source>
<year>2018</year>, <volume>9</volume>, <fpage>884</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00884</pub-id>.<pub-id pub-id-type="pmid">29755468</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Donlan</surname><given-names>A. N.</given-names></name>; <name><surname>Petri</surname><given-names>W. A.</given-names></name>
<article-title>Mucosal Immunity and the Eradication of
Polio</article-title>. <source>Science</source>
<year>2020</year>, <volume>368</volume>, <fpage>362</fpage>&#x02013;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb8588</pub-id>.<pub-id pub-id-type="pmid">32327582</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Macklin</surname><given-names>G. R.</given-names></name>; <name><surname>O&#x02019;Reilly</surname><given-names>K. M.</given-names></name>; <name><surname>Grassly</surname><given-names>N. C.</given-names></name>; <name><surname>Edmunds</surname><given-names>W. J.</given-names></name>; <name><surname>Mach</surname><given-names>O.</given-names></name>; <name><surname>Santhana Gopala Krishnan</surname><given-names>R.</given-names></name>; <name><surname>Voorman</surname><given-names>A.</given-names></name>; <name><surname>Vertefeuille</surname><given-names>J. F.</given-names></name>; <name><surname>Abdelwahab</surname><given-names>J.</given-names></name>; <name><surname>Gumede</surname><given-names>N.</given-names></name>; <name><surname>Goel</surname><given-names>A.</given-names></name>; <name><surname>Sosler</surname><given-names>S.</given-names></name>; <name><surname>Sever</surname><given-names>J.</given-names></name>; <name><surname>Bandyopadhyay</surname><given-names>A. S.</given-names></name>; <name><surname>Pallansch</surname><given-names>M. A.</given-names></name>; <name><surname>Nandy</surname><given-names>R.</given-names></name>; <name><surname>Mkanda</surname><given-names>P.</given-names></name>; <name><surname>Diop</surname><given-names>O. M.</given-names></name>; <name><surname>Sutter</surname><given-names>R. W.</given-names></name>
<article-title>Evolving Epidemiology of Poliovirus Serotype 2
following Withdrawal of the Serotype 2 Oral Poliovirus
Vaccine</article-title>. <source>Science</source>
<year>2020</year>, <volume>368</volume>, <fpage>401</fpage>&#x02013;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1126/science.aba1238</pub-id>.<pub-id pub-id-type="pmid">32193361</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Yeh</surname><given-names>M. T.</given-names></name>; <name><surname>Bujaki</surname><given-names>E.</given-names></name>; <name><surname>Dolan</surname><given-names>P. T.</given-names></name>; <name><surname>Smith</surname><given-names>M.</given-names></name>; <name><surname>Wahid</surname><given-names>R.</given-names></name>; <name><surname>Konz</surname><given-names>J.</given-names></name>; <name><surname>Weiner</surname><given-names>A. J.</given-names></name>; <name><surname>Bandyopadhyay</surname><given-names>A. S.</given-names></name>; <name><surname>Van Damme</surname><given-names>P.</given-names></name>; <name><surname>De Coster</surname><given-names>I.</given-names></name>; <name><surname>Revets</surname><given-names>H.</given-names></name>; <name><surname>Macadam</surname><given-names>A.</given-names></name>; <name><surname>Andino</surname><given-names>R.</given-names></name>
<article-title>Engineering the Live-Attenuated Polio Vaccine to
Prevent Reversion to Virulence</article-title>. <source>Cell Host Microbe</source>
<year>2020</year>, <volume>27</volume>, <fpage>736</fpage>&#x02013;<lpage>751</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.04.003</pub-id>.<pub-id pub-id-type="pmid">32330425</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Robert-Guroff</surname><given-names>M.</given-names></name>
<article-title>Replicating and Non-Replicating Viral Vectors for
Vaccine Development</article-title>. <source>Curr. Opin. Biotechnol.</source>
<year>2007</year>, <volume>18</volume>, <fpage>546</fpage>&#x02013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1016/j.copbio.2007.10.010</pub-id>.<pub-id pub-id-type="pmid">18063357</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Zhu</surname><given-names>F.-C.</given-names></name>; <name><surname>Li</surname><given-names>Y.-H.</given-names></name>; <name><surname>Guan</surname><given-names>X.-H.</given-names></name>; <name><surname>Hou</surname><given-names>L.-H.</given-names></name>; <name><surname>Wang</surname><given-names>W.-J.</given-names></name>; <name><surname>Li</surname><given-names>J.-X.</given-names></name>; <name><surname>Wu</surname><given-names>S.-P.</given-names></name>; <name><surname>Wang</surname><given-names>B.-S.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Jia</surname><given-names>S.-Y.</given-names></name>; <name><surname>Jiang</surname><given-names>H.-D.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Jiang</surname><given-names>T.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Gou</surname><given-names>J.-B.</given-names></name>; <name><surname>Xu</surname><given-names>S.-B.</given-names></name>; <name><surname>Xu</surname><given-names>J.-J.</given-names></name>; <name><surname>Wang</surname><given-names>X.-W.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; et al. <article-title>Safety, Tolerability, and Immunogenicity of a
Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine: A
Dose-Escalation, Open-Label, Non-Randomised, First-in-Human
Trial</article-title>. <source>Lancet</source>
<year>2020</year>, <volume>395</volume>, <fpage>1845</fpage>&#x02013;<lpage>1854</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31208-3</pub-id>.<pub-id pub-id-type="pmid">32450106</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>van Doremalen</surname><given-names>N.</given-names></name>; <name><surname>Haddock</surname><given-names>E.</given-names></name>; <name><surname>Feldmann</surname><given-names>F.</given-names></name>; <name><surname>Meade-White</surname><given-names>K.</given-names></name>; <name><surname>Bushmaker</surname><given-names>T.</given-names></name>; <name><surname>Fischer</surname><given-names>R. J.</given-names></name>; <name><surname>Okumura</surname><given-names>A.</given-names></name>; <name><surname>Hanley</surname><given-names>P. W.</given-names></name>; <name><surname>Saturday</surname><given-names>G.</given-names></name>; <name><surname>Edwards</surname><given-names>N. J.</given-names></name>; <name><surname>Clark</surname><given-names>M. H. A.</given-names></name>; <name><surname>Lambe</surname><given-names>T.</given-names></name>; <name><surname>Gilbert</surname><given-names>S. C.</given-names></name>; <name><surname>Munster</surname><given-names>V. J.</given-names></name>
<article-title>A Single Dose of ChAdOx1MERS Provides Protective
Immunity in Rhesus Macaques</article-title>. <source>Sci. Adv.</source>
<year>2020</year>, <volume>6</volume>, <elocation-id>eaba8399</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba8399</pub-id>.<pub-id pub-id-type="pmid">32577525</pub-id></mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Gary</surname><given-names>E. N.</given-names></name>; <name><surname>Weiner</surname><given-names>D. B.</given-names></name>
<article-title>DNA Vaccines: Prime Time Is Now</article-title>. <source>Curr. Opin. Immunol.</source>
<year>2020</year>, <volume>65</volume>, <fpage>21</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2020.01.006</pub-id>.<pub-id pub-id-type="pmid">32259744</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Modjarrad</surname><given-names>K.</given-names></name>; <name><surname>Roberts</surname><given-names>C. C.</given-names></name>; <name><surname>Mills</surname><given-names>K. T.</given-names></name>; <name><surname>Castellano</surname><given-names>A. R.</given-names></name>; <name><surname>Paolino</surname><given-names>K.</given-names></name>; <name><surname>Muthumani</surname><given-names>K.</given-names></name>; <name><surname>Reuschel</surname><given-names>E. L.</given-names></name>; <name><surname>Robb</surname><given-names>M. L.</given-names></name>; <name><surname>Racine</surname><given-names>T.</given-names></name>; <name><surname>Oh</surname><given-names>M.-d.</given-names></name>; <name><surname>Lamarre</surname><given-names>C.</given-names></name>; <name><surname>Zaidi</surname><given-names>F. I.</given-names></name>; <name><surname>Boyer</surname><given-names>J.</given-names></name>; <name><surname>Kudchodkar</surname><given-names>S. B.</given-names></name>; <name><surname>Jeong</surname><given-names>M.</given-names></name>; <name><surname>Darden</surname><given-names>J. M.</given-names></name>; <name><surname>Park</surname><given-names>Y. K.</given-names></name>; <name><surname>Scott</surname><given-names>P. T.</given-names></name>; <name><surname>Remigio</surname><given-names>C.</given-names></name>; <name><surname>Parikh</surname><given-names>A. P.</given-names></name>; et al. <article-title>Safety and Immunogenicity of an Anti-Middle East
Respiratory Syndrome Coronavirus DNA Vaccine: A Phase 1,
Open-Label, Single-Arm, Dose-Escalation Trial</article-title>. <source>Lancet Infect. Dis.</source>
<year>2019</year>, <volume>19</volume>, <fpage>1013</fpage>&#x02013;<lpage>1022</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(19)30266-X</pub-id>.<pub-id pub-id-type="pmid">31351922</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Muthumani</surname><given-names>K.</given-names></name>; <name><surname>Falzarano</surname><given-names>D.</given-names></name>; <name><surname>Reuschel</surname><given-names>E. L.</given-names></name>; <name><surname>Tingey</surname><given-names>C.</given-names></name>; <name><surname>Flingai</surname><given-names>S.</given-names></name>; <name><surname>Villarreal</surname><given-names>D. O.</given-names></name>; <name><surname>Wise</surname><given-names>M.</given-names></name>; <name><surname>Patel</surname><given-names>A.</given-names></name>; <name><surname>Izmirly</surname><given-names>A.</given-names></name>; <name><surname>Aljuaid</surname><given-names>A.</given-names></name>; <name><surname>Seliga</surname><given-names>A. M.</given-names></name>; <name><surname>Soule</surname><given-names>G.</given-names></name>; <name><surname>Morrow</surname><given-names>M.</given-names></name>; <name><surname>Kraynyak</surname><given-names>K. A.</given-names></name>; <name><surname>Khan</surname><given-names>A. S.</given-names></name>; <name><surname>Scott</surname><given-names>D. P.</given-names></name>; <name><surname>Feldmann</surname><given-names>F.</given-names></name>; <name><surname>LaCasse</surname><given-names>R.</given-names></name>; <name><surname>Meade-White</surname><given-names>K.</given-names></name>; <name><surname>Okumura</surname><given-names>A.</given-names></name>; et al. <article-title>A Synthetic Consensus Anti-Spike Protein DNA Vaccine
Induces Protective Immunity against Middle East Respiratory
Syndrome Coronavirus in Nonhuman Primates</article-title>. <source>Sci. Transl. Med.</source>
<year>2015</year>, <volume>7</volume>, <fpage>301</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac7462</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Pardi</surname><given-names>N.</given-names></name>; <name><surname>Hogan</surname><given-names>M. J.</given-names></name>; <name><surname>Porter</surname><given-names>F. W.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>
<article-title>mRNA Vaccines &#x02014; A New Era in
Vaccinology</article-title>. <source>Nat. Rev. Drug Discovery</source>
<year>2018</year>, <volume>17</volume>, <fpage>261</fpage>&#x02013;<lpage>279</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id>.<pub-id pub-id-type="pmid">29326426</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Suschak</surname><given-names>J. J.</given-names></name>; <name><surname>Williams</surname><given-names>J. A.</given-names></name>; <name><surname>Schmaljohn</surname><given-names>C. S.</given-names></name>
<article-title>Advancements in DNA Vaccine Vectors, Non-Mechanical
Delivery Methods, and Molecular Adjuvants to Increase
Immunogenicity</article-title>. <source>Hum. Vaccines Immunother.</source>
<year>2017</year>, <volume>13</volume>, <fpage>2837</fpage>&#x02013;<lpage>2848</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2017.1330236</pub-id>.</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Gallie</surname><given-names>D. R.</given-names></name>
<article-title>The Cap and Poly (A) Tail Function Synergistically to
Regulate mRNA Translational Efficiency</article-title>. <source>Genes Dev.</source>
<year>1991</year>, <volume>5</volume>, <fpage>2108</fpage>&#x02013;<lpage>2116</lpage>. <pub-id pub-id-type="doi">10.1101/gad.5.11.2108</pub-id>.<pub-id pub-id-type="pmid">1682219</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Gustafsson</surname><given-names>C.</given-names></name>; <name><surname>Govindarajan</surname><given-names>S.</given-names></name>; <name><surname>Minshull</surname><given-names>J.</given-names></name>
<article-title>Codon Bias and Heterologous Protein
Expression</article-title>. <source>Trends Biotechnol.</source>
<year>2004</year>, <volume>22</volume>, <fpage>346</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2004.04.006</pub-id>.<pub-id pub-id-type="pmid">15245907</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>; <name><surname>Muramatsu</surname><given-names>H.</given-names></name>; <name><surname>Welsh</surname><given-names>F. A.</given-names></name>; <name><surname>Ludwig</surname><given-names>J.</given-names></name>; <name><surname>Kato</surname><given-names>H.</given-names></name>; <name><surname>Akira</surname><given-names>S.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>
<article-title>Incorporation of Pseudouridine into mRNA Yields
Superior Nonimmunogenic Vector with Increased Translational
Capacity and Biological Stability</article-title>. <source>Mol. Ther.</source>
<year>2008</year>, <volume>16</volume>, <fpage>1833</fpage>&#x02013;<lpage>1840</lpage>. <pub-id pub-id-type="doi">10.1038/mt.2008.200</pub-id>.<pub-id pub-id-type="pmid">18797453</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>; <name><surname>Buckstein</surname><given-names>M.</given-names></name>; <name><surname>Ni</surname><given-names>H.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>
<article-title>Suppression of RNA Recognition by Toll-Like Receptors:
the Impact of Nucleoside Modification and the Evolutionary
Origin of RNA</article-title>. <source>Immunity</source>
<year>2005</year>, <volume>23</volume>, <fpage>165</fpage>&#x02013;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2005.06.008</pub-id>.<pub-id pub-id-type="pmid">16111635</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Chen</surname><given-names>N.</given-names></name>; <name><surname>Xia</surname><given-names>P.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>T. T.</given-names></name>; <name><surname>Zhu</surname><given-names>J.</given-names></name>
<article-title>RNA Sensors of the Innate Immune System and Their
Detection of Pathogens</article-title>. <source>IUBMB Life</source>
<year>2017</year>, <volume>69</volume>, <fpage>297</fpage>&#x02013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1002/iub.1625</pub-id>.<pub-id pub-id-type="pmid">28374903</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Kariko</surname><given-names>K.</given-names></name>; <name><surname>Muramatsu</surname><given-names>H.</given-names></name>; <name><surname>Ludwig</surname><given-names>J.</given-names></name>; <name><surname>Weissman</surname><given-names>D.</given-names></name>
<article-title>Generating the Optimal mRNA for Therapy: HPLC
Purification Eliminates Immune Activation and Improves
Translation of Nucleoside-Modified, Protein-Encoding
mRNA</article-title>. <source>Nucleic Acids Res.</source>
<year>2011</year>, <volume>39</volume>, <fpage>142</fpage><pub-id pub-id-type="doi">10.1093/nar/gkr695</pub-id>.</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Cohen</surname><given-names>J.</given-names></name>
<article-title>Designer Proteins Produce Potent HIV
Defense</article-title>. <source>Science</source>
<year>2015</year>, <volume>348</volume>, <fpage>1297</fpage><pub-id pub-id-type="doi">10.1126/science.348.6241.1297</pub-id>.<pub-id pub-id-type="pmid">26089490</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Bijker</surname><given-names>M. S.</given-names></name>; <name><surname>van den Eeden</surname><given-names>S. J.</given-names></name>; <name><surname>Franken</surname><given-names>K. L.</given-names></name>; <name><surname>Melief</surname><given-names>C. J.</given-names></name>; <name><surname>Offringa</surname><given-names>R.</given-names></name>; <name><surname>van der Burg</surname><given-names>S. H.</given-names></name>
<article-title>CD8+ CTL Priming by Exact Peptide Epitopes in
Incomplete Freund&#x02019;s Adjuvant Induces a Vanishing CTL
Response, Whereas Long Peptides Induce Sustained CTL
Reactivity</article-title>. <source>J. Immunol.</source>
<year>2007</year>, <volume>179</volume>, <fpage>5033</fpage>&#x02013;<lpage>5040</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.8.5033</pub-id>.<pub-id pub-id-type="pmid">17911588</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Bijker</surname><given-names>M. S.</given-names></name>; <name><surname>van den Eeden</surname><given-names>S. J.</given-names></name>; <name><surname>Franken</surname><given-names>K. L.</given-names></name>; <name><surname>Melief</surname><given-names>C. J.</given-names></name>; <name><surname>van der Burg</surname><given-names>S. H.</given-names></name>; <name><surname>Offringa</surname><given-names>R.</given-names></name>
<article-title>Superior Induction of Anti-Tumor CTL Immunity by
Extended Peptide Vaccines Involves Prolonged, DC-Focused Antigen
Presentation</article-title>. <source>Eur. J. Immunol.</source>
<year>2008</year>, <volume>38</volume>, <fpage>1033</fpage>&#x02013;<lpage>1042</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200737995</pub-id>.<pub-id pub-id-type="pmid">18350546</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Jackson</surname><given-names>D. C.</given-names></name>; <name><surname>Lau</surname><given-names>Y. F.</given-names></name>; <name><surname>Le</surname><given-names>T.</given-names></name>; <name><surname>Suhrbier</surname><given-names>A.</given-names></name>; <name><surname>Deliyannis</surname><given-names>G.</given-names></name>; <name><surname>Cheers</surname><given-names>C.</given-names></name>; <name><surname>Smith</surname><given-names>C.</given-names></name>; <name><surname>Zeng</surname><given-names>W.</given-names></name>; <name><surname>Brown</surname><given-names>L. E.</given-names></name>
<article-title>A Totally Synthetic Vaccine of Generic Structure That
Targets Toll-Like Receptor 2 on Dendritic Cells and Promotes
Antibody or Cytotoxic T Cell Responses</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2004</year>, <volume>101</volume>, <fpage>15440</fpage><pub-id pub-id-type="doi">10.1073/pnas.0406740101</pub-id>.<pub-id pub-id-type="pmid">15489266</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Enayatkhani</surname><given-names>M.</given-names></name>; <name><surname>Hasaniazad</surname><given-names>M.</given-names></name>; <name><surname>Faezi</surname><given-names>S.</given-names></name>; <name><surname>Guklani</surname><given-names>H.</given-names></name>; <name><surname>Davoodian</surname><given-names>P.</given-names></name>; <name><surname>Ahmadi</surname><given-names>N.</given-names></name>; <name><surname>Einakian</surname><given-names>M. A.</given-names></name>; <name><surname>Karmostaji</surname><given-names>A.</given-names></name>; <name><surname>Ahmadi</surname><given-names>K.</given-names></name>
<article-title>Reverse Vaccinology Approach to Design a Novel
Multi-Epitope Vaccine Candidate against COVID-19: An In Silico
Study</article-title>. <source>J. Biomol. Struct. Dyn.</source>
<year>2020</year>, <fpage>1</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/07391102.2020.1756411</pub-id>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Kapsenberg</surname><given-names>M. L.</given-names></name>
<article-title>Dendritic-Cell Control of Pathogen-Driven T-Cell
Polarization</article-title>. <source>Nat. Rev. Immunol.</source>
<year>2003</year>, <volume>3</volume>, <fpage>984</fpage>&#x02013;<lpage>993</lpage>. <pub-id pub-id-type="doi">10.1038/nri1246</pub-id>.<pub-id pub-id-type="pmid">14647480</pub-id></mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Malowany</surname><given-names>J. I.</given-names></name>; <name><surname>McCormick</surname><given-names>S.</given-names></name>; <name><surname>Santosuosso</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Aoki</surname><given-names>N.</given-names></name>; <name><surname>Ngai</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Leitch</surname><given-names>J.</given-names></name>; <name><surname>Bramson</surname><given-names>J.</given-names></name>; <name><surname>Wan</surname><given-names>Y.</given-names></name>; <name><surname>Xing</surname><given-names>Z.</given-names></name>
<article-title>Development of Cell-Based Tuberculosis Vaccines:
Genetically Modified Dendritic Cell Vaccine Is a Much More
Potent Activator of CD4 and CD8 T Cells Than Peptide- or
Protein-Loaded Counterparts</article-title>. <source>Mol. Ther.</source>
<year>2006</year>, <volume>13</volume>, <fpage>766</fpage>&#x02013;<lpage>775</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymthe.2005.10.018</pub-id>.<pub-id pub-id-type="pmid">16343993</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Benteyn</surname><given-names>D.</given-names></name>; <name><surname>Heirman</surname><given-names>C.</given-names></name>; <name><surname>Bonehill</surname><given-names>A.</given-names></name>; <name><surname>Thielemans</surname><given-names>K.</given-names></name>; <name><surname>Breckpot</surname><given-names>K.</given-names></name>
<article-title>mRNA-Based Dendritic Cell Vaccines</article-title>. <source>Expert Rev. Vaccines</source>
<year>2015</year>, <volume>14</volume>, <fpage>161</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2014.957684</pub-id>.<pub-id pub-id-type="pmid">25196947</pub-id></mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Perez</surname><given-names>C. R.</given-names></name>; <name><surname>De Palma</surname><given-names>M.</given-names></name>
<article-title>Engineering Dendritic Cell Vaccines to Improve Cancer
Immunotherapy</article-title>. <source>Nat. Commun.</source>
<year>2019</year>, <volume>10</volume>, <fpage>5408</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13368-y</pub-id>.<pub-id pub-id-type="pmid">31776331</pub-id></mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Vela Ramirez</surname><given-names>J. E.</given-names></name>; <name><surname>Sharpe</surname><given-names>L. A.</given-names></name>; <name><surname>Peppas</surname><given-names>N. A.</given-names></name>
<article-title>Current State and Challenges in Developing Oral
Vaccines</article-title>. <source>Adv. Drug Delivery Rev.</source>
<year>2017</year>, <volume>114</volume>, <fpage>116</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2017.04.008</pub-id>.</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Melief</surname><given-names>C. J. M.</given-names></name>; <name><surname>van der Burg</surname><given-names>S. H.</given-names></name>
<article-title>Immunotherapy of Established (Pre)malignant Disease by
Synthetic Long Peptide Vaccines</article-title>. <source>Nat. Rev. Cancer</source>
<year>2008</year>, <volume>8</volume>, <fpage>351</fpage>&#x02013;<lpage>360</lpage>. <pub-id pub-id-type="doi">10.1038/nrc2373</pub-id>.<pub-id pub-id-type="pmid">18418403</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Napolitani</surname><given-names>G.</given-names></name>; <name><surname>Rinaldi</surname><given-names>A.</given-names></name>; <name><surname>Bertoni</surname><given-names>F.</given-names></name>; <name><surname>Sallusto</surname><given-names>F.</given-names></name>; <name><surname>Lanzavecchia</surname><given-names>A.</given-names></name>
<article-title>Selected Toll-Like Receptor Agonist Combinations
Synergistically Trigger a T Helper Type 1-Polarizing Program in
Dendritic Cells</article-title>. <source>Nat. Immunol.</source>
<year>2005</year>, <volume>6</volume>, <fpage>769</fpage>&#x02013;<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1038/ni1223</pub-id>.<pub-id pub-id-type="pmid">15995707</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Coffman</surname><given-names>R. L.</given-names></name>; <name><surname>Sher</surname><given-names>A.</given-names></name>; <name><surname>Seder</surname><given-names>R. A.</given-names></name>
<article-title>Vaccine Adjuvants: Putting Innate Immunity to
Work</article-title>. <source>Immunity</source>
<year>2010</year>, <volume>33</volume>, <fpage>492</fpage>&#x02013;<lpage>503</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id>.<pub-id pub-id-type="pmid">21029960</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Stephan</surname><given-names>M. T.</given-names></name>; <name><surname>Moon</surname><given-names>J. J.</given-names></name>; <name><surname>Um</surname><given-names>S. H.</given-names></name>; <name><surname>Bershteyn</surname><given-names>A.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Therapeutic Cell Engineering with Surface-Conjugated
Synthetic Nanoparticles</article-title>. <source>Nat. Med.</source>
<year>2010</year>, <volume>16</volume>, <fpage>1035</fpage>&#x02013;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2198</pub-id>.<pub-id pub-id-type="pmid">20711198</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Yong</surname><given-names>C. Y.</given-names></name>; <name><surname>Ong</surname><given-names>H. K.</given-names></name>; <name><surname>Yeap</surname><given-names>S. K.</given-names></name>; <name><surname>Ho</surname><given-names>K. L.</given-names></name>; <name><surname>Tan</surname><given-names>W. S.</given-names></name>
<article-title>Recent Advances in the Vaccine Development against
Middle East Respiratory Syndrome-Coronavirus</article-title>. <source>Front. Microbiol.</source>
<year>2019</year>, <volume>10</volume>, <fpage>1781</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01781</pub-id>.<pub-id pub-id-type="pmid">31428074</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Hajj</surname><given-names>K. A.</given-names></name>; <name><surname>Whitehead</surname><given-names>K. A.</given-names></name>
<article-title>Tools for Translation: Non-Viral Materials for
Therapeutic mRNA Delivery</article-title>. <source>Nat. Rev. Mater.</source>
<year>2017</year>, <volume>2</volume>, <fpage>17056</fpage><pub-id pub-id-type="doi">10.1038/natrevmats.2017.56</pub-id>.</mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Moyer</surname><given-names>T. J.</given-names></name>; <name><surname>Zmolek</surname><given-names>A. C.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Beyond Antigens and Adjuvants: Formulating Future
Vaccines</article-title>. <source>J. Clin. Invest.</source>
<year>2016</year>, <volume>126</volume>, <fpage>799</fpage>&#x02013;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1172/JCI81083</pub-id>.<pub-id pub-id-type="pmid">26928033</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Hu</surname><given-names>Q.</given-names></name>; <name><surname>Ji</surname><given-names>W.</given-names></name>; <name><surname>Wright</surname><given-names>G.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>
<article-title>Leveraging Physiology for Precision Drug
Delivery</article-title>. <source>Physiol. Rev.</source>
<year>2017</year>, <volume>97</volume>, <fpage>189</fpage>&#x02013;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00015.2016</pub-id>.</mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Moon</surname><given-names>J. J.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Engineering Nano-and Microparticles to Tune
Immunity</article-title>. <source>Adv. Mater.</source>
<year>2012</year>, <volume>24</volume>, <fpage>3724</fpage>&#x02013;<lpage>3746</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201200446</pub-id>.<pub-id pub-id-type="pmid">22641380</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>Oberli</surname><given-names>M. A.</given-names></name>; <name><surname>Reichmuth</surname><given-names>A. M.</given-names></name>; <name><surname>Dorkin</surname><given-names>J. R.</given-names></name>; <name><surname>Mitchell</surname><given-names>M. J.</given-names></name>; <name><surname>Fenton</surname><given-names>O. S.</given-names></name>; <name><surname>Jaklenec</surname><given-names>A.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Blankschtein</surname><given-names>D.</given-names></name>
<article-title>Lipid Nanoparticle Assisted mRNA Delivery for Potent
Cancer Immunotherapy</article-title>. <source>Nano Lett.</source>
<year>2017</year>, <volume>17</volume>, <fpage>1326</fpage>&#x02013;<lpage>1335</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03329</pub-id>.<pub-id pub-id-type="pmid">28273716</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Moon</surname><given-names>J. J.</given-names></name>; <name><surname>Suh</surname><given-names>H.</given-names></name>; <name><surname>Bershteyn</surname><given-names>A.</given-names></name>; <name><surname>Stephan</surname><given-names>M. T.</given-names></name>; <name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Sohail</surname><given-names>M.</given-names></name>; <name><surname>Luo</surname><given-names>S.</given-names></name>; <name><surname>Ho Um</surname><given-names>S.</given-names></name>; <name><surname>Khant</surname><given-names>H.</given-names></name>; <name><surname>Goodwin</surname><given-names>J. T.</given-names></name>; <name><surname>Ramos</surname><given-names>J.</given-names></name>; <name><surname>Chiu</surname><given-names>W.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Interbilayer-Crosslinked Multilamellar Vesicles as
Synthetic Vaccines for Potent Humoral and Cellular Immune
Responses</article-title>. <source>Nat. Mater.</source>
<year>2011</year>, <volume>10</volume>, <fpage>243</fpage>&#x02013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1038/nmat2960</pub-id>.<pub-id pub-id-type="pmid">21336265</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Kranz</surname><given-names>L. M.</given-names></name>; <name><surname>Diken</surname><given-names>M.</given-names></name>; <name><surname>Haas</surname><given-names>H.</given-names></name>; <name><surname>Kreiter</surname><given-names>S.</given-names></name>; <name><surname>Loquai</surname><given-names>C.</given-names></name>; <name><surname>Reuter</surname><given-names>K. C.</given-names></name>; <name><surname>Meng</surname><given-names>M.</given-names></name>; <name><surname>Fritz</surname><given-names>D.</given-names></name>; <name><surname>Vascotto</surname><given-names>F.</given-names></name>; <name><surname>Hefesha</surname><given-names>H.</given-names></name>; <name><surname>Grunwitz</surname><given-names>C.</given-names></name>; <name><surname>Vormehr</surname><given-names>M.</given-names></name>; <name><surname>H&#x000fc;semann</surname><given-names>Y.</given-names></name>; <name><surname>Selmi</surname><given-names>A.</given-names></name>; <name><surname>Kuhn</surname><given-names>A. N.</given-names></name>; <name><surname>Buck</surname><given-names>J.</given-names></name>; <name><surname>Derhovanessian</surname><given-names>E.</given-names></name>; <name><surname>Rae</surname><given-names>R.</given-names></name>; <name><surname>Attig</surname><given-names>S.</given-names></name>; <name><surname>Diekmann</surname><given-names>J.</given-names></name>; et al. <article-title>Systemic RNA Delivery to Dendritic Cells Exploits
Antiviral Defence for Cancer Immunotherapy</article-title>. <source>Nature</source>
<year>2016</year>, <volume>534</volume>, <fpage>396</fpage>&#x02013;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1038/nature18300</pub-id>.<pub-id pub-id-type="pmid">27281205</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Irvine</surname><given-names>D. J.</given-names></name>; <name><surname>Read</surname><given-names>B. J.</given-names></name>
<article-title>Shaping Humoral Immunity to Vaccines through
Antigen-Displaying Nanoparticles</article-title>. <source>Curr. Opin. Immunol.</source>
<year>2020</year>, <volume>65</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2020.01.007</pub-id>.<pub-id pub-id-type="pmid">32200132</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Kuai</surname><given-names>R.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>; <name><surname>Yuan</surname><given-names>W.</given-names></name>; <name><surname>Ochyl</surname><given-names>L. J.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Hassani Najafabadi</surname><given-names>A.</given-names></name>; <name><surname>Scheetz</surname><given-names>L.</given-names></name>; <name><surname>Yu</surname><given-names>M.-Z.</given-names></name>; <name><surname>Balwani</surname><given-names>I.</given-names></name>; <name><surname>Schwendeman</surname><given-names>A.</given-names></name>; <name><surname>Moon</surname><given-names>J. J.</given-names></name>
<article-title>Dual TLR Agonist Nanodiscs as a Strong Adjuvant System
for Vaccines and Immunotherapy</article-title>. <source>J. Controlled Release</source>
<year>2018</year>, <volume>282</volume>, <fpage>131</fpage>&#x02013;<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2018.04.041</pub-id>.</mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Miao</surname><given-names>L.</given-names></name>; <name><surname>Li</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Delcassian</surname><given-names>D.</given-names></name>; <name><surname>Chahal</surname><given-names>J.</given-names></name>; <name><surname>Han</surname><given-names>J.</given-names></name>; <name><surname>Shi</surname><given-names>Y.</given-names></name>; <name><surname>Sadtler</surname><given-names>K.</given-names></name>; <name><surname>Gao</surname><given-names>W.</given-names></name>; <name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Doloff</surname><given-names>J. C.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Delivery of mRNA Vaccines with Heterocyclic Lipids
Increases Anti-Tumor Efficacy by STING-Mediated Immune Cell
Activation</article-title>. <source>Nat. Biotechnol.</source>
<year>2019</year>, <volume>37</volume>, <fpage>1174</fpage>&#x02013;<lpage>1185</lpage>. <pub-id pub-id-type="doi">10.1038/s41587-019-0247-3</pub-id>.<pub-id pub-id-type="pmid">31570898</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Chahal</surname><given-names>J. S.</given-names></name>; <name><surname>Khan</surname><given-names>O. F.</given-names></name>; <name><surname>Cooper</surname><given-names>C. L.</given-names></name>; <name><surname>McPartlan</surname><given-names>J. S.</given-names></name>; <name><surname>Tsosie</surname><given-names>J. K.</given-names></name>; <name><surname>Tilley</surname><given-names>L. D.</given-names></name>; <name><surname>Sidik</surname><given-names>S. M.</given-names></name>; <name><surname>Lourido</surname><given-names>S.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Bavari</surname><given-names>S.</given-names></name>; <name><surname>Ploegh</surname><given-names>H. L.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Dendrimer-RNA Nanoparticles Generate Protective
Immunity against Lethal Ebola, H1N1 Influenza, and Toxoplasma
Gondii Challenges with a Single Dose</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2016</year>, <volume>113</volume>, <fpage>E4133</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1600299113</pub-id>.<pub-id pub-id-type="pmid">27382155</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Zeng</surname><given-names>Q.</given-names></name>; <name><surname>Jiang</surname><given-names>H.</given-names></name>; <name><surname>Wang</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Gong</surname><given-names>T.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>
<article-title>Cationic Micelle Delivery of Trp2 Peptide for Efficient
Lymphatic Draining and Enhanced Cytotoxic T-Lymphocyte
Responses</article-title>. <source>J. Controlled Release</source>
<year>2015</year>, <volume>200</volume>, <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.12.024</pub-id>.</mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Gong</surname><given-names>T.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>
<article-title>Induction of HIV-1 Gag Specific Immune Responses by
Cationic Micelles Mediated Delivery of Gag mRNA</article-title>. <source>Drug Delivery</source>
<year>2016</year>, <volume>23</volume>, <fpage>2596</fpage>&#x02013;<lpage>2607</lpage>. <pub-id pub-id-type="doi">10.3109/10717544.2015.1038856</pub-id>.<pub-id pub-id-type="pmid">26024387</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Fu</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Gong</surname><given-names>T.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Sun</surname><given-names>X.</given-names></name>
<article-title>Enhanced Intranasal Delivery of mRNA Vaccine by
Overcoming the Nasal Epithelial Barrier <italic>via</italic>
Intra- and Paracellular Pathways</article-title>. <source>J. Controlled Release</source>
<year>2016</year>, <volume>228</volume>, <fpage>9</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2016.02.043</pub-id>.</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Demento</surname><given-names>S. L.</given-names></name>; <name><surname>Cui</surname><given-names>W.</given-names></name>; <name><surname>Criscione</surname><given-names>J. M.</given-names></name>; <name><surname>Stern</surname><given-names>E.</given-names></name>; <name><surname>Tulipan</surname><given-names>J.</given-names></name>; <name><surname>Kaech</surname><given-names>S. M.</given-names></name>; <name><surname>Fahmy</surname><given-names>T. M.</given-names></name>
<article-title>Role of Sustained Antigen Release from Nanoparticle
Vaccines in Shaping the T Cell Memory Phenotype</article-title>. <source>Biomaterials</source>
<year>2012</year>, <volume>33</volume>, <fpage>4957</fpage>&#x02013;<lpage>4964</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.03.041</pub-id>.<pub-id pub-id-type="pmid">22484047</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Gu</surname><given-names>P.</given-names></name>; <name><surname>Wusiman</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Bo</surname><given-names>R.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>
<article-title>Rational Design of PLGA Nanoparticle Vaccine Delivery
Systems to Improve Immune Responses</article-title>. <source>Mol. Pharmaceutics</source>
<year>2019</year>, <volume>16</volume>, <fpage>5000</fpage>&#x02013;<lpage>5012</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00860</pub-id>.</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Fan</surname><given-names>B.</given-names></name>; <name><surname>Ma</surname><given-names>X.</given-names></name>; <name><surname>Yuan</surname><given-names>Q.</given-names></name>; <name><surname>Ma</surname><given-names>G.</given-names></name>; <name><surname>Su</surname><given-names>Z.</given-names></name>
<article-title>Enhanced Humoral and Cell-Mediated Immune Responses
Generated by Cationic Polymer-Coated PLA Microspheres with
Adsorbed HBsAg</article-title>. <source>Mol. Pharmaceutics</source>
<year>2014</year>, <volume>11</volume>, <fpage>1772</fpage>&#x02013;<lpage>1784</lpage>. <pub-id pub-id-type="doi">10.1021/mp400597z</pub-id>.</mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>P.</given-names></name>; <name><surname>Yin</surname><given-names>Y.</given-names></name>; <name><surname>Cai</surname><given-names>X.</given-names></name>; <name><surname>Huang</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Dong</surname><given-names>L.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>
<article-title>The Promotion of Type 1 T Helper Cell Responses to
Cationic Polymers <italic>in Vivo via</italic> Toll-Like
Receptor-4 Mediated IL-12 Secretion</article-title>. <source>Biomaterials</source>
<year>2010</year>, <volume>31</volume>, <fpage>8172</fpage>&#x02013;<lpage>8180</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.07.056</pub-id>.<pub-id pub-id-type="pmid">20692033</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Fields</surname><given-names>R. J.</given-names></name>; <name><surname>Cheng</surname><given-names>C. J.</given-names></name>; <name><surname>Quijano</surname><given-names>E.</given-names></name>; <name><surname>Weller</surname><given-names>C.</given-names></name>; <name><surname>Kristofik</surname><given-names>N.</given-names></name>; <name><surname>Duong</surname><given-names>N.</given-names></name>; <name><surname>Hoimes</surname><given-names>C.</given-names></name>; <name><surname>Egan</surname><given-names>M. E.</given-names></name>; <name><surname>Saltzman</surname><given-names>W. M.</given-names></name>
<article-title>Surface Modified Poly(&#x003b2; Amino Ester)-Containing
Nanoparticles for Plasmid DNA Delivery</article-title>. <source>J. Controlled Release</source>
<year>2012</year>, <volume>164</volume>, <fpage>41</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.09.020</pub-id>.</mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Kowalski</surname><given-names>P. S.</given-names></name>; <name><surname>Capasso Palmiero</surname><given-names>U.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Rudra</surname><given-names>A.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>
<article-title>Ionizable Amino-Polyesters Synthesized
<italic>via</italic> Ring Opening Polymerization of
Tertiary Amino-Alcohols for Tissue Selective mRNA
Delivery</article-title>. <source>Adv. Mater.</source>
<year>2018</year>, <volume>30</volume>, <fpage>1801151</fpage><pub-id pub-id-type="doi">10.1002/adma.201801151</pub-id>.</mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Fornaguera</surname><given-names>C.</given-names></name>; <name><surname>Guerra-Rebollo</surname><given-names>M.</given-names></name>; <name><surname>&#x000c1;ngel L&#x000e1;zaro</surname><given-names>M.</given-names></name>; <name><surname>Castells-Sala</surname><given-names>C.</given-names></name>; <name><surname>Meca-Cort&#x000e9;s</surname><given-names>O.</given-names></name>; <name><surname>Ramos-P&#x000e9;rez</surname><given-names>V.</given-names></name>; <name><surname>Cascante</surname><given-names>A.</given-names></name>; <name><surname>Rubio</surname><given-names>N.</given-names></name>; <name><surname>Blanco</surname><given-names>J.</given-names></name>; <name><surname>Borr&#x000f3;s</surname><given-names>S.</given-names></name>
<article-title>mRNA Delivery System for Targeting Antigen-Presenting
Cells <italic>in Vivo</italic></article-title>. <source>Adv. Healthcare Mater.</source>
<year>2018</year>, <volume>7</volume>, <fpage>1800335</fpage><pub-id pub-id-type="doi">10.1002/adhm.201800335</pub-id>.</mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Liu</surname><given-names>H.</given-names></name>; <name><surname>Moynihan</surname><given-names>K. D.</given-names></name>; <name><surname>Zheng</surname><given-names>Y.</given-names></name>; <name><surname>Szeto</surname><given-names>G. L.</given-names></name>; <name><surname>Li</surname><given-names>A. V.</given-names></name>; <name><surname>Huang</surname><given-names>B.</given-names></name>; <name><surname>Van Egeren</surname><given-names>D. S.</given-names></name>; <name><surname>Park</surname><given-names>C.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Structure-Based Programming of Lymph-Node Targeting in
Molecular Vaccines</article-title>. <source>Nature</source>
<year>2014</year>, <volume>507</volume>, <fpage>519</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/nature12978</pub-id>.<pub-id pub-id-type="pmid">24531764</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Son</surname><given-names>S.</given-names></name>; <name><surname>Nam</surname><given-names>J.</given-names></name>; <name><surname>Zenkov</surname><given-names>I.</given-names></name>; <name><surname>Ochyl</surname><given-names>L. J.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Scheetz</surname><given-names>L.</given-names></name>; <name><surname>Shi</surname><given-names>J.</given-names></name>; <name><surname>Farokhzad</surname><given-names>O. C.</given-names></name>; <name><surname>Moon</surname><given-names>J. J.</given-names></name>
<article-title>Sugar-Nanocapsules Imprinted with Microbial Molecular
Patterns for mRNA Vaccination</article-title>. <source>Nano Lett.</source>
<year>2020</year>, <volume>20</volume>, <fpage>1499</fpage>&#x02013;<lpage>1509</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.9b03483</pub-id>.<pub-id pub-id-type="pmid">32023415</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Moyer</surname><given-names>T. J.</given-names></name>; <name><surname>Kato</surname><given-names>Y.</given-names></name>; <name><surname>Abraham</surname><given-names>W.</given-names></name>; <name><surname>Chang</surname><given-names>J. Y. H.</given-names></name>; <name><surname>Kulp</surname><given-names>D. W.</given-names></name>; <name><surname>Watson</surname><given-names>N.</given-names></name>; <name><surname>Turner</surname><given-names>H. L.</given-names></name>; <name><surname>Menis</surname><given-names>S.</given-names></name>; <name><surname>Abbott</surname><given-names>R. K.</given-names></name>; <name><surname>Bhiman</surname><given-names>J. N.</given-names></name>; <name><surname>Melo</surname><given-names>M. B.</given-names></name>; <name><surname>Simon</surname><given-names>H. A.</given-names></name>; <name><surname>Herrera-De la Mata</surname><given-names>S.</given-names></name>; <name><surname>Liang</surname><given-names>S.</given-names></name>; <name><surname>Seumois</surname><given-names>G.</given-names></name>; <name><surname>Agarwal</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>N.</given-names></name>; <name><surname>Burton</surname><given-names>D. R.</given-names></name>; <name><surname>Ward</surname><given-names>A. B.</given-names></name>; <name><surname>Schief</surname><given-names>W. R.</given-names></name>; et al. <article-title>Engineered Immunogen Binding to Alum Adjuvant Enhances
Humoral Immunity</article-title>. <source>Nat. Med.</source>
<year>2020</year>, <volume>26</volume>, <fpage>430</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0753-3</pub-id>.<pub-id pub-id-type="pmid">32066977</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Moyano</surname><given-names>D. F.</given-names></name>; <name><surname>Goldsmith</surname><given-names>M.</given-names></name>; <name><surname>Solfiell</surname><given-names>D. J.</given-names></name>; <name><surname>Landesman-Milo</surname><given-names>D.</given-names></name>; <name><surname>Miranda</surname><given-names>O. R.</given-names></name>; <name><surname>Peer</surname><given-names>D.</given-names></name>; <name><surname>Rotello</surname><given-names>V. M.</given-names></name>
<article-title>Nanoparticle Hydrophobicity Dictates Immune
Response</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2012</year>, <volume>134</volume>, <fpage>3965</fpage>&#x02013;<lpage>3967</lpage>. <pub-id pub-id-type="doi">10.1021/ja2108905</pub-id>.<pub-id pub-id-type="pmid">22339432</pub-id></mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Ji</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Ma</surname><given-names>L.</given-names></name>; <name><surname>Shao</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Surface-Engineered Gold Nanorods: Promising DNA Vaccine
Adjuvant for HIV-1 Treatment</article-title>. <source>Nano Lett.</source>
<year>2012</year>, <volume>12</volume>, <fpage>2003</fpage>&#x02013;<lpage>2012</lpage>. <pub-id pub-id-type="doi">10.1021/nl300027p</pub-id>.<pub-id pub-id-type="pmid">22372996</pub-id></mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Qiu</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Bai</surname><given-names>R.</given-names></name>; <name><surname>Ji</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>X.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Surface Chemistry and Aspect Ratio Mediated Cellular
Uptake of Au Nanorods</article-title>. <source>Biomaterials</source>
<year>2010</year>, <volume>31</volume>, <fpage>7606</fpage>&#x02013;<lpage>7619</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.06.051</pub-id>.<pub-id pub-id-type="pmid">20656344</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Zhou</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Du</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>Y.</given-names></name>; <name><surname>Fu</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Zhan</surname><given-names>L.</given-names></name>
<article-title>Different-Sized Gold Nanoparticle Activator/Antigen
Increases Dendritic Cells Accumulation in Liver-Draining Lymph
Nodes and CD8+ T Cell Responses</article-title>. <source>ACS Nano</source>
<year>2016</year>, <volume>10</volume>, <fpage>2678</fpage>&#x02013;<lpage>2692</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.5b07716</pub-id>.<pub-id pub-id-type="pmid">26771692</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Mercuri</surname><given-names>L. P.</given-names></name>; <name><surname>Carvalho</surname><given-names>L. V.</given-names></name>; <name><surname>Lima</surname><given-names>F. A.</given-names></name>; <name><surname>Quayle</surname><given-names>C.</given-names></name>; <name><surname>Fantini</surname><given-names>M. C. A.</given-names></name>; <name><surname>Tanaka</surname><given-names>G. S.</given-names></name>; <name><surname>Cabrera</surname><given-names>W. H.</given-names></name>; <name><surname>Furtado</surname><given-names>M. F. D.</given-names></name>; <name><surname>Tambourgi</surname><given-names>D. V.</given-names></name>; <name><surname>Matos</surname><given-names>J. d. R.</given-names></name>; <name><surname>Jaroniec</surname><given-names>M.</given-names></name>; <name><surname>Sant&#x02019;Anna</surname><given-names>O. A.</given-names></name>
<article-title>Ordered Mesoporous Silica SBA-15: A New Effective
Adjuvant to Induce Antibody Response</article-title>. <source>Small</source>
<year>2006</year>, <volume>2</volume>, <fpage>254</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="doi">10.1002/smll.200500274</pub-id>.<pub-id pub-id-type="pmid">17193031</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Mahony</surname><given-names>D.</given-names></name>; <name><surname>Cavallaro</surname><given-names>A. S.</given-names></name>; <name><surname>Mody</surname><given-names>K. T.</given-names></name>; <name><surname>Xiong</surname><given-names>L.</given-names></name>; <name><surname>Mahony</surname><given-names>T. J.</given-names></name>; <name><surname>Qiao</surname><given-names>S. Z.</given-names></name>; <name><surname>Mitter</surname><given-names>N.</given-names></name>
<article-title><italic>In Vivo</italic> Delivery of Bovine Viral
Diahorrea Virus, E2 Protein Using Hollow Mesoporous Silica
Nanoparticles</article-title>. <source>Nanoscale</source>
<year>2014</year>, <volume>6</volume>, <fpage>6617</fpage>&#x02013;<lpage>6626</lpage>. <pub-id pub-id-type="doi">10.1039/C4NR01202J</pub-id>.<pub-id pub-id-type="pmid">24811899</pub-id></mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Hess</surname><given-names>K. L.</given-names></name>; <name><surname>Oh</surname><given-names>E.</given-names></name>; <name><surname>Tostanoski</surname><given-names>L. H.</given-names></name>; <name><surname>Andorko</surname><given-names>J. I.</given-names></name>; <name><surname>Susumu</surname><given-names>K.</given-names></name>; <name><surname>Deschamps</surname><given-names>J. R.</given-names></name>; <name><surname>Medintz</surname><given-names>I. L.</given-names></name>; <name><surname>Jewell</surname><given-names>C. M.</given-names></name>
<article-title>Engineering Immunological Tolerance Using Quantum Dots
to Tune the Density of Self-Antigen Display</article-title>. <source>Adv. Funct. Mater.</source>
<year>2017</year>, <volume>27</volume>, <fpage>1700290</fpage><pub-id pub-id-type="doi">10.1002/adfm.201700290</pub-id>.<pub-id pub-id-type="pmid">29503604</pub-id></mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Hu</surname><given-names>Z.</given-names></name>; <name><surname>Song</surname><given-names>B.</given-names></name>; <name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Zhong</surname><given-names>Y.</given-names></name>; <name><surname>Peng</surname><given-names>F.</given-names></name>; <name><surname>Ji</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>F.</given-names></name>; <name><surname>Yang</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Su</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>S.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>He</surname><given-names>S.</given-names></name>
<article-title>Aqueous Synthesized Quantum Dots Interfere with the
NF-&#x003ba;B Pathway and Confer Anti-Tumor, Anti-Viral and
Anti-Inflammatory Effects</article-title>. <source>Biomaterials</source>
<year>2016</year>, <volume>108</volume>, <fpage>187</fpage>&#x02013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.08.047</pub-id>.<pub-id pub-id-type="pmid">27639114</pub-id></mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Faria</surname><given-names>P. C. B. d.</given-names></name>; <name><surname>Santos</surname><given-names>L. I. d.</given-names></name>; <name><surname>Coelho</surname><given-names>J. P.</given-names></name>; <name><surname>Ribeiro</surname><given-names>H. B.</given-names></name>; <name><surname>Pimenta</surname><given-names>M. A.</given-names></name>; <name><surname>Ladeira</surname><given-names>L. O.</given-names></name>; <name><surname>Gomes</surname><given-names>D. A.</given-names></name>; <name><surname>Furtado</surname><given-names>C. A.</given-names></name>; <name><surname>Gazzinelli</surname><given-names>R. T.</given-names></name>
<article-title>Oxidized Multiwalled Carbon Nanotubes as Antigen
Delivery System to Promote Superior CD8+ T Cell Response and
Protection against Cancer</article-title>. <source>Nano Lett.</source>
<year>2014</year>, <volume>14</volume>, <fpage>5458</fpage>&#x02013;<lpage>5470</lpage>. <pub-id pub-id-type="doi">10.1021/nl502911a</pub-id>.<pub-id pub-id-type="pmid">25115645</pub-id></mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Chan</surname><given-names>J. M.</given-names></name>; <name><surname>Gu</surname><given-names>F. X.</given-names></name>; <name><surname>Rhee</surname><given-names>J.-W.</given-names></name>; <name><surname>Wang</surname><given-names>A. Z.</given-names></name>; <name><surname>Radovic-Moreno</surname><given-names>A. F.</given-names></name>; <name><surname>Alexis</surname><given-names>F.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Farokhzad</surname><given-names>O. C.</given-names></name>
<article-title>Self-Assembled Lipid-Polymer Hybrid Nanoparticles: A
Robust Drug Delivery Platform</article-title>. <source>ACS Nano</source>
<year>2008</year>, <volume>2</volume>, <fpage>1696</fpage>&#x02013;<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1021/nn800275r</pub-id>.<pub-id pub-id-type="pmid">19206374</pub-id></mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name><surname>Walsh</surname><given-names>C. L.</given-names></name>; <name><surname>Nguyen</surname><given-names>J.</given-names></name>; <name><surname>Tiffany</surname><given-names>M. R.</given-names></name>; <name><surname>Szoka</surname><given-names>F. C.</given-names></name>
<article-title>Synthesis, Characterization, and Evaluation of
Ionizable Lysine-Based Lipids for siRNA Delivery</article-title>. <source>Bioconjugate Chem.</source>
<year>2013</year>, <volume>24</volume>, <fpage>36</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1021/bc300346h</pub-id>.</mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>Jokerst</surname><given-names>J. V.</given-names></name>; <name><surname>Lobovkina</surname><given-names>T.</given-names></name>; <name><surname>Zare</surname><given-names>R. N.</given-names></name>; <name><surname>Gambhir</surname><given-names>S. S.</given-names></name>
<article-title>Nanoparticle PEGylation for Imaging and
Therapy</article-title>. <source>Nanomedicine</source>
<year>2011</year>, <volume>6</volume>, <fpage>715</fpage>&#x02013;<lpage>728</lpage>. <pub-id pub-id-type="doi">10.2217/nnm.11.19</pub-id>.<pub-id pub-id-type="pmid">21718180</pub-id></mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Beltr&#x000e1;n-Gracia</surname><given-names>E.</given-names></name>; <name><surname>L&#x000f3;pez-Camacho</surname><given-names>A.</given-names></name>; <name><surname>Higuera-Ciapara</surname><given-names>I.</given-names></name>; <name><surname>Vel&#x000e1;zquez-Fern&#x000e1;ndez</surname><given-names>J. B.</given-names></name>; <name><surname>Vallejo-Cardona</surname><given-names>A. A.</given-names></name>
<article-title>Nanomedicine Review: Clinical Developments in Liposomal
Applications</article-title>. <source>Cancer Nanotechnol.</source>
<year>2019</year>, <volume>10</volume>, <fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s12645-019-0055-y</pub-id>.</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Tam</surname><given-names>H. H.</given-names></name>; <name><surname>Melo</surname><given-names>M. B.</given-names></name>; <name><surname>Kang</surname><given-names>M.</given-names></name>; <name><surname>Pelet</surname><given-names>J. M.</given-names></name>; <name><surname>Ruda</surname><given-names>V. M.</given-names></name>; <name><surname>Foley</surname><given-names>M. H.</given-names></name>; <name><surname>Hu</surname><given-names>J. K.</given-names></name>; <name><surname>Kumari</surname><given-names>S.</given-names></name>; <name><surname>Crampton</surname><given-names>J.</given-names></name>; <name><surname>Baldeon</surname><given-names>A. D.</given-names></name>; <name><surname>Sanders</surname><given-names>R. W.</given-names></name>; <name><surname>Moore</surname><given-names>J. P.</given-names></name>; <name><surname>Crotty</surname><given-names>S.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>; <name><surname>Chakraborty</surname><given-names>A. K.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Sustained Antigen Availability during Germinal Center
Initiation Enhances Antibody Responses to
Vaccination</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2016</year>, <volume>113</volume>, <fpage>E6639</fpage>&#x02013;<lpage>E6648</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1606050113</pub-id>.<pub-id pub-id-type="pmid">27702895</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="journal" id="cit88"><name><surname>Diebold</surname><given-names>S. S.</given-names></name>; <name><surname>Kaisho</surname><given-names>T.</given-names></name>; <name><surname>Hemmi</surname><given-names>H.</given-names></name>; <name><surname>Akira</surname><given-names>S.</given-names></name>; <name><surname>Reis e Sousa</surname><given-names>C.</given-names></name>
<article-title>Innate Antiviral Responses by Means of TLR7-Mediated
Recognition of Single-Stranded RNA</article-title>. <source>Science</source>
<year>2004</year>, <volume>303</volume>, <fpage>1529</fpage>&#x02013;<lpage>1531</lpage>. <pub-id pub-id-type="doi">10.1126/science.1093616</pub-id>.<pub-id pub-id-type="pmid">14976261</pub-id></mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>Kuai</surname><given-names>R.</given-names></name>; <name><surname>Ochyl</surname><given-names>L. J.</given-names></name>; <name><surname>Bahjat</surname><given-names>K. S.</given-names></name>; <name><surname>Schwendeman</surname><given-names>A.</given-names></name>; <name><surname>Moon</surname><given-names>J. J.</given-names></name>
<article-title>Designer Vaccine Nanodiscs for Personalized Cancer
Immunotherapy</article-title>. <source>Nat. Mater.</source>
<year>2017</year>, <volume>16</volume>, <fpage>489</fpage>&#x02013;<lpage>496</lpage>. <pub-id pub-id-type="doi">10.1038/nmat4822</pub-id>.<pub-id pub-id-type="pmid">28024156</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name><surname>Dobrovolskaia</surname><given-names>M. A.</given-names></name>; <name><surname>McNeil</surname><given-names>S. E.</given-names></name>
<article-title>Immunological Properties of Engineered
Nanomaterials</article-title>. <source>Nat. Nanotechnol.</source>
<year>2007</year>, <volume>2</volume>, <fpage>469</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1038/nnano.2007.223</pub-id>.<pub-id pub-id-type="pmid">18654343</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name><surname>Akinc</surname><given-names>A.</given-names></name>; <name><surname>Thomas</surname><given-names>M.</given-names></name>; <name><surname>Klibanov</surname><given-names>A. M.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>
<article-title>Exploring Polyethylenimine-Mediated DNA Transfection
and the Proton Sponge Hypothesis</article-title>. <source>J. Gene Med.</source>
<year>2005</year>, <volume>7</volume>, <fpage>657</fpage>&#x02013;<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1002/jgm.696</pub-id>.<pub-id pub-id-type="pmid">15543529</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name><surname>Boussif</surname><given-names>O.</given-names></name>; <name><surname>Lezoualch</surname><given-names>F.</given-names></name>; <name><surname>Zanta</surname><given-names>M. A.</given-names></name>; <name><surname>Mergny</surname><given-names>M. D.</given-names></name>; <name><surname>Scherman</surname><given-names>D.</given-names></name>; <name><surname>Demeneix</surname><given-names>B.</given-names></name>; <name><surname>Behr</surname><given-names>J. P.</given-names></name>
<article-title>A Versatile Vector for Gene and Oligonucleotide
Transfer into Cells in Culture and <italic>in Vivo</italic>:
Polyethylenimine</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>1995</year>, <volume>92</volume>, <fpage>7297</fpage>&#x02013;<lpage>7301</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.16.7297</pub-id>.<pub-id pub-id-type="pmid">7638184</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name><surname>Anderson</surname><given-names>J. M.</given-names></name>; <name><surname>Shive</surname><given-names>M. S.</given-names></name>
<article-title>Biodegradation and Biocompatibility of PLA and PLGA
Microspheres</article-title>. <source>Adv. Drug Delivery Rev.</source>
<year>2012</year>, <volume>64</volume>, <fpage>72</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2012.09.004</pub-id>.</mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name><surname>Sunshine</surname><given-names>J. C.</given-names></name>; <name><surname>Perica</surname><given-names>K.</given-names></name>; <name><surname>Schneck</surname><given-names>J. P.</given-names></name>; <name><surname>Green</surname><given-names>J. J.</given-names></name>
<article-title>Particle Shape Dependence of CD8+ T Cell Activation by
Artificial Antigen Presenting Cells</article-title>. <source>Biomaterials</source>
<year>2014</year>, <volume>35</volume>, <fpage>269</fpage>&#x02013;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.09.050</pub-id>.<pub-id pub-id-type="pmid">24099710</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="journal" id="cit95"><name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Tan</surname><given-names>M. T.</given-names></name>; <name><surname>Keegan</surname><given-names>B. P.</given-names></name>; <name><surname>Barry</surname><given-names>M. A.</given-names></name>; <name><surname>Heffernan</surname><given-names>M. J.</given-names></name>
<article-title>Time Course Study of the Antigen-Specific Immune
Response to a PLGA Microparticle Vaccine
Formulation</article-title>. <source>Biomaterials</source>
<year>2014</year>, <volume>35</volume>, <fpage>8385</fpage>&#x02013;<lpage>8393</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.05.067</pub-id>.<pub-id pub-id-type="pmid">24986256</pub-id></mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name><surname>Chan</surname><given-names>J. M.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Yuet</surname><given-names>K. P.</given-names></name>; <name><surname>Liao</surname><given-names>G.</given-names></name>; <name><surname>Rhee</surname><given-names>J.-W.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Farokhzad</surname><given-names>O. C.</given-names></name>
<article-title>PLGA-Lecithin-PEG Core-Shell Nanoparticles for
Controlled Drug Delivery</article-title>. <source>Biomaterials</source>
<year>2009</year>, <volume>30</volume>, <fpage>1627</fpage>&#x02013;<lpage>1634</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.12.013</pub-id>.<pub-id pub-id-type="pmid">19111339</pub-id></mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Hu</surname><given-names>Q.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Khademhosseini</surname><given-names>A.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>
<article-title>CRISPR-Cas12a Delivery by DNA-Mediated Bioresponsive
Editing for Cholesterol Regulation</article-title>. <source>Sci. Adv.</source>
<year>2020</year>, <volume>6</volume>, <elocation-id>eaba2983</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aba2983</pub-id>.<pub-id pub-id-type="pmid">32490205</pub-id></mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name><surname>Dong</surname><given-names>L.</given-names></name>; <name><surname>Xia</surname><given-names>S.</given-names></name>; <name><surname>Chen</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>
<article-title>Anti-Arthritis Activity of Cationic
Materials</article-title>. <source>J. Cell. Mol. Med.</source>
<year>2010</year>, <volume>14</volume>, <fpage>2015</fpage>&#x02013;<lpage>2024</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00806.x</pub-id>.<pub-id pub-id-type="pmid">19538477</pub-id></mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name><surname>Little</surname><given-names>S. R.</given-names></name>; <name><surname>Lynn</surname><given-names>D. M.</given-names></name>; <name><surname>Ge</surname><given-names>Q.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>; <name><surname>Puram</surname><given-names>S. V.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Eisen</surname><given-names>H. N.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>
<article-title>Poly-&#x003b2; Amino Ester-Containing Microparticles
Enhance the Activity of Nonviral Genetic
Vaccines</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2004</year>, <volume>101</volume>, <fpage>9534</fpage>&#x02013;<lpage>9539</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0403549101</pub-id>.<pub-id pub-id-type="pmid">15210954</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Liu</surname><given-names>Z.</given-names></name>; <name><surname>Jiao</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>
<article-title>Polysaccharides-Based Nanoparticles as Drug Delivery
Systems</article-title>. <source>Adv. Drug Delivery Rev.</source>
<year>2008</year>, <volume>60</volume>, <fpage>1650</fpage>&#x02013;<lpage>1662</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2008.09.001</pub-id>.</mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name><surname>Acharya</surname><given-names>A. P.</given-names></name>; <name><surname>Sinha</surname><given-names>M.</given-names></name>; <name><surname>Ratay</surname><given-names>M. L.</given-names></name>; <name><surname>Ding</surname><given-names>X.</given-names></name>; <name><surname>Balmert</surname><given-names>S. C.</given-names></name>; <name><surname>Workman</surname><given-names>C. J.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Vignali</surname><given-names>D. A. A.</given-names></name>; <name><surname>Little</surname><given-names>S. R.</given-names></name>
<article-title>Localized Multi-Component Delivery Platform Generates
Local and Systemic Anti-Tumor Immunity</article-title>. <source>Adv. Funct. Mater.</source>
<year>2017</year>, <volume>27</volume>, <fpage>1604366</fpage><pub-id pub-id-type="doi">10.1002/adfm.201604366</pub-id>.</mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name><surname>Dosta</surname><given-names>P.</given-names></name>; <name><surname>Segovia</surname><given-names>N.</given-names></name>; <name><surname>Cascante</surname><given-names>A.</given-names></name>; <name><surname>Ramos</surname><given-names>V.</given-names></name>; <name><surname>Borr&#x000f3;s</surname><given-names>S.</given-names></name>
<article-title>Surface Charge Tunability as a Powerful Strategy to
Control Electrostatic Interaction for High Efficiency Silencing,
Using Tailored Oligopeptide-Modified Poly(Beta-Amino Ester)s
(PBAEs)</article-title>. <source>Acta Biomater.</source>
<year>2015</year>, <volume>20</volume>, <fpage>82</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2015.03.029</pub-id>.<pub-id pub-id-type="pmid">25839122</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name><surname>Tsopelas</surname><given-names>C.</given-names></name>; <name><surname>Sutton</surname><given-names>R.</given-names></name>
<article-title>Why Certain Dyes Are Useful for Localizing the Sentinel
Lymph Node</article-title>. <source>J. Nucl. Med.</source>
<year>2002</year>, <volume>43</volume>, <fpage>1377</fpage>&#x02013;<lpage>1382</lpage>.<pub-id pub-id-type="pmid">12368377</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name><surname>Seong</surname><given-names>S.-Y.</given-names></name>; <name><surname>Matzinger</surname><given-names>P.</given-names></name>
<article-title>Hydrophobicity: An Ancient Damage-Associated Molecular
Pattern That Initiates Innate Immune Responses</article-title>. <source>Nat. Rev. Immunol.</source>
<year>2004</year>, <volume>4</volume>, <fpage>469</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1038/nri1372</pub-id>.<pub-id pub-id-type="pmid">15173835</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name><surname>Shokouhi</surname><given-names>B.</given-names></name>; <name><surname>Coban</surname><given-names>C.</given-names></name>; <name><surname>Hasirci</surname><given-names>V.</given-names></name>; <name><surname>Aydin</surname><given-names>E.</given-names></name>; <name><surname>Dhanasingh</surname><given-names>A.</given-names></name>; <name><surname>Shi</surname><given-names>N.</given-names></name>; <name><surname>Koyama</surname><given-names>S.</given-names></name>; <name><surname>Akira</surname><given-names>S.</given-names></name>; <name><surname>Zenke</surname><given-names>M.</given-names></name>; <name><surname>Sechi</surname><given-names>A. S.</given-names></name>
<article-title>The Role of Multiple Toll-Like Receptor Signalling
Cascades on Interactions between Biomedical Polymers and
Dendritic Cells</article-title>. <source>Biomaterials</source>
<year>2010</year>, <volume>31</volume>, <fpage>5759</fpage>&#x02013;<lpage>5771</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2010.04.015</pub-id>.<pub-id pub-id-type="pmid">20452017</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name><surname>Glenny</surname><given-names>A.</given-names></name>; <name><surname>Pope</surname><given-names>C.</given-names></name>; <name><surname>Waddington</surname><given-names>H.</given-names></name>; <name><surname>Wallace</surname><given-names>U.</given-names></name>
<article-title>Immunological Notes. xvii-xxiv</article-title>. <source>J. Pathol. Bacteriol.</source>
<year>1926</year>, <volume>29</volume>, <fpage>31</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/path.1700290106</pub-id>.</mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name><surname>Levitz</surname><given-names>S. M.</given-names></name>; <name><surname>Golenbock</surname><given-names>D. T.</given-names></name>
<article-title>Beyond Empiricism: Informing Vaccine Development
through Innate Immunity Research</article-title>. <source>Cell</source>
<year>2012</year>, <volume>148</volume>, <fpage>1284</fpage>&#x02013;<lpage>1292</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.02.012</pub-id>.<pub-id pub-id-type="pmid">22424235</pub-id></mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name><surname>Mannhalter</surname><given-names>J.</given-names></name>; <name><surname>Neychev</surname><given-names>H.</given-names></name>; <name><surname>Zlabinger</surname><given-names>G.</given-names></name>; <name><surname>Ahmad</surname><given-names>R.</given-names></name>; <name><surname>Eibl</surname><given-names>M.</given-names></name>
<article-title>Modulation of the Human Immune Response by the
Non-Toxic and Non-Pyrogenic Adjuvant Aluminium Hydroxide: Effect
on Antigen Uptake and Antigen Presentation</article-title>. <source>Clin. Exp. Immunol.</source>
<year>1985</year>, <volume>61</volume>, <fpage>143</fpage>&#x02013;<lpage>151</lpage>.<pub-id pub-id-type="pmid">3876178</pub-id></mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name><surname>McKee</surname><given-names>A. S.</given-names></name>; <name><surname>Munks</surname><given-names>M. W.</given-names></name>; <name><surname>Marrack</surname><given-names>P.</given-names></name>
<article-title>How Do Adjuvants Work? Important Considerations for New
Generation Adjuvants</article-title>. <source>Immunity</source>
<year>2007</year>, <volume>27</volume>, <fpage>687</fpage>&#x02013;<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.11.003</pub-id>.<pub-id pub-id-type="pmid">18031690</pub-id></mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name><surname>Hornung</surname><given-names>V.</given-names></name>; <name><surname>Bauernfeind</surname><given-names>F.</given-names></name>; <name><surname>Halle</surname><given-names>A.</given-names></name>; <name><surname>Samstad</surname><given-names>E. O.</given-names></name>; <name><surname>Kono</surname><given-names>H.</given-names></name>; <name><surname>Rock</surname><given-names>K. L.</given-names></name>; <name><surname>Fitzgerald</surname><given-names>K. A.</given-names></name>; <name><surname>Latz</surname><given-names>E.</given-names></name>
<article-title>Silica Crystals and Aluminum Salts Activate the NALP3
Inflammasome through Phagosomal Destabilization</article-title>. <source>Nat. Immunol.</source>
<year>2008</year>, <volume>9</volume>, <fpage>847</fpage>&#x02013;<lpage>856</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1631</pub-id>.<pub-id pub-id-type="pmid">18604214</pub-id></mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name><surname>Hess</surname><given-names>K. L.</given-names></name>; <name><surname>Medintz</surname><given-names>I. L.</given-names></name>; <name><surname>Jewell</surname><given-names>C. M.</given-names></name>
<article-title>Designing Inorganic Nanomaterials for Vaccines and
Immunotherapies</article-title>. <source>Nano Today</source>
<year>2019</year>, <volume>27</volume>, <fpage>73</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2019.04.005</pub-id>.<pub-id pub-id-type="pmid">32292488</pub-id></mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name><surname>Reddy</surname><given-names>S. T.</given-names></name>; <name><surname>van der Vlies</surname><given-names>A. J.</given-names></name>; <name><surname>Simeoni</surname><given-names>E.</given-names></name>; <name><surname>Angeli</surname><given-names>V.</given-names></name>; <name><surname>Randolph</surname><given-names>G. J.</given-names></name>; <name><surname>O&#x02019;Neil</surname><given-names>C. P.</given-names></name>; <name><surname>Lee</surname><given-names>L. K.</given-names></name>; <name><surname>Swartz</surname><given-names>M. A.</given-names></name>; <name><surname>Hubbell</surname><given-names>J. A.</given-names></name>
<article-title>Exploiting Lymphatic Transport and Complement
Activation in Nanoparticle Vaccines</article-title>. <source>Nat. Biotechnol.</source>
<year>2007</year>, <volume>25</volume>, <fpage>1159</fpage>&#x02013;<lpage>1164</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1332</pub-id>.<pub-id pub-id-type="pmid">17873867</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name><surname>Sokolova</surname><given-names>V.</given-names></name>; <name><surname>Epple</surname><given-names>M.</given-names></name>
<article-title>Inorganic Nanoparticles as Carriers of Nucleic Acids
into Cells</article-title>. <source>Angew. Chem., Int. Ed.</source>
<year>2008</year>, <volume>47</volume>, <fpage>1382</fpage>&#x02013;<lpage>1395</lpage>. <pub-id pub-id-type="doi">10.1002/anie.200703039</pub-id>.</mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name><surname>Moon</surname><given-names>J. J.</given-names></name>; <name><surname>Suh</surname><given-names>H.</given-names></name>; <name><surname>Li</surname><given-names>A. V.</given-names></name>; <name><surname>Ockenhouse</surname><given-names>C. F.</given-names></name>; <name><surname>Yadava</surname><given-names>A.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Enhancing Humoral Responses to a Malaria Antigen with
Nanoparticle Vaccines That Expand Tfh Cells and Promote Germinal
Center Induction</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2012</year>, <volume>109</volume>, <fpage>1080</fpage>&#x02013;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1112648109</pub-id>.<pub-id pub-id-type="pmid">22247289</pub-id></mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name><surname>Lin</surname><given-names>W.-H. W.</given-names></name>; <name><surname>Kouyos</surname><given-names>R. D.</given-names></name>; <name><surname>Adams</surname><given-names>R. J.</given-names></name>; <name><surname>Grenfell</surname><given-names>B. T.</given-names></name>; <name><surname>Griffin</surname><given-names>D. E.</given-names></name>
<article-title>Prolonged Persistence of Measles Virus RNA Is
Characteristic of Primary Infection Dynamics</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2012</year>, <volume>109</volume>, <fpage>14989</fpage>&#x02013;<lpage>14994</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1211138109</pub-id>.<pub-id pub-id-type="pmid">22872860</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name><surname>Pape</surname><given-names>K. A.</given-names></name>; <name><surname>Catron</surname><given-names>D. M.</given-names></name>; <name><surname>Itano</surname><given-names>A. A.</given-names></name>; <name><surname>Jenkins</surname><given-names>M. K.</given-names></name>
<article-title>The Humoral Immune Response Is Initiated in Lymph Nodes
by B Cells That Acquire Soluble Antigen Directly in the
Follicles</article-title>. <source>Immunity</source>
<year>2007</year>, <volume>26</volume>, <fpage>491</fpage>&#x02013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2007.02.011</pub-id>.<pub-id pub-id-type="pmid">17379546</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name><surname>McHugh</surname><given-names>K. J.</given-names></name>; <name><surname>Guarecuco</surname><given-names>R.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Jaklenec</surname><given-names>A.</given-names></name>
<article-title>Single-Injection Vaccines: Progress, Challenges, and
Opportunities</article-title>. <source>J. Controlled Release</source>
<year>2015</year>, <volume>219</volume>, <fpage>596</fpage>&#x02013;<lpage>609</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2015.07.029</pub-id>.</mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name><surname>Zhu</surname><given-names>Q.</given-names></name>; <name><surname>Zarnitsyn</surname><given-names>V. G.</given-names></name>; <name><surname>Ye</surname><given-names>L.</given-names></name>; <name><surname>Wen</surname><given-names>Z.</given-names></name>; <name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Pan</surname><given-names>L.</given-names></name>; <name><surname>Skountzou</surname><given-names>I.</given-names></name>; <name><surname>Gill</surname><given-names>H. S.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>; <name><surname>Yang</surname><given-names>C.</given-names></name>; <name><surname>Compans</surname><given-names>R. W.</given-names></name>
<article-title>Immunization by Vaccine-Coated Microneedle Arrays
Protects against Lethal Influenza Virus
Challenge</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2009</year>, <volume>106</volume>, <fpage>7968</fpage>&#x02013;<lpage>7973</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0812652106</pub-id>.<pub-id pub-id-type="pmid">19416832</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name><surname>Sullivan</surname><given-names>S. P.</given-names></name>; <name><surname>Koutsonanos</surname><given-names>D. G.</given-names></name>; <name><surname>del Pilar Martin</surname><given-names>M.</given-names></name>; <name><surname>Lee</surname><given-names>J. W.</given-names></name>; <name><surname>Zarnitsyn</surname><given-names>V.</given-names></name>; <name><surname>Choi</surname><given-names>S.-O.</given-names></name>; <name><surname>Murthy</surname><given-names>N.</given-names></name>; <name><surname>Compans</surname><given-names>R. W.</given-names></name>; <name><surname>Skountzou</surname><given-names>I.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>
<article-title>Dissolving Polymer Microneedle Patches for Influenza
Vaccination</article-title>. <source>Nat. Med.</source>
<year>2010</year>, <volume>16</volume>, <fpage>915</fpage>&#x02013;<lpage>920</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2182</pub-id>.<pub-id pub-id-type="pmid">20639891</pub-id></mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name><surname>Kim</surname><given-names>E.</given-names></name>; <name><surname>Erdos</surname><given-names>G.</given-names></name>; <name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Kenniston</surname><given-names>T. W.</given-names></name>; <name><surname>Balmert</surname><given-names>S. C.</given-names></name>; <name><surname>Carey</surname><given-names>C. D.</given-names></name>; <name><surname>Raj</surname><given-names>V. S.</given-names></name>; <name><surname>Epperly</surname><given-names>M. W.</given-names></name>; <name><surname>Klimstra</surname><given-names>W. B.</given-names></name>; <name><surname>Haagmans</surname><given-names>B. L.</given-names></name>; <name><surname>Korkmaz</surname><given-names>E.</given-names></name>; <name><surname>Falo</surname><given-names>L. D.</given-names></name>; <name><surname>Gambotto</surname><given-names>A.</given-names></name>
<article-title>Microneedle Array Delivered Recombinant Coronavirus
Vaccines: Immunogenicity and Rapid Translational
Development</article-title>. <source>EBioMedicine</source>
<year>2020</year>, <volume>55</volume>, <fpage>102743</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2020.102743</pub-id>.<pub-id pub-id-type="pmid">32249203</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name><surname>Rouphael</surname><given-names>N. G.</given-names></name>; <name><surname>Paine</surname><given-names>M.</given-names></name>; <name><surname>Mosley</surname><given-names>R.</given-names></name>; <name><surname>Henry</surname><given-names>S.</given-names></name>; <name><surname>McAllister</surname><given-names>D. V.</given-names></name>; <name><surname>Kalluri</surname><given-names>H.</given-names></name>; <name><surname>Pewin</surname><given-names>W.</given-names></name>; <name><surname>Frew</surname><given-names>P. M.</given-names></name>; <name><surname>Yu</surname><given-names>T.</given-names></name>; <name><surname>Thornburg</surname><given-names>N. J.</given-names></name>; <name><surname>Kabbani</surname><given-names>S.</given-names></name>; <name><surname>Lai</surname><given-names>L.</given-names></name>; <name><surname>Vassilieva</surname><given-names>E. V.</given-names></name>; <name><surname>Skountzou</surname><given-names>I.</given-names></name>; <name><surname>Compans</surname><given-names>R. W.</given-names></name>; <name><surname>Mulligan</surname><given-names>M. J.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>; <name><surname>Beck</surname><given-names>A.</given-names></name>; <name><surname>Edupuganti</surname><given-names>S.</given-names></name>; <name><surname>Heeke</surname><given-names>S.</given-names></name>; et al. <article-title>The Safety, Immunogenicity, and Acceptability of
Inactivated Influenza Vaccine Delivered by Microneedle Patch
(TIV-MNP 2015): A Randomised, Partly Blinded,
Placebo-Controlled, Phase 1 Trial</article-title>. <source>Lancet</source>
<year>2017</year>, <volume>390</volume>, <fpage>649</fpage>&#x02013;<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)30575-5</pub-id>.<pub-id pub-id-type="pmid">28666680</pub-id></mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name><surname>Boopathy</surname><given-names>A. V.</given-names></name>; <name><surname>Mandal</surname><given-names>A.</given-names></name>; <name><surname>Kulp</surname><given-names>D. W.</given-names></name>; <name><surname>Menis</surname><given-names>S.</given-names></name>; <name><surname>Bennett</surname><given-names>N. R.</given-names></name>; <name><surname>Watkins</surname><given-names>H. C.</given-names></name>; <name><surname>Wang</surname><given-names>W.</given-names></name>; <name><surname>Martin</surname><given-names>J. T.</given-names></name>; <name><surname>Thai</surname><given-names>N. T.</given-names></name>; <name><surname>He</surname><given-names>Y.</given-names></name>; <name><surname>Schief</surname><given-names>W. R.</given-names></name>; <name><surname>Hammond</surname><given-names>P. T.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Enhancing Humoral Immunity <italic>via</italic>
Sustained-Release Implantable Microneedle Patch
Vaccination</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2019</year>, <volume>116</volume>, <fpage>16473</fpage>&#x02013;<lpage>16478</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1902179116</pub-id>.<pub-id pub-id-type="pmid">31358641</pub-id></mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name><surname>DeMuth</surname><given-names>P. C.</given-names></name>; <name><surname>Moon</surname><given-names>J. J.</given-names></name>; <name><surname>Suh</surname><given-names>H.</given-names></name>; <name><surname>Hammond</surname><given-names>P. T.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Releasable Layer-by-Layer Assembly of Stabilized Lipid
Nanocapsules on Microneedles for Enhanced Transcutaneous Vaccine
Delivery</article-title>. <source>ACS Nano</source>
<year>2012</year>, <volume>6</volume>, <fpage>8041</fpage>&#x02013;<lpage>8051</lpage>. <pub-id pub-id-type="doi">10.1021/nn302639r</pub-id>.<pub-id pub-id-type="pmid">22920601</pub-id></mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name><surname>Zaric</surname><given-names>M.</given-names></name>; <name><surname>Lyubomska</surname><given-names>O.</given-names></name>; <name><surname>Touzelet</surname><given-names>O.</given-names></name>; <name><surname>Poux</surname><given-names>C.</given-names></name>; <name><surname>Al-Zahrani</surname><given-names>S.</given-names></name>; <name><surname>Fay</surname><given-names>F.</given-names></name>; <name><surname>Wallace</surname><given-names>L.</given-names></name>; <name><surname>Terhorst</surname><given-names>D.</given-names></name>; <name><surname>Malissen</surname><given-names>B.</given-names></name>; <name><surname>Henri</surname><given-names>S.</given-names></name>; <name><surname>Power</surname><given-names>U. F.</given-names></name>; <name><surname>Scott</surname><given-names>C. J.</given-names></name>; <name><surname>Donnelly</surname><given-names>R. F.</given-names></name>; <name><surname>Kissenpfennig</surname><given-names>A.</given-names></name>
<article-title>Skin Dendritic Cell Targeting <italic>via</italic>
Microneedle Arrays Laden with Antigen-Encapsulated Poly-d,
l-lactide-co-Glycolide Nanoparticles Induces Efficient Antitumor
and Antiviral Immune Responses</article-title>. <source>ACS Nano</source>
<year>2013</year>, <volume>7</volume>, <fpage>2042</fpage>&#x02013;<lpage>2055</lpage>. <pub-id pub-id-type="doi">10.1021/nn304235j</pub-id>.<pub-id pub-id-type="pmid">23373658</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name><surname>Bae</surname><given-names>W.-G.</given-names></name>; <name><surname>Ko</surname><given-names>H.</given-names></name>; <name><surname>So</surname><given-names>J.-Y.</given-names></name>; <name><surname>Yi</surname><given-names>H.</given-names></name>; <name><surname>Lee</surname><given-names>C.-H.</given-names></name>; <name><surname>Lee</surname><given-names>D.-H.</given-names></name>; <name><surname>Ahn</surname><given-names>Y.</given-names></name>; <name><surname>Lee</surname><given-names>S.-H.</given-names></name>; <name><surname>Lee</surname><given-names>K.</given-names></name>; <name><surname>Jun</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>H.-H.</given-names></name>; <name><surname>Jeon</surname><given-names>N. L.</given-names></name>; <name><surname>Jung</surname><given-names>W.</given-names></name>; <name><surname>Song</surname><given-names>C.-S.</given-names></name>; <name><surname>Kim</surname><given-names>T.</given-names></name>; <name><surname>Kim</surname><given-names>Y.-C.</given-names></name>; <name><surname>Jeong</surname><given-names>H. E.</given-names></name>
<article-title>Snake Fang-Inspired Stamping Patch for Transdermal
Delivery of Liquid Formulations</article-title>. <source>Sci. Transl. Med.</source>
<year>2019</year>, <volume>11</volume>, <elocation-id>eaaw3329</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw3329</pub-id>.<pub-id pub-id-type="pmid">31366579</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name><surname>Tzeng</surname><given-names>S. Y.</given-names></name>; <name><surname>McHugh</surname><given-names>K. J.</given-names></name>; <name><surname>Behrens</surname><given-names>A. M.</given-names></name>; <name><surname>Rose</surname><given-names>S.</given-names></name>; <name><surname>Sugarman</surname><given-names>J. L.</given-names></name>; <name><surname>Ferber</surname><given-names>S.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Jaklenec</surname><given-names>A.</given-names></name>
<article-title>Stabilized Single-Injection Inactivated Polio Vaccine
Elicits a Strong Neutralizing Immune Response</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2018</year>, <volume>115</volume>, <fpage>E5269</fpage>&#x02013;<lpage>E5278</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1720970115</pub-id>.<pub-id pub-id-type="pmid">29784798</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name><surname>McHugh</surname><given-names>K. J.</given-names></name>; <name><surname>Nguyen</surname><given-names>T. D.</given-names></name>; <name><surname>Linehan</surname><given-names>A. R.</given-names></name>; <name><surname>Yang</surname><given-names>D.</given-names></name>; <name><surname>Behrens</surname><given-names>A. M.</given-names></name>; <name><surname>Rose</surname><given-names>S.</given-names></name>; <name><surname>Tochka</surname><given-names>Z. L.</given-names></name>; <name><surname>Tzeng</surname><given-names>S. Y.</given-names></name>; <name><surname>Norman</surname><given-names>J. J.</given-names></name>; <name><surname>Anselmo</surname><given-names>A. C.</given-names></name>; <name><surname>Xu</surname><given-names>X.</given-names></name>; <name><surname>Tomasic</surname><given-names>S.</given-names></name>; <name><surname>Taylor</surname><given-names>M. A.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Guarecuco</surname><given-names>R.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Jaklenec</surname><given-names>A.</given-names></name>
<article-title>Fabrication of Fillable Microparticles and Other
Complex 3D Microstructures</article-title>. <source>Science</source>
<year>2017</year>, <volume>357</volume>, <fpage>1138</fpage>&#x02013;<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaf7447</pub-id>.<pub-id pub-id-type="pmid">28912242</pub-id></mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name><surname>Lu</surname><given-names>X.</given-names></name>; <name><surname>Miao</surname><given-names>L.</given-names></name>; <name><surname>Gao</surname><given-names>W.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>McHugh</surname><given-names>K. J.</given-names></name>; <name><surname>Sun</surname><given-names>Y.</given-names></name>; <name><surname>Tochka</surname><given-names>Z.</given-names></name>; <name><surname>Tomasic</surname><given-names>S.</given-names></name>; <name><surname>Sadtler</surname><given-names>K.</given-names></name>; <name><surname>Hyacinthe</surname><given-names>A.</given-names></name>; <name><surname>Huang</surname><given-names>Y.</given-names></name>; <name><surname>Graf</surname><given-names>T.</given-names></name>; <name><surname>Hu</surname><given-names>Q.</given-names></name>; <name><surname>Sarmadi</surname><given-names>M.</given-names></name>; <name><surname>Langer</surname><given-names>R.</given-names></name>; <name><surname>Anderson</surname><given-names>D. G.</given-names></name>; <name><surname>Jaklenec</surname><given-names>A.</given-names></name>
<article-title>Engineered PLGA Microparticles for Long-Term, Pulsatile
Release of STING Agonist for Cancer
Immunotherapy</article-title>. <source>Sci. Transl. Med.</source>
<year>2020</year>, <volume>12</volume>, <elocation-id>eaaz6606</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaz6606</pub-id>.<pub-id pub-id-type="pmid">32801144</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name><surname>Ali</surname><given-names>O. A.</given-names></name>; <name><surname>Huebsch</surname><given-names>N.</given-names></name>; <name><surname>Cao</surname><given-names>L.</given-names></name>; <name><surname>Dranoff</surname><given-names>G.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Infection-Mimicking Materials to Program Dendritic
Cells <italic>in Situ</italic></article-title>. <source>Nat. Mater.</source>
<year>2009</year>, <volume>8</volume>, <fpage>151</fpage>&#x02013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1038/nmat2357</pub-id>.<pub-id pub-id-type="pmid">19136947</pub-id></mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>W. A.</given-names></name>; <name><surname>Choi</surname><given-names>Y.</given-names></name>; <name><surname>Lewin</surname><given-names>S. A.</given-names></name>; <name><surname>Verbeke</surname><given-names>C. S.</given-names></name>; <name><surname>Dranoff</surname><given-names>G.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Injectable, Spontaneously Assembling, Inorganic
Scaffolds Modulate Immune Cells <italic>in Vivo</italic> and
Increase Vaccine Efficacy</article-title>. <source>Nat. Biotechnol.</source>
<year>2015</year>, <volume>33</volume>, <fpage>64</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3071</pub-id>.<pub-id pub-id-type="pmid">25485616</pub-id></mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name><surname>Li</surname><given-names>A. W.</given-names></name>; <name><surname>Sobral</surname><given-names>M. C.</given-names></name>; <name><surname>Badrinath</surname><given-names>S.</given-names></name>; <name><surname>Choi</surname><given-names>Y.</given-names></name>; <name><surname>Graveline</surname><given-names>A.</given-names></name>; <name><surname>Stafford</surname><given-names>A. G.</given-names></name>; <name><surname>Weaver</surname><given-names>J. C.</given-names></name>; <name><surname>Dellacherie</surname><given-names>M. O.</given-names></name>; <name><surname>Shih</surname><given-names>T.-Y.</given-names></name>; <name><surname>Ali</surname><given-names>O. A.</given-names></name>; <name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Wucherpfennig</surname><given-names>K. W.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>A Facile Approach to Enhance Antigen Response for
Personalized Cancer Vaccination</article-title>. <source>Nat. Mater.</source>
<year>2018</year>, <volume>17</volume>, <fpage>528</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1038/s41563-018-0028-2</pub-id>.<pub-id pub-id-type="pmid">29507416</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name><surname>Dellacherie</surname><given-names>M. O.</given-names></name>; <name><surname>Li</surname><given-names>A.</given-names></name>; <name><surname>Lu</surname><given-names>B. Y.</given-names></name>; <name><surname>Verbeke</surname><given-names>C. S.</given-names></name>; <name><surname>Gu</surname><given-names>L.</given-names></name>; <name><surname>Stafford</surname><given-names>A. G.</given-names></name>; <name><surname>Doherty</surname><given-names>E. J.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Single-Shot Mesoporous Silica Rods Scaffold for
Induction of Humoral Responses against Small
Antigens</article-title>. <source>Adv. Funct. Mater.</source>
<year>2020</year>, <volume>30</volume>, <fpage>2002448</fpage><pub-id pub-id-type="doi">10.1002/adfm.202002448</pub-id>.</mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name><surname>Shih</surname><given-names>T.-Y.</given-names></name>; <name><surname>Blacklow</surname><given-names>S. O.</given-names></name>; <name><surname>Li</surname><given-names>A. W.</given-names></name>; <name><surname>Freedman</surname><given-names>B. R.</given-names></name>; <name><surname>Bencherif</surname><given-names>S.</given-names></name>; <name><surname>Koshy</surname><given-names>S. T.</given-names></name>; <name><surname>Darnell</surname><given-names>M. C.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Injectable, Tough Alginate Cryogels as Cancer
Vaccines</article-title>. <source>Adv. Healthcare Mater.</source>
<year>2018</year>, <volume>7</volume>, <fpage>1701469</fpage><pub-id pub-id-type="doi">10.1002/adhm.201701469</pub-id>.</mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name><surname>Bencherif</surname><given-names>S. A.</given-names></name>; <name><surname>Sands</surname><given-names>R. W.</given-names></name>; <name><surname>Bhatta</surname><given-names>D.</given-names></name>; <name><surname>Arany</surname><given-names>P.</given-names></name>; <name><surname>Verbeke</surname><given-names>C. S.</given-names></name>; <name><surname>Edwards</surname><given-names>D. A.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Injectable Preformed Scaffolds with Shape-Memory
Properties</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2012</year>, <volume>109</volume>, <fpage>19590</fpage>&#x02013;<lpage>19595</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1211516109</pub-id>.<pub-id pub-id-type="pmid">23150549</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name><surname>Hori</surname><given-names>Y.</given-names></name>; <name><surname>Winans</surname><given-names>A. M.</given-names></name>; <name><surname>Huang</surname><given-names>C. C.</given-names></name>; <name><surname>Horrigan</surname><given-names>E. M.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Injectable Dendritic Cell-Carrying Alginate Gels for
Immunization and Immunotherapy</article-title>. <source>Biomaterials</source>
<year>2008</year>, <volume>29</volume>, <fpage>3671</fpage>&#x02013;<lpage>3682</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.05.033</pub-id>.<pub-id pub-id-type="pmid">18565578</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal" id="cit136"><name><surname>Guo</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>M.</given-names></name>; <name><surname>Tang</surname><given-names>H.</given-names></name>; <name><surname>Cao</surname><given-names>X.</given-names></name>
<article-title>Fas Signal Links Innate and Adaptive Immunity by
Promoting Dendritic-Cell Secretion of CC and CXC
Chemokines</article-title>. <source>Blood</source>
<year>2005</year>, <volume>106</volume>, <fpage>2033</fpage>&#x02013;<lpage>2041</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-12-4831</pub-id>.<pub-id pub-id-type="pmid">15941911</pub-id></mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal" id="cit137"><name><surname>Hori</surname><given-names>Y.</given-names></name>; <name><surname>Winans</surname><given-names>A. M.</given-names></name>; <name><surname>Irvine</surname><given-names>D. J.</given-names></name>
<article-title>Modular Injectable Matrices Based on Alginate
Solution/Microsphere Mixtures That Gel <italic>in Situ</italic>
and Co-deliver Immunomodulatory factors</article-title>. <source>Acta Biomater.</source>
<year>2009</year>, <volume>5</volume>, <fpage>969</fpage>&#x02013;<lpage>982</lpage>. <pub-id pub-id-type="doi">10.1016/j.actbio.2008.11.019</pub-id>.<pub-id pub-id-type="pmid">19117820</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal" id="cit138"><name><surname>Roy</surname><given-names>K.</given-names></name>; <name><surname>Wang</surname><given-names>D.</given-names></name>; <name><surname>Hedley</surname><given-names>M. L.</given-names></name>; <name><surname>Barman</surname><given-names>S. P.</given-names></name>
<article-title>Gene Delivery with <italic>In-Situ</italic>
Crosslinking Polymer Networks Generates Long-Term Systemic
Protein Expression</article-title>. <source>Mol. Ther.</source>
<year>2003</year>, <volume>7</volume>, <fpage>401</fpage>&#x02013;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1016/S1525-0016(03)00008-X</pub-id>.<pub-id pub-id-type="pmid">12668136</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Wei</surname><given-names>W.</given-names></name>; <name><surname>Zhou</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Ma</surname><given-names>G.</given-names></name>; <name><surname>Su</surname><given-names>Z.</given-names></name>
<article-title>Thermal-Sensitive Hydrogel as Adjuvant-Free Vaccine
Delivery System for H5N1 Intranasal Immunization</article-title>. <source>Biomaterials</source>
<year>2012</year>, <volume>33</volume>, <fpage>2351</fpage>&#x02013;<lpage>2360</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2011.11.068</pub-id>.<pub-id pub-id-type="pmid">22192540</pub-id></mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name><surname>Hiemstra</surname><given-names>C.</given-names></name>; <name><surname>van der Aa</surname><given-names>L. J.</given-names></name>; <name><surname>Zhong</surname><given-names>Z.</given-names></name>; <name><surname>Dijkstra</surname><given-names>P. J.</given-names></name>; <name><surname>Feijen</surname><given-names>J.</given-names></name>
<article-title>Rapidly <italic>in Situ</italic>-Forming Degradable
Hydrogels from Dextran Thiols through Michael
Addition</article-title>. <source>Biomacromolecules</source>
<year>2007</year>, <volume>8</volume>, <fpage>1548</fpage>&#x02013;<lpage>1556</lpage>. <pub-id pub-id-type="doi">10.1021/bm061191m</pub-id>.<pub-id pub-id-type="pmid">17425366</pub-id></mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal" id="cit141"><name><surname>Singh</surname><given-names>A.</given-names></name>; <name><surname>Suri</surname><given-names>S.</given-names></name>; <name><surname>Roy</surname><given-names>K.</given-names></name>
<article-title><italic>In-Situ</italic> Crosslinking Hydrogels for
Combinatorial Delivery of Chemokines and siRNA-DNA Carrying
Microparticles to Dendritic Cells</article-title>. <source>Biomaterials</source>
<year>2009</year>, <volume>30</volume>, <fpage>5187</fpage>&#x02013;<lpage>5200</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.06.001</pub-id>.<pub-id pub-id-type="pmid">19560815</pub-id></mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal" id="cit142"><name><surname>Singh</surname><given-names>A.</given-names></name>; <name><surname>Qin</surname><given-names>H.</given-names></name>; <name><surname>Fernandez</surname><given-names>I.</given-names></name>; <name><surname>Wei</surname><given-names>J.</given-names></name>; <name><surname>Lin</surname><given-names>J.</given-names></name>; <name><surname>Kwak</surname><given-names>L. W.</given-names></name>; <name><surname>Roy</surname><given-names>K.</given-names></name>
<article-title>An Injectable Synthetic Immune-Priming Center Mediates
Efficient T-Cell Class Switching and T-Helper 1 Response against
B Cell Lymphoma</article-title>. <source>J. Controlled Release</source>
<year>2011</year>, <volume>155</volume>, <fpage>184</fpage>&#x02013;<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2011.06.008</pub-id>.</mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal" id="cit143"><name><surname>Umeki</surname><given-names>Y.</given-names></name>; <name><surname>Mohri</surname><given-names>K.</given-names></name>; <name><surname>Kawasaki</surname><given-names>Y.</given-names></name>; <name><surname>Watanabe</surname><given-names>H.</given-names></name>; <name><surname>Takahashi</surname><given-names>R.</given-names></name>; <name><surname>Takahashi</surname><given-names>Y.</given-names></name>; <name><surname>Takakura</surname><given-names>Y.</given-names></name>; <name><surname>Nishikawa</surname><given-names>M.</given-names></name>
<article-title>Induction of Potent Antitumor Immunity by Sustained
Release of Cationic Antigen from a DNA-Based Hydrogel with
Adjuvant Activity</article-title>. <source>Adv. Funct. Mater.</source>
<year>2015</year>, <volume>25</volume>, <fpage>5758</fpage>&#x02013;<lpage>5767</lpage>. <pub-id pub-id-type="doi">10.1002/adfm.201502139</pub-id>.</mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal" id="cit144"><name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>; <name><surname>Mikszta</surname><given-names>J. A.</given-names></name>; <name><surname>Cormier</surname><given-names>M.</given-names></name>; <name><surname>Andrianov</surname><given-names>A. K.</given-names></name>
<article-title>Microneedle-Based Vaccines</article-title>. <source>Curr. Top. Microbiol. Immunol.</source>
<year>2009</year>, <volume>333</volume>, <fpage>369</fpage>&#x02013;<lpage>393</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-92165-3_18</pub-id>.<pub-id pub-id-type="pmid">19768415</pub-id></mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal" id="cit145"><name><surname>Chen</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Wen</surname><given-names>D.</given-names></name>; <name><surname>Wang</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>H.</given-names></name>; <name><surname>Zeng</surname><given-names>Y.</given-names></name>; <name><surname>Dotti</surname><given-names>G.</given-names></name>; <name><surname>Wirz</surname><given-names>R. E.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>
<article-title>Transdermal Cold Atmospheric Plasma-Mediated Immune
Checkpoint Blockade Therapy</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2020</year>, <volume>117</volume>, <fpage>3687</fpage>&#x02013;<lpage>3692</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1917891117</pub-id>.<pub-id pub-id-type="pmid">32029590</pub-id></mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal" id="cit146"><name><surname>Ye</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Hu</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>Q.</given-names></name>; <name><surname>Wen</surname><given-names>D.</given-names></name>; <name><surname>Milligan</surname><given-names>J.</given-names></name>; <name><surname>Bellotti</surname><given-names>A.</given-names></name>; <name><surname>Huang</surname><given-names>L.</given-names></name>; <name><surname>Dotti</surname><given-names>G.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>
<article-title>A Melanin-Mediated Cancer Immunotherapy
Patch</article-title>. <source>Sci. Immunol.</source>
<year>2017</year>, <volume>2</volume>, <elocation-id>eaan5692</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aan5692</pub-id>.<pub-id pub-id-type="pmid">29127106</pub-id></mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal" id="cit147"><person-group person-group-type="allauthors"><name><surname>Erdos</surname><given-names>G.</given-names></name>;
<name><surname>Balmert</surname><given-names>S.
C.</given-names></name>;
<name><surname>Carey</surname><given-names>C.
D.</given-names></name>; <name><surname>Falo</surname><given-names>G. D.</given-names></name>;
<name><surname>Patel</surname><given-names>N.
A.</given-names></name>;
<name><surname>Zhang</surname><given-names>J.</given-names></name>;
<name><surname>Gambotto</surname><given-names>A.</given-names></name>;
<name><surname>Korkmaz</surname><given-names>E.</given-names></name>;
<name><surname>Falo</surname><given-names>L.
D.</given-names></name></person-group><article-title>Improved Cutaneous Genetic Immunization by Microneedle
Array Delivery of an Adjuvanted Adenovirus
Vaccine</article-title>. <source>J. Invest. Dermatol.</source><year>2020</year>, <pub-id pub-id-type="doi">10.1016/j.jid.2020.03.966</pub-id>.</mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal" id="cit148"><person-group person-group-type="allauthors"><name><surname>Lee</surname><given-names>K.</given-names></name>;
<name><surname>Goudie</surname><given-names>M.
J.</given-names></name>;
<name><surname>Tebon</surname><given-names>P.</given-names></name>;
<name><surname>Sun</surname><given-names>W.</given-names></name>;
<name><surname>Luo</surname><given-names>Z.</given-names></name>;
<name><surname>Lee</surname><given-names>J.</given-names></name>;
<name><surname>Zhang</surname><given-names>S.</given-names></name>;
<name><surname>Fetah</surname><given-names>K.</given-names></name>;
<name><surname>Kim</surname><given-names>H.-J.</given-names></name>;
<name><surname>Xue</surname><given-names>Y.</given-names></name>;
<name><surname>Darabi</surname><given-names>M.
A.</given-names></name>;
<name><surname>Ahadian</surname><given-names>S.</given-names></name>;
<name><surname>Sarikhani</surname><given-names>E.</given-names></name>;
<name><surname>Ryu</surname><given-names>W.</given-names></name>;
<name><surname>Gu</surname><given-names>Z.</given-names></name>;
<name><surname>Weiss</surname><given-names>P.
S.</given-names></name>;
<name><surname>Dokmeci</surname><given-names>M.
R.</given-names></name>;
<name><surname>Ashammakhi</surname><given-names>N.</given-names></name>;
<name><surname>Khademhosseini</surname><given-names>A.</given-names></name></person-group>,
<article-title>Non-Transdermal Microneedles for Advanced Drug
Delivery</article-title>. <source>Adv. Drug Delivery
Rev.</source><year>2019</year>, <pub-id pub-id-type="doi">10.1016/j.addr.2019.11.010</pub-id>.</mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal" id="cit149"><name><surname>van der Maaden</surname><given-names>K.</given-names></name>; <name><surname>Jiskoot</surname><given-names>W.</given-names></name>; <name><surname>Bouwstra</surname><given-names>J.</given-names></name>
<article-title>Microneedle Technologies for (Trans)dermal Drug and
Vaccine Delivery</article-title>. <source>J. Controlled Release</source>
<year>2012</year>, <volume>161</volume>, <fpage>645</fpage>&#x02013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.01.042</pub-id>.</mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal" id="cit150"><name><surname>Kim</surname><given-names>Y.-C.</given-names></name>; <name><surname>Quan</surname><given-names>F.-S.</given-names></name>; <name><surname>Compans</surname><given-names>R. W.</given-names></name>; <name><surname>Kang</surname><given-names>S.-M.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>
<article-title>Stability Kinetics of Influenza Vaccine Coated onto
Microneedles during Drying and Storage</article-title>. <source>Pharm. Res.</source>
<year>2011</year>, <volume>28</volume>, <fpage>135</fpage>&#x02013;<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1007/s11095-010-0134-6</pub-id>.<pub-id pub-id-type="pmid">20387097</pub-id></mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal" id="cit151"><name><surname>Sanders</surname><given-names>R. W.</given-names></name>; <name><surname>van Gils</surname><given-names>M. J.</given-names></name>; <name><surname>Derking</surname><given-names>R.</given-names></name>; <name><surname>Sok</surname><given-names>D.</given-names></name>; <name><surname>Ketas</surname><given-names>T. J.</given-names></name>; <name><surname>Burger</surname><given-names>J. A.</given-names></name>; <name><surname>Ozorowski</surname><given-names>G.</given-names></name>; <name><surname>Cupo</surname><given-names>A.</given-names></name>; <name><surname>Simonich</surname><given-names>C.</given-names></name>; <name><surname>Goo</surname><given-names>L.</given-names></name>; <name><surname>Arendt</surname><given-names>H.</given-names></name>; <name><surname>Kim</surname><given-names>H. J.</given-names></name>; <name><surname>Lee</surname><given-names>J. H.</given-names></name>; <name><surname>Pugach</surname><given-names>P.</given-names></name>; <name><surname>Williams</surname><given-names>M.</given-names></name>; <name><surname>Debnath</surname><given-names>G.</given-names></name>; <name><surname>Moldt</surname><given-names>B.</given-names></name>; <name><surname>van Breemen</surname><given-names>M. J.</given-names></name>; <name><surname>Isik</surname><given-names>G.</given-names></name>; <name><surname>Medina-Ram&#x000ed;rez</surname><given-names>M.</given-names></name>; et al. <article-title>HIV-1 Neutralizing Antibodies Induced by Native-Like
Envelope Trimers</article-title>. <source>Science</source>
<year>2015</year>, <volume>349</volume>, <elocation-id>aac4223</elocation-id><pub-id pub-id-type="doi">10.1126/science.aac4223</pub-id>.<pub-id pub-id-type="pmid">26089353</pub-id></mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal" id="cit152"><name><surname>Wang</surname><given-names>W.</given-names></name>
<article-title>Lyophilization and Development of Solid Protein
Pharmaceuticals</article-title>. <source>Int. J. Pharm.</source>
<year>2000</year>, <volume>203</volume>, <fpage>1</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(00)00423-3</pub-id>.<pub-id pub-id-type="pmid">10967427</pub-id></mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal" id="cit153"><name><surname>Dellacherie</surname><given-names>M. O.</given-names></name>; <name><surname>Seo</surname><given-names>B. R.</given-names></name>; <name><surname>Mooney</surname><given-names>D. J.</given-names></name>
<article-title>Macroscale Biomaterials Strategies for Local
Immunomodulation</article-title>. <source>Nat. Rev. Mater.</source>
<year>2019</year>, <volume>4</volume>, <fpage>379</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1038/s41578-019-0106-3</pub-id>.</mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal" id="cit154"><name><surname>Wu</surname><given-names>Y.</given-names></name>; <name><surname>Jane Grande-Allen</surname><given-names>K.</given-names></name>; <name><surname>West</surname><given-names>J. L.</given-names></name>
<article-title>Adhesive Peptide Sequences Regulate Valve Interstitial
Cell Adhesion, Phenotype and Extracellular Matrix
Deposition</article-title>. <source>Cell. Mol. Bioeng.</source>
<year>2016</year>, <volume>9</volume>, <fpage>479</fpage>&#x02013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1007/s12195-016-0451-x</pub-id>.<pub-id pub-id-type="pmid">28220141</pub-id></mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal" id="cit155"><name><surname>Diehl</surname><given-names>M. C.</given-names></name>; <name><surname>Lee</surname><given-names>J. C.</given-names></name>; <name><surname>Daniels</surname><given-names>S. E.</given-names></name>; <name><surname>Tebas</surname><given-names>P.</given-names></name>; <name><surname>Khan</surname><given-names>A. S.</given-names></name>; <name><surname>Giffear</surname><given-names>M.</given-names></name>; <name><surname>Sardesai</surname><given-names>N. Y.</given-names></name>; <name><surname>Bagarazzi</surname><given-names>M. L.</given-names></name>
<article-title>Tolerability of Intramuscular and Intradermal Delivery
by CELLECTRA&#x000ae; Adaptive Constant Current Electroporation
Device in Healthy Volunteers</article-title>. <source>Hum. Vaccines Immunother.</source>
<year>2013</year>, <volume>9</volume>, <fpage>2246</fpage>&#x02013;<lpage>2252</lpage>. <pub-id pub-id-type="doi">10.4161/hv.24702</pub-id>.</mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal" id="cit156"><name><surname>Smith</surname><given-names>T. R. F.</given-names></name>; <name><surname>Patel</surname><given-names>A.</given-names></name>; <name><surname>Ramos</surname><given-names>S.</given-names></name>; <name><surname>Elwood</surname><given-names>D.</given-names></name>; <name><surname>Zhu</surname><given-names>X.</given-names></name>; <name><surname>Yan</surname><given-names>J.</given-names></name>; <name><surname>Gary</surname><given-names>E. N.</given-names></name>; <name><surname>Walker</surname><given-names>S. N.</given-names></name>; <name><surname>Schultheis</surname><given-names>K.</given-names></name>; <name><surname>Purwar</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>Z.</given-names></name>; <name><surname>Walters</surname><given-names>J.</given-names></name>; <name><surname>Bhojnagarwala</surname><given-names>P.</given-names></name>; <name><surname>Yang</surname><given-names>M.</given-names></name>; <name><surname>Chokkalingam</surname><given-names>N.</given-names></name>; <name><surname>Pezzoli</surname><given-names>P.</given-names></name>; <name><surname>Parzych</surname><given-names>E.</given-names></name>; <name><surname>Reuschel</surname><given-names>E. L.</given-names></name>; <name><surname>Doan</surname><given-names>A.</given-names></name>; <name><surname>Tursi</surname><given-names>N.</given-names></name>; et al. <article-title>Immunogenicity of a DNA Vaccine Candidate for
COVID-19</article-title>. <source>Nat. Commun.</source>
<year>2020</year>, <volume>11</volume>, <fpage>2601</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16505-0</pub-id>.<pub-id pub-id-type="pmid">32433465</pub-id></mixed-citation></ref><ref id="ref157"><mixed-citation publication-type="journal" id="cit157"><name><surname>Choi</surname><given-names>S.-O.</given-names></name>; <name><surname>Kim</surname><given-names>Y.-C.</given-names></name>; <name><surname>Lee</surname><given-names>J. W.</given-names></name>; <name><surname>Park</surname><given-names>J.-H.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>; <name><surname>Allen</surname><given-names>M. G.</given-names></name>
<article-title>Intracellular Protein Delivery and Gene Transfection by
Electroporation Using a Microneedle Electrode
Array</article-title>. <source>Small</source>
<year>2012</year>, <volume>8</volume>, <fpage>1081</fpage>&#x02013;<lpage>1091</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201101747</pub-id>.<pub-id pub-id-type="pmid">22328093</pub-id></mixed-citation></ref><ref id="ref158"><mixed-citation publication-type="journal" id="cit158"><name><surname>Banga</surname><given-names>A. K.</given-names></name>; <name><surname>Bose</surname><given-names>S.</given-names></name>; <name><surname>Ghosh</surname><given-names>T. K.</given-names></name>
<article-title>Iontophoresis and Electroporation: Comparisons and
Contrasts</article-title>. <source>Int. J. Pharm.</source>
<year>1999</year>, <volume>179</volume>, <fpage>1</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(98)00360-3</pub-id>.<pub-id pub-id-type="pmid">10053197</pub-id></mixed-citation></ref><ref id="ref159"><mixed-citation publication-type="journal" id="cit159"><name><surname>Tadros</surname><given-names>A. R.</given-names></name>; <name><surname>Romanyuk</surname><given-names>A.</given-names></name>; <name><surname>Miller</surname><given-names>I. C.</given-names></name>; <name><surname>Santiago</surname><given-names>A.</given-names></name>; <name><surname>Noel</surname><given-names>R. K.</given-names></name>; <name><surname>O&#x02019;Farrell</surname><given-names>L.</given-names></name>; <name><surname>Kwong</surname><given-names>G. A.</given-names></name>; <name><surname>Prausnitz</surname><given-names>M. R.</given-names></name>
<article-title>STAR Particles for Enhanced Topical Drug and Vaccine
Delivery</article-title>. <source>Nat. Med.</source>
<year>2020</year>, <volume>26</volume>, <fpage>341</fpage>&#x02013;<lpage>347</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0787-6</pub-id>.<pub-id pub-id-type="pmid">32152581</pub-id></mixed-citation></ref><ref id="ref160"><mixed-citation publication-type="journal" id="cit160"><name><surname>Lamson</surname><given-names>N. G.</given-names></name>; <name><surname>Berger</surname><given-names>A.</given-names></name>; <name><surname>Fein</surname><given-names>K. C.</given-names></name>; <name><surname>Whitehead</surname><given-names>K. A.</given-names></name>
<article-title>Anionic Nanoparticles Enable the Oral Delivery of
Proteins by Enhancing Intestinal Permeability</article-title>. <source>Nat. Biomed. Eng.</source>
<year>2020</year>, <volume>4</volume>, <fpage>84</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1038/s41551-019-0465-5</pub-id>.<pub-id pub-id-type="pmid">31686002</pub-id></mixed-citation></ref><ref id="ref161"><mixed-citation publication-type="journal" id="cit161"><name><surname>Wei</surname><given-names>X.</given-names></name>; <name><surname>Beltr&#x000e1;n-Gast&#x000e9;lum</surname><given-names>M.</given-names></name>; <name><surname>Karshalev</surname><given-names>E.</given-names></name>; <name><surname>Esteban-Fern&#x000e1;ndez de &#x000c1;vila</surname><given-names>B.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Ran</surname><given-names>D.</given-names></name>; <name><surname>Angsantikul</surname><given-names>P.</given-names></name>; <name><surname>Fang</surname><given-names>R. H.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>
<article-title>Biomimetic Micromotor Enables Active Delivery of
Antigens for Oral Vaccination</article-title>. <source>Nano Lett.</source>
<year>2019</year>, <volume>19</volume>, <fpage>1914</fpage>&#x02013;<lpage>1921</lpage>. <pub-id pub-id-type="doi">10.1021/acs.nanolett.8b05051</pub-id>.<pub-id pub-id-type="pmid">30724085</pub-id></mixed-citation></ref><ref id="ref162"><mixed-citation publication-type="journal" id="cit162"><name><surname>Karshalev</surname><given-names>E.</given-names></name>; <name><surname>Esteban-Fern&#x000e1;ndez de &#x000c1;vila</surname><given-names>B.</given-names></name>; <name><surname>Beltr&#x000e1;n-Gast&#x000e9;lum</surname><given-names>M.</given-names></name>; <name><surname>Angsantikul</surname><given-names>P.</given-names></name>; <name><surname>Tang</surname><given-names>S.</given-names></name>; <name><surname>Mundaca-Uribe</surname><given-names>R.</given-names></name>; <name><surname>Zhang</surname><given-names>F.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>
<article-title>Micromotor Pills as a Dynamic Oral Delivery
Platform</article-title>. <source>ACS Nano</source>
<year>2018</year>, <volume>12</volume>, <fpage>8397</fpage>&#x02013;<lpage>8405</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.8b03760</pub-id>.<pub-id pub-id-type="pmid">30059616</pub-id></mixed-citation></ref><ref id="ref163"><mixed-citation publication-type="journal" id="cit163"><name><surname>Aran</surname><given-names>K.</given-names></name>; <name><surname>Chooljian</surname><given-names>M.</given-names></name>; <name><surname>Paredes</surname><given-names>J.</given-names></name>; <name><surname>Rafi</surname><given-names>M.</given-names></name>; <name><surname>Lee</surname><given-names>K.</given-names></name>; <name><surname>Kim</surname><given-names>A. Y.</given-names></name>; <name><surname>An</surname><given-names>J.</given-names></name>; <name><surname>Yau</surname><given-names>J. F.</given-names></name>; <name><surname>Chum</surname><given-names>H.</given-names></name>; <name><surname>Conboy</surname><given-names>I.</given-names></name>; <name><surname>Murthy</surname><given-names>N.</given-names></name>; <name><surname>Liepmann</surname><given-names>D.</given-names></name>
<article-title>An Oral Microjet Vaccination System Elicits Antibody
Production in Rabbits</article-title>. <source>Sci. Transl. Med.</source>
<year>2017</year>, <volume>9</volume>, <elocation-id>eaaf6413</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf6413</pub-id>.<pub-id pub-id-type="pmid">28275153</pub-id></mixed-citation></ref><ref id="ref164"><mixed-citation publication-type="journal" id="cit164"><name><surname>Abramson</surname><given-names>A.</given-names></name>; <name><surname>Caffarel-Salvador</surname><given-names>E.</given-names></name>; <name><surname>Khang</surname><given-names>M.</given-names></name>; <name><surname>Dellal</surname><given-names>D.</given-names></name>; <name><surname>Silverstein</surname><given-names>D.</given-names></name>; <name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Frederiksen</surname><given-names>M. R.</given-names></name>; <name><surname>Vegge</surname><given-names>A.</given-names></name>; <name><surname>Hub&#x000e1;lek</surname><given-names>F.</given-names></name>; <name><surname>Water</surname><given-names>J. J.</given-names></name>; <name><surname>Friderichsen</surname><given-names>A. V.</given-names></name>; <name><surname>Fels</surname><given-names>J.</given-names></name>; <name><surname>Kirk</surname><given-names>R. K.</given-names></name>; <name><surname>Cleveland</surname><given-names>C.</given-names></name>; <name><surname>Collins</surname><given-names>J.</given-names></name>; <name><surname>Tamang</surname><given-names>S.</given-names></name>; <name><surname>Hayward</surname><given-names>A.</given-names></name>; <name><surname>Landh</surname><given-names>T.</given-names></name>; <name><surname>Buckley</surname><given-names>S. T.</given-names></name>; <name><surname>Roxhed</surname><given-names>N.</given-names></name>; et al. <article-title>An Ingestible Self-Orienting System for Oral Delivery
of Macromolecules</article-title>. <source>Science</source>
<year>2019</year>, <volume>363</volume>, <fpage>611</fpage>&#x02013;<lpage>615</lpage>. <pub-id pub-id-type="doi">10.1126/science.aau2277</pub-id>.<pub-id pub-id-type="pmid">30733413</pub-id></mixed-citation></ref><ref id="ref165"><mixed-citation publication-type="journal" id="cit165"><name><surname>Shin</surname><given-names>M. D.</given-names></name>; <name><surname>Shukla</surname><given-names>S.</given-names></name>; <name><surname>Chung</surname><given-names>Y. H.</given-names></name>; <name><surname>Beiss</surname><given-names>V.</given-names></name>; <name><surname>Chan</surname><given-names>S. K.</given-names></name>; <name><surname>Ortega-Rivera</surname><given-names>O. A.</given-names></name>; <name><surname>Wirth</surname><given-names>D. M.</given-names></name>; <name><surname>Chen</surname><given-names>A.</given-names></name>; <name><surname>Sack</surname><given-names>M.</given-names></name>; <name><surname>Pokorski</surname><given-names>J. K.</given-names></name>; <name><surname>Steinmetz</surname><given-names>N. F.</given-names></name>
<article-title>COVID-19 Vaccine Development and a Potential
Nanomaterial Path Forward</article-title>. <source>Nat. Nanotechnol.</source>
<year>2020</year>, <volume>15</volume>, <fpage>646</fpage>&#x02013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-020-0737-y</pub-id>.<pub-id pub-id-type="pmid">32669664</pub-id></mixed-citation></ref><ref id="ref166"><mixed-citation publication-type="journal" id="cit166"><name><surname>Weiss</surname><given-names>C.</given-names></name>; <name><surname>Carriere</surname><given-names>M.</given-names></name>; <name><surname>Fusco</surname><given-names>L.</given-names></name>; <name><surname>Capua</surname><given-names>I.</given-names></name>; <name><surname>Regla-Nava</surname><given-names>J. A.</given-names></name>; <name><surname>Pasquali</surname><given-names>M.</given-names></name>; <name><surname>Scott</surname><given-names>J. A.</given-names></name>; <name><surname>Vitale</surname><given-names>F.</given-names></name>; <name><surname>Unal</surname><given-names>M. A.</given-names></name>; <name><surname>Mattevi</surname><given-names>C.</given-names></name>; <name><surname>Bedognetti</surname><given-names>D.</given-names></name>; <name><surname>Merko&#x000e7;i</surname><given-names>A.</given-names></name>; <name><surname>Tasciotti</surname><given-names>E.</given-names></name>; <name><surname>Yilmazer</surname><given-names>A.</given-names></name>; <name><surname>Gogotsi</surname><given-names>Y.</given-names></name>; <name><surname>Stellacci</surname><given-names>F.</given-names></name>; <name><surname>Delogu</surname><given-names>L. G.</given-names></name>
<article-title>Toward Nanotechnology-Enabled Approaches against the
COVID-19 Pandemic</article-title>. <source>ACS Nano</source>
<year>2020</year>, <volume>14</volume>, <fpage>6383</fpage>&#x02013;<lpage>6406</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.0c03697</pub-id>.<pub-id pub-id-type="pmid">32519842</pub-id></mixed-citation></ref><ref id="ref167"><mixed-citation publication-type="journal" id="cit167"><name><surname>Fang</surname><given-names>J.</given-names></name>; <name><surname>Hsueh</surname><given-names>Y.-Y.</given-names></name>; <name><surname>Soto</surname><given-names>J.</given-names></name>; <name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>Gu</surname><given-names>Z.</given-names></name>; <name><surname>Khademhosseini</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>S.</given-names></name>
<article-title>Engineering Biomaterials with Micro/Nanotechnologies
for Cell Reprogramming</article-title>. <source>ACS Nano</source>
<year>2020</year>, <volume>14</volume>, <fpage>1296</fpage>&#x02013;<lpage>1318</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.9b04837</pub-id>.<pub-id pub-id-type="pmid">32011856</pub-id></mixed-citation></ref><ref id="ref168"><mixed-citation publication-type="journal" id="cit168"><name><surname>Sun</surname><given-names>J.</given-names></name>; <name><surname>Zhuang</surname><given-names>Z.</given-names></name>; <name><surname>Zheng</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>K.</given-names></name>; <name><surname>Wong</surname><given-names>R. L.-Y.</given-names></name>; <name><surname>Liu</surname><given-names>D.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>He</surname><given-names>J.</given-names></name>; <name><surname>Zhu</surname><given-names>A.</given-names></name>; <name><surname>Zhao</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xi</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Alshukairi</surname><given-names>A. N.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>F.</given-names></name>; <name><surname>Lai</surname><given-names>X.</given-names></name>; et al. <article-title>Generation of a Broadly Useful Model for COVID-19
Pathogenesis, Vaccination, and Treatment</article-title>. <source>Cell</source>
<year>2020</year>, <volume>182</volume>, <fpage>734</fpage>&#x02013;<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.06.010</pub-id>.<pub-id pub-id-type="pmid">32643603</pub-id></mixed-citation></ref><ref id="ref169"><mixed-citation publication-type="weblink" id="cit169"><person-group person-group-type="allauthors"><name><surname>Si</surname><given-names>L.</given-names></name>;
<name><surname>Bai</surname><given-names>H.</given-names></name>;
<name><surname>Rodas</surname><given-names>M.</given-names></name>;
<name><surname>Cao</surname><given-names>W.</given-names></name>;
<name><surname>Oh</surname><given-names>C.
Y.</given-names></name>;
<name><surname>Jiang</surname><given-names>A.</given-names></name>;
<name><surname>Nurani</surname><given-names>A.</given-names></name>;
<name><surname>Zhu</surname><given-names>D.
Y.</given-names></name>;
<name><surname>Goyal</surname><given-names>G.</given-names></name>;
<name><surname>Gilpin</surname><given-names>S.
E.</given-names></name>;
<name><surname>Prantil-Baun</surname><given-names>R.</given-names></name>;
<name><surname>Ingber</surname><given-names>D.
E.</given-names></name></person-group>,
<article-title>Human Organs-on-Chips as Tools for Repurposing
Approved Drugs as Potential Influenza and COVID19 Therapeutics
in Viral Pandemics</article-title>. <italic>bioRxiv</italic>,
April 14, 2020, ver. 1. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biorxiv.org/content/10.1101/2020.04.13.039917v1">https://www.biorxiv.org/content/10.1101/2020.04.13.039917v1</uri>
(accessed 2020-08-25).</mixed-citation></ref><ref id="ref170"><mixed-citation publication-type="journal" id="cit170"><name><surname>Sun</surname><given-names>W.</given-names></name>; <name><surname>Luo</surname><given-names>Z.</given-names></name>; <name><surname>Lee</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>H.-J.</given-names></name>; <name><surname>Lee</surname><given-names>K.</given-names></name>; <name><surname>Tebon</surname><given-names>P.</given-names></name>; <name><surname>Feng</surname><given-names>Y.</given-names></name>; <name><surname>Dokmeci</surname><given-names>M. R.</given-names></name>; <name><surname>Sengupta</surname><given-names>S.</given-names></name>; <name><surname>Khademhosseini</surname><given-names>A.</given-names></name>
<article-title>Organ-on-a-Chip for Cancer and Immune Organs
Modeling</article-title>. <source>Adv. Healthcare Mater.</source>
<year>2019</year>, <volume>8</volume>, <fpage>1801363</fpage><pub-id pub-id-type="doi">10.1002/adhm.201801363</pub-id>.</mixed-citation></ref><ref id="ref171"><mixed-citation publication-type="journal" id="cit171"><name><surname>Segaliny</surname><given-names>A. I.</given-names></name>; <name><surname>Li</surname><given-names>G.</given-names></name>; <name><surname>Kong</surname><given-names>L.</given-names></name>; <name><surname>Ren</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>J. K.</given-names></name>; <name><surname>Baltimore</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>G.</given-names></name>; <name><surname>Zhao</surname><given-names>W.</given-names></name>
<article-title>Functional TCR T Cell Screening Using Single-Cell
Droplet Microfluidics</article-title>. <source>Lab Chip</source>
<year>2018</year>, <volume>18</volume>, <fpage>3733</fpage>&#x02013;<lpage>3749</lpage>. <pub-id pub-id-type="doi">10.1039/C8LC00818C</pub-id>.<pub-id pub-id-type="pmid">30397689</pub-id></mixed-citation></ref><ref id="ref172"><mixed-citation publication-type="journal" id="cit172"><name><surname>Monteil</surname><given-names>V.</given-names></name>; <name><surname>Kwon</surname><given-names>H.</given-names></name>; <name><surname>Prado</surname><given-names>P.</given-names></name>; <name><surname>Hagelkr&#x000fc;ys</surname><given-names>A.</given-names></name>; <name><surname>Wimmer</surname><given-names>R. A.</given-names></name>; <name><surname>Stahl</surname><given-names>M.</given-names></name>; <name><surname>Leopoldi</surname><given-names>A.</given-names></name>; <name><surname>Garreta</surname><given-names>E.</given-names></name>; <name><surname>Hurtado del Pozo</surname><given-names>C.</given-names></name>; <name><surname>Prosper</surname><given-names>F.</given-names></name>; <name><surname>Romero</surname><given-names>J. P.</given-names></name>; <name><surname>Wirnsberger</surname><given-names>G.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Slutsky</surname><given-names>A. S.</given-names></name>; <name><surname>Conder</surname><given-names>R.</given-names></name>; <name><surname>Montserrat</surname><given-names>N.</given-names></name>; <name><surname>Mirazimi</surname><given-names>A.</given-names></name>; <name><surname>Penninger</surname><given-names>J. M.</given-names></name>
<article-title>Inhibition of SARS-CoV-2 Infections in Engineered Human
Tissues Using Clinical-Grade Soluble Human ACE2</article-title>. <source>Cell</source>
<year>2020</year>, <volume>181</volume>, <fpage>905</fpage>&#x02013;<lpage>913</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.004</pub-id>.<pub-id pub-id-type="pmid">32333836</pub-id></mixed-citation></ref><ref id="ref173"><mixed-citation publication-type="journal" id="cit173"><name><surname>Shah</surname><given-names>S. K.</given-names></name>; <name><surname>Miller</surname><given-names>F. G.</given-names></name>; <name><surname>Darton</surname><given-names>T. C.</given-names></name>; <name><surname>Duenas</surname><given-names>D.</given-names></name>; <name><surname>Emerson</surname><given-names>C.</given-names></name>; <name><surname>Lynch</surname><given-names>H. F.</given-names></name>; <name><surname>Jamrozik</surname><given-names>E.</given-names></name>; <name><surname>Jecker</surname><given-names>N. S.</given-names></name>; <name><surname>Kamuya</surname><given-names>D.</given-names></name>; <name><surname>Kapulu</surname><given-names>M.</given-names></name>; <name><surname>Kimmelman</surname><given-names>J.</given-names></name>; <name><surname>MacKay</surname><given-names>D.</given-names></name>; <name><surname>Memoli</surname><given-names>M. J.</given-names></name>; <name><surname>Murphy</surname><given-names>S. C.</given-names></name>; <name><surname>Palacios</surname><given-names>R.</given-names></name>; <name><surname>Richie</surname><given-names>T. L.</given-names></name>; <name><surname>Roestenberg</surname><given-names>M.</given-names></name>; <name><surname>Saxena</surname><given-names>A.</given-names></name>; <name><surname>Saylor</surname><given-names>K.</given-names></name>; <name><surname>Selgelid</surname><given-names>M. J.</given-names></name>; et al. <article-title>Ethics of Controlled Human Infection to Address
COVID-19</article-title>. <source>Science</source>
<year>2020</year>, <volume>368</volume>, <fpage>832</fpage>&#x02013;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc1076</pub-id>.<pub-id pub-id-type="pmid">32381590</pub-id></mixed-citation></ref></ref-list></back></article>